Cover Page  for Protocol  
Sponsor name:  Novo Nordisk A/S  
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  NN7999 -3895  
Official title of study:  An Open -label Single -arm Multicentre Non -controlled Phase 3 
a Trial Investigating Safety and Efficacy of Nonacog Beta 
Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia 
B (FIX Activity Below or  Equal to 2 Percent)  
Document date:  05 November 2019  
*Document date refers to the date on which the document was most recently updated.
Note: The date in the header of Page 2 is the date of compilation of the documents and not of an update to content.
Link
LinkList of contents
Protocol ...............................................................................................................................................
Protocol attachment ...........................................................................................................................CONFIDENTIALDate: Novo Nordisk
Version:
Status:nonacog beta pegol
Trial ID: NN7999-3895 Final
Clinical Trial Report
Appendix 16.1.124 February 2023
1.0
Final
16.1.1 Protocol and protocol amendments
 
 
 
 
 
Redacted protocol  
Includes redaction of personal identifiable information only.  
 
 
 
. 
 
 
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 1of 119
  Protocol
Trial ID: NN7999 -3895
Safety and Efficacy of nonacog beta pegol (N9 -GP) in 
Previously Untreated Patients with Haemophilia B
An open -label single -arm multicentre non -controlled phase 3a trial invest igating safet y and efficacy  
of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously 
untreated patients with haemophilia B (FIX activit y ≤2%)
Includes:
Protocol  Amendment no 1 (25 -Mar-2015), Protocol Amendment no 2 (15- Jan-2016), Protocol  
Amendment no 4 (13- Dec-2016), Protocol Amendment no 5 (11- Dec-2017), Protocol Amendment 
no 6 (29 -Jun-2018), Local  Protocol  Amendment no 7 (31 -Jul-2019) (Only applicable for Spain) and 
Protocol  Amendment no 8 (05 -Nov-2019).
Trial phase: 3a
Protocol originator: 
, International Trial Manager
Biopharm , Trial Operati ons 2
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 1 . -  | 1
 |
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
CONFIDENTIAL

Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 2of 119
  Table of c ontents
Page
Table of contents .........................................................................................................................................2
Table of figures ...........................................................................................................................................7
Table of tables .............................................................................................................................................7
List of abbreviations ...................................................................................................................................8
1Summary ............................................................................................................................................ 11
2Flow chart .......................................................................................................................................... 14
3Background information and rationale for the trial ......................................................................... 19
3.1 Background information .......................................................................................................... 19
3.2 Rationale for the trial ............................................................................................................... 20
3.3 N9-GP (nonacog beta pegol) ................................................................................................... 20
3.4 Risk and benefits ..................................................................................................................... 21
4Objective( s) and endpoint(s) .............................................................................................................. 23
4.1 Objective(s) ............................................................................................................................ 23
4.2 Endpoint(s) ............................................................................................................................. 23
4.2.1 Primary Endpoint ................................................................................................... 23
4.2.2 Secondary Endpoint ............................................................................................... 23
5Trial design ........................................................................................................................................ 24
5.1 Type of trial ............................................................................................................................ 24
5.2 Rationale for trial design ......................................................................................................... 24
5.3 Treatment of patients ............................................................................................................... 25
5.3.1 Previous exposure to FIX products ......................................................................... 25
5.3.2 Pre-prophylaxis treatment ...................................................................................... 26
5.3.3 Prophylaxis treatment ............................................................................................ 26
5.3.4 Treatment of bleeding episodes .............................................................................. 26
5.3.5 Requir ements for the first 20 injections .................................................................. 27
5.3.6 Treatment of bleeding episodes in low titre inhibitor (<5 BU) patients .................... 27
5.3.7 Treatment of suspected severe bleeding episodes ................................................... 27
5.3.8 Surgery .................................................................................................................. 27
5.3.9 Vaccinations .......................................................................................................... 29
5.4 Treatment after end of trial ...................................................................................................... 29
5.5 Rationale for treatment ............................................................................................................ 30
6Trial population .................................................................................................................................31
6.1 Num ber of patients .................................................................................................................. 31
6.2 Inclusion criteria ..................................................................................................................... 31
6.3 Exclusion criteria .................................................................................................................... 31
6.4 Withdr awal criteria ................................................................................................................. 32
6.4.1 Only applicable for Spain: Temporary discontinuation of trial treatment ................. 32
6.5 Patient replacement ................................................................................................................. 32
6.6 Ration ale for trial population ................................................................................................... 33
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 2 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 3of 119
  6.6.1 Rationale for inclusion criteria ............................................................................... 33
6.6.2 Rationale for exclusion criteria ............................................................................... 33
6.6.3 Rationale for withdrawal criteria ............................................................................ 33
7Milestones ........................................................................................................................................... 34
8Methods and assessments .................................................................................................................. 35
8.1 Visit procedures ...................................................................................................................... 35
8.1.1 Visit 0 –screening visit .......................................................................................... 37
8.1.1.1 Pre-prophylaxis treatment .................................................................38
8.1.1.2 Prophylaxis treatment ....................................................................... 39
8.1.2 Visit 1 –first dosing with N9 -GP........................................................................... 39
8.1.3 Visit 2 -20 – main phase .......................................................................................... 40
8.1.3.1 Treatment outside trial site ............................................................... 40
8.1.4 Visit 21 -22 – main phase ........................................................................................ 41
8.1.5 Visit 23 –end of main phase .................................................................................. 42
8.1.6 Visit 24 -27 – extension phase ................................................................................. 42
8.1.7 Visit 28 -end of extension phase ............................................................................ 43
8.1.8 Visit 29 -X until end of trial .................................................................................... 43
8.1.9 End-of-trial visit .................................................................................................... 44
8.1.10 Unscheduled visit ................................................................................................... 44
8.1.11 Inhibitor Follow -Up visit ....................................................................................... 44
8.1.12 Home treatment ..................................................................................................... 45
8.1.12.1 Prophylactic home treatment ............................................................ 45
8.1.12.2 Home treatment of bleeding episodes ............................................... 46
8.2 Patient related information ...................................................................................................... 46
8.2.1 Concomitant illness and medical history.................................................................46
8.2.1.1 Details on haemophilia and haemophilia treatment history ................ 46
8.2.1.2 Allergies .......................................................................................... 46
8.2.2 Concomitant medication ........................................................................................ 47
8.2.3 Treatment of bleeding episodes in low titre inhibitor patients < 5 BU ..................... 47
8.2.4 Prohibited medication ............................................................................................ 47
8.2.5 Demography .......................................................................................................... 47
8.3 Clinical assessments ................................................................................................................ 47
8.3.1 Body measurements ............................................................................................... 48
8.3.2 Physical examinations ............................................................................................ 48
8.3.2.1 Neur ological Examination ................................................................ 48
8.3.3 Neur ocognitive assessments ................................................................................... 49
8.3.4 Vital signs .............................................................................................................. 54
8.4 Laboratory assessments ........................................................................................................... 54
8.4.1 Local laboratory assessments ................................................................................. 55
8.4.1.1 FIX activity ...................................................................................... 55
8.4.2 Central laboratory assessments ............................................................................... 55
8.4.2.1 FIX activity ...................................................................................... 56
8.4.2.2 Antibody assessments ....................................................................... 56
8.4.2.3 HIV testing and CD4+ lymphocyte count ......................................... 58
8.4.2.4 Haematology .................................................................................... 59
8.4.2.5 Bioche mistry .................................................................................... 59
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 3 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 4of 119
  8.4.2.6 F9and HLA genotype testing ........................................................... 60
8.4.2.7 Investigation of allergic reactions ..................................................... 60
8.4.2.8 Urinalysis ......................................................................................... 61
8.4.2.9 Explor atory analysis of PEG in plasma ............................................. 61
8.4.3 Blood sampling in infants and children ................................................................... 62
8.4.4 Storage of samples .................................................................................................62
8.5 N9-GP administration ............................................................................................................. 62
8.6 Bleeding episodes ................................................................................................................... 64
8.6.1 Assess ments of bleeding episodes and treatment response ...................................... 64
8.7 Surgery ................................................................................................................................... 66
8.7.1 Minor surgery ........................................................................................................ 67
8.7.2 Major su rgery ........................................................................................................ 67
8.8 Training and reminders ........................................................................................................... 68
8.8.1 Trial card dispensing .............................................................................................. 68
8.8.2 Home treatment training ......................................................................................... 68
8.8.3 Electronic diary (eDiary) ........................................................................................ 69
8.8.3.1 eDiary dispensing and collection ...................................................... 69
8.8.4 Contact between the investigator/medically qualified person and the patient ........... 69
8.8.5 Interactive web response system ............................................................................. 70
8.9 Patient compliance .................................................................................................................. 70
9Trial supplies ...................................................................................................................................... 72
9.1 Trial produc t........................................................................................................................... 72
9.2 Packing, labelling and dispensing ............................................................................................ 73
9.3 Storage .................................................................................................................................... 74
9.4 Drug accountabilit yand destruction ........................................................................................ 75
9.5 Auxiliary supply ...................................................................................................................... 75
9.6 Shipment of trial product to patient’s home ............................................................................. 75
10Interactive /web response system  (IWRS) ......................................................................................... 77
11Adverse events and technical complaints .......................................................................................... 78
11.1 Definitions .............................................................................................................................. 78
11.2 Reporting of adverse events ..................................................................................................... 83
11.3 Follow -up of adverse events .................................................................................................... 85
11.4 Technical complaints and technical complaint samples ............................................................ 86
11.4.1 Reporting of technical complaints .......................................................................... 86
11.4.2 Collection, storage and shipment of technical complaint samples ........................... 87
11.5 Precautions and/or overdose .................................................................................................... 87
11.6 Committees related to safety ................................................................................................... 87
11.6.1 Novo Nordisk safety committee ............................................................................. 87
12Case report forms .............................................................................................................................. 89
12.1 Corrections to case report forms .............................................................................................. 89
12.2 Case report form flow ............................................................................................................. 90
12.3 Electronic diary ....................................................................................................................... 90
12.4 Tablets for neurocognitive assessments ................................................................................... 91
13Monitoring procedures ...................................................................................................................... 92
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 4 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 5of 119
  14Data management .............................................................................................................................. 94
15Computerise d systems ....................................................................................................................... 95
16Statistical considerations ................................................................................................................... 96
16.1 Sample size calculation ........................................................................................................... 97
16.2 Definition of analysis sets ........................................................................................................ 97
16.3 Primary endpoint ..................................................................................................................... 97
16.4 Secondary endpoints ............................................................................................................... 98
16.4.1 Confir matory secondary endpoints ......................................................................... 98
16.4.2 Supportive secondary endpoints ............................................................................. 98
16.4.2.1 Num ber of bleeding episodes during prophylaxis .............................. 98
16.4.2.2 Haemostatic effect ............................................................................ 98
16.4.2.3 FIX activity ...................................................................................... 99
16.4.2.4 FIXconsumption .............................................................................. 99
16.4.2.5 Safety endpoints ............................................................................... 99
16.5 Neur ocognitive assessments .................................................................................................. 100
16.6 Interim reporting ................................................................................................................... 100
16.7 Sequential safety analysis and safety monitoring ................................................................... 101
16.8 Reporting of F9 and HLA genotype ....................................................................................... 101
17Ethics ................................................................................................................................................ 102
17.1 Infor med consent .................................................................................................................. 102
17.2 Data handling ........................................................................................................................ 103
17.3 Infor mation to patient, parent(s)/LAR(s) during the trial ........................................................ 103
17.4 Prem ature termination of the trial and/or trial site .................................................................. 104
18Protocol compliance ......................................................................................................................... 105
19Audits and inspections ..................................................................................................................... 106
20Critical documents ........................................................................................................................... 107
21Responsibilities .................................................................................................................................109
22Reports a nd publications ................................................................................................................. 110
22.1 Communication of results ...................................................................................................... 110
22.1.1 Authorship ........................................................................................................... 111
22.1.2 Trial s ite-specific publication(s) by investigator(s) ............................................... 111
22.2 Investigator access to data and review of results .................................................................... 112
23Retention of clinical trial documentation and human biospecimens .............................................. 113
23.1 Retention of clinical trial documentation ............................................................................... 113
23.2 Retention of human biospecimens ......................................................................................... 113
24Institutional Review Boards/Independent Ethics Committees and regulatory authorities ........... 115
25Indemnity statement ........................................................................................................................ 116
26References ........................................................................................................................................ 118
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 5 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 6of 119
  Approval of Final Protocol
Agreement on Final Protocol
Attachment I –Global List of key staff and relevant departments and vendors
Attachment II –Country List of key staff and relevant departments
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 6 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 7of 119
  Table of f igures
Page
Figur e 5–1 Patient flow chart ................................ .................................................................................... 25
Figur e 8–1 Visit flow diagram ................................ .................................................................................. 35
Figure 16–1 Individual patient flow and time period for main trial report .................................................... 96
Table of t ables
Page
Table 2–1 Flow chart visits and assessments ................................ ............................................................ 14
Table 2–2 Flow chart explanatory descriptions ................................ ........................................................ 17
Table 3-1 T he clinical development programme of N9 -GP................................ ...................................... 21
Table 5-1 Intravenous N9 -GP treatment ................................ .................................................................. 29
Table 8-1 Neur ocognitive assessments by age for all countries ................................ ................................ 51
Table 8-2 Additional neurocognitive assessments by age for English speaking c ountries (e.g. 
Australia, Canada, United Kingdom, and the United States) ..................................................... 52
Table 8-3 4- point scale ................................ ............................................................................................ 66
Table 9-1 Trial Product ................................ ........................................................................................... 72
Table 9-2 Storage ................................ .................................................................................................... 74
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 7 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 8of 119
  List of abbreviations
ABAS -3 Adapt ive Behavior Assessment Sy stem  –Third Edi tion
AE adverse event
BASC -3 Behavior Assessment System for Children –Third Edi tion
BRIEF2 Behavior Rating Inventory  of Execut ive Funct ion –Second 
Edition
BRIEF -P Behavior Rating Inventory  of Execut ive Funct ion –Preschool 
Edition.
BP blood pressure
BU Bethesda units
BW body  weight
CFR code of federal regulat ions
CHMP committee for medical products for human use
CHO Chinese hamster ovary
CNS central  nervous system
CLAE clinical laboratory  adverse event
CRF case report form 
CRO contract research organisat ion
CTA clinical trial applicat ion
CTR clinical trial report
DCF data clarificat ion form
DUN dispensing unit number
eCOA electroni c clinical  outcom e assessment
eCRF electroni c case report form
ED exposure day  (Defini tion: One exposure day  is defined as each 
day when a pati ent is administered coagulation factor IX/blood 
components for any reason regardl ess number of doses )
eDiary electronic diary
eGFR estimated glo merular filtrat ion rate
EMA European Medicines A gency
EOT end of trial
FAS full analysis set
FDA food and drug a dministration
FPFV first pati ent first visit
FVII a activated coagul ation factor VII
FIX coagul ation factor IX
FIXa activated coagulat ion factor IX
FX coagul ation factor X
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 8 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 9of 119
  GCP good clinical pract ice
HCP host cell protein
HLA human leucocy te ant igen
IB investi gator’s brochure
ICH International Council for Harmonisat ion of Technical 
Requi rements for Pharmaceut icals for Hum an Use
ICMJE International Committee of Medical Journal Editors
IEC independent ethics co mmittee
IgE immunogl obulin E
IFU inhibitor follow up
IND investigat ional new drug
IRB institutional review board
IR30min incremental recovery 30 min
IU internat ional unit (1 IU of N9 -GP and 1 U of N9-GP are 
equivalent and can be used interchangeably. In this protocol IU is 
used, however U may appear in so me trial related documents, e.g. 
IMP l abels)
I.V. intravenous
IWRS interact ive web response system 
LAR legally acceptable representative
LOCF last observat ion carri ed forward
LPFV last pati ent first visit
LPLV last pati ent last visit
M months
MESI medical event of special interest
N9-GP nonacog beta pegol, glycopegylated recombinant coagulat ion 
factor IX
NIMP non-invest igational medicinal product
OD on-demand
PDCO paediatric committee (EMA)
Pd-aPCC plasma -derived act ivated prothrombin co mplex concentrates 
PEG polyethylene glyco l
PI principal investigator
PIP paedi atric invest igation plan
PK pharmacokinet ics
PPX prophylaxis
PUP previously untreated patient
rFIX recombinant coagulat ion factor IX
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 9 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 10of 119
  SAE serious adverse event
SAP statist ical analysis plan
SAS safet y analysis set
SI the internat ional system  of units
SIF safet y informat ion form
SUSAR suspected unexpected serious adverse reaction
TEAE treatm ent emergent adverse event
TESAE treatm ent emergent serious adverse event
TMM trial materials manual
UTN universal trial number
V visit
W weeks
WASI -II Wechsler Abbreviated Scale of Intelligence, Second Edit ion 
WPPSI -IV Wechsler Preschool and Primary  Scale of Intelligence, Fourth 
Edition 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 10 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 11of 119
  1Summary
Primary Objective
To evaluate immunogenicit y of N9-GP (nonacog beta pegol)
Primary Endpoint
Incidence of inhibitory  antibodies against FIX 
Secondary Objectives
To evaluate safety  of N9-GP (nonacog beta pegol)
To evaluate efficacy o f N9-GP (nonacog beta pegol)
oin long-term prophylaxis treatment 
oin the treatment of bleeding episodes 
othrough the surrogate marker: FIX activit y
othrough m onitoring of number of doses and consumpt ion of N9 -GP
Key Secondary Endpoint
Number and frequency  of adverse events, serious adverse events, and Medical Ev ents of Special 
Interest
Number of breakthrough bleeding episodes during prophyl axis (annualised bleeding rate)
Haem ostati c effect by  4-point haemostatic response scale (“excellent”, “good”, “moderate” and 
“poor”)
Time Frame of the Objectives/Endpoint
All objectives/endpo ints will be evaluated when minimum 20 PUPs have reached at least 50 
exposure days ( EDs), when minimum 40 PUPs have reached at least 100 EDs, and at end of trial. 
End of tri al will be 30 Oct 2022.
Trial design
The tri al is an open label, single -arm, mul tinational, non -controlled confirmatory  trial investi gating 
safet y and efficacy o f N9-GP in prophylaxis and treatment of breakthrough bleeding episodes in 
haemophilia B previously untreated patients with FIX activit y ≤ 2%.The trial has one treatment arm 
in which at least 40 patients should achieve at least 100 exposur e days with N9-GP.
The European medicines agency requires submission of safet y and efficacy data fro m a minimum of 
50 exposure day sin at least 20 patients for approval of the indicat ion in previ ously untreated 
patients , with a post -approval extensi on phase according to guideline to follow-up in at least40 
patients, for a minimum of 100 exposure day s.When minimum 20 pati ents have reached at least 50 
exposure days, the analysis and evaluat ion for the main trial report will be performed. All pat ients 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 11 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 12of 119
  continue in the extensio n phase for the purpose of acquiring dat a for a minimum of 100 exposure 
days in at least 40 patients. 
Trial population
60 pati ents are pl anned to be screened and at least 40 patients are expected to complete the trial.
The tri al popul ation is characterised by the fo llowing incl usion and exclusi on criteria:
Inclusion Criteria
Inform ed consent obtained before any  trial-related activit ies. Tri al-related activit ies are any 
procedures that are carried out as part of the trial, including act ivities to determine suitabili ty for 
the trial
Male,  <6 yea rs of age at the time o f signing inform edconsent
Patients wi th the di agnosis of haemophilia B (FIX activit y level  ≤ 2%) based on medical records 
or central laboratory  resul ts
Previously  untreated or exposed to FIX containing products less than or equal to 3 exposure 
days (5 previous exposure days to blood components are acceptable)
Exclusion Criteria
Any history  of FIX inhibitors (defined by medical records)
Known or suspected hy persensi tivity to trial product or related products 
Previous participat ion in this trial. Participat ion is defined as first dose administered of trial 
product
Receipt of any  investi gational medicinal product wit hin 30 days before screening
Congenital or acquired coagulat ion disorder other than haemophilia B
Any chronic disorder o r severe disease which, in the opinion o f the Invest igator, might 
jeopardi se pat ient’s safet y or com pliance wi th the protocol
Patient’s parent(s)/LAR(s) m ental  incapacit y, unwillingness to cooperate, or a language barrier 
precl uding adequate understanding and cooperation
Assessments
Safety assessments
The fo llowing key  assessments for safet y will be used in the trial:
Antibody  assessment: inhibitory  and binding antibodies
Other adverse events, incl. allergic react ions, anaphylact ic react ions and thromboembo lic events
Efficacy assessments
The fo llowing key  assessments for efficacy  will be used in the tri al:
Bleeding episodes
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 12 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 13of 119
  Haem ostati c effect i n treatm ent of bleeding episodes
Number of doses to treat a bleed
Pharmacokinetics, pharmacodynamics and other assessments
The fo llowing key  assessments for pharmacokinet ics, pharmacodynamics and other assessments 
will be used in the trial:
FIX activit y measured as trough and peak
Trial product
The fo llowing tri al product will be used in the trial:
nonacog beta peg ol hereafter referred to as N9 -GP 
N9-GP is supplied as a sterile freeze -dried powder for solut ion for inject ion in single use vials wit h 
a nominal content of 2000 IU/vial or 500 IU/vial to be reconstituted with 4.2 mL Histidine so lvent. 
After reconstituti on each vial contains 500 IU/mL or 125 IU/mL N9 -GP, respectively. 
Patients are treated with 40 IU/kg N9 -GP for:
bleeding episodes
pre-prophylaxis or 
prophylaxis
A bleeding episode should be treated with a single dose of 40 IU/kg, unless the bleeding epis ode is 
severe in which case it should be treated with 80 IU/kg.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 13 . -  | 1
 |
CONFIDENTIAL
Protocol UTN: U1111 -1135-9557 Date: 05 November 2019 Status: Final Novo Nordisk
Trial ID: NN7999 -3895 EudraCT No.: 2012 -004867 -38 Version: 8.0 Page: 14of 119
  2Flow chart
Table 2–1 Flow chart visits and assessments
Visit number 0151-2013, 1521-22 23 24-27 28 29-X17IFU EOT
Visit purpose Screening Dosing DosingEnd of 
MainDosingEnd of 
extensionDosing
(until 
EOT)ONLY for 
inhibitor 
patientsEnd of 
Trial
Time of visit (ED(s))190 1-20 30,40 5060, 70, 80, 
90100124, 148, 
172, …
Visit interval 19 ±1
Day10 ± 2 
weeks10+2
Weeks10 ± 2
weeks10+2
weeks24 ± 417
weeks
PATIENT RELATED 
INFORMATION
Informed consent 10X
Assent form, if applicable1(X) (X) (X) (X) (X) (X) (X)
Inclusion / Exclusion criteria X
Eligibility evaluation X
Withdrawal criteria X X X X X X
Demography X
Concomitant illness &  
medical historyX
Details on haemophilia and 
haemophilia treatment historyX
Concomitant medication X X X X X X X X X
ADVERSE EVENTS
Adverse events2X X X X X X X X X
CLINICAL 
ASSESSMENTS
Body measurements3X21X21X21X21X21X21X21X21
Physical examination X X X X
Neurological examination24 Visit 1 and 
20X Visit 26 X X X
Neurocognitive assessments25Visit 1 and X Visit 26 X X XVV-TMF-1261484|1.0|NN7999 -NN7999-3895
  Protocol  v 8|14 of 119
CONFIDENTIAL
Protocol UTN: U1111 -1135-9557 Date: 05 November 2019 Status: Final Novo Nordisk
Trial ID: NN7999 -3895 EudraCT No.: 2012 -004867 -38 Version: 8.0 Page: 15of 119
  Visit number 0151-2013, 1521-22 23 24-27 28 29-X17IFU EOT
Visit purpose Screening Dosing DosingEnd of 
MainDosingEnd of 
extensionDosing
(until 
EOT)ONLY for 
inhibitor 
patientsEnd of 
Trial
Time of visit (ED(s))190 1-20 30,40 5060, 70, 80, 
90100124, 148, 
172, …
Visit interval 19 ±1
Day10 ± 2 
weeks10+2
Weeks10 ± 2
weeks10+2
weeks24 ± 417
weeks
20
Vital signs4X Visit 14X X X
CENTRAL 
LABORATORY 
ASSESSMENTS
FIX activity –trough7(X)5 Visit 1, 
5,10,15, 20X X X X XXX
FIX activity –recovery
30 min post -dose6Visit 1,10, 
20X X
N9-GP binding antibodies7 Visit 1, 
5,10,15,20X X X X XXX
FIX inhibitor test7, 16 Visit 1,5,10, -
15,20X X X X XXX
HCP antibodies7X X X X
HIV  antibodies (X)8
CD4+ lymphocyte count and 
HIV viral load(X)8
Haematology X (Visit 1)9X X X
Biochemistry X (Visit 1)9Visit 21 X Visit 26 X X X
F9+ HLA genotype testing (X)10(X)10
Allergic reaction testing20(X) (X)
Plasma PEG levels X22Visit 21 X Visit 26 X X X
Urinalysis23 Visit 1 and 
20X Visit 26 X X X
TRIAL PRODUCT 
ADMINISTRATION
N9-GP administration X X X X X XVV-TMF-1261484|1.0|NN7999 -NN7999-3895
  Protocol  v 8|15 of 119
CONFIDENTIAL
Protocol UTN: U1111 -1135-9557 Date: 05 November 2019 Status: Final Novo Nordisk
Trial ID: NN7999 -3895 EudraCT No.: 2012 -004867 -38 Version: 8.0 Page: 16of 119
  Visit number 0151-2013, 1521-22 23 24-27 28 29-X17IFU EOT
Visit purpose Screening Dosing DosingEnd of 
MainDosingEnd of 
extensionDosing
(until 
EOT)ONLY for 
inhibitor 
patientsEnd of 
Trial
Time of visit (ED(s))190 1-20 30,40 5060, 70, 80, 
90100124, 148, 
172, …
Visit interval 19 ±1
Day10 ± 2 
weeks10+2
Weeks10 ± 2
weeks10+2
weeks24 ± 417
weeks
N9-GP dispensing for home 
treatment(X)13X X X X X18
N9-GP accountability X X X X X X X
TRAINING AND 
REMINDERS
Trial card dispensing X
Home treatment training X X X X X X
eDiary training X11X11X11X11X11X11
Compliance check of eDiary 
data, protocol requirements, 
used drug and bleeding 
episode evaluation X X X X X X X
Contact with 
patients/parent/LAR12 (X)12(X)12
IWRS14X X X X X X X X
End of trial form XVV-TMF-1261484|1.0|NN7999 -NN7999-3895
  Protocol  v 8|16 of 119
CONFIDENTIAL
Protocol UTN: U1111 -1135-9557 Date: 05 November 2019 Status: Final Novo Nordisk
Trial ID: NN7999 -3895 EudraCT No.: 2012 -004867 -38 Version: 8.0 Page: 17of 119
  Table 2–2 Flow chart explanatory descriptions
Footer Description
1Any patient above the age of 3 years should sign a child assent form, if capable, and if required by local requirements. This can be performed on a separate day. As this is a 
long term trial the investigator should check the progressing maturation of the c hild and its ability to assent throughout the trial
2 When Informed consent has been obtained all adverse events must be reported in the eCRF
3For practical purposes, when dispensing trial drug, the body weight from an earlier measurement (or visit) can be used if the measurement was performed within the previous 
12 weeks (in children < 3 years of age, within 6 weeks) . After visit 29, a body weight measured within the previous 12 weeks for all age groups can be used. Please refer to 
Section 8.3.1 .
4Vital signs should be measured prior to dosing at screening, V1, V23, V28 and EOT. In addition vital signs should also be measured 30±10 minutes after the first injection 
with N9 -GP at V1
5FIX activity should only be measured at V0 if diagnosis of haemophilia B (FIX ≤2%) has not been documented in the patients’ me dical record. FIX activity at V0 can either be 
measured at local or central laboratory depending on the urgency of receiving the result i.e. in case V0 and V1 are combined
6 FIX recovery  activity  is measured 30 min ±10 min after dosing at the following EDs: 1 , 10, 20, 50 and 100 . For details please refer to Section 8.4.2.1
7 Blood samples must be collected within 1 hour prior to dosing at dosing visits
8HIV antibodies are only to be asse ssed, if status is u nknown (i.e. previous test older than 6 months). Tests for CD4+ lymphocyte count and HIV viral load are only req uired 
for HIV positive patients . Sampling can be postponed to the earliest convenient visit to ensure that the allowed blood volume is not excee ded
9In case V1 is more than a month after V0, haematology and b iochemistry need to be retaken at V1 prior to dosing. Biochemistry also needs to be retaken at visit 1 if 
biochemistry at V0 was a local assessment. P lease refer to Section 8.4.2.4 and 8.4.2.5
10F9and HLA genotype sample should be taken prior to administrating the first dose of N9 -GP or at a visit as soon as possible thereafter taking the limitation of the allowed 
blood sampling volume into account .  
11eDiary training prior to initiating home treatment to ensure that the patient’s parent(s)/LAR(s) are comfortable entering data in the eDiary. Retrain in the use of the eDiary a s 
applicable at V21 -VX to ensure entry of correct eDiary data
12When site visits are more than 3 months apart the Investigator must contact the patient’s parents/LAR at least every 12 weeks ± 1week to ensure thepatients well -being. For 
details please refer to Section 8.8.4 . Primarily expected to be applicable for patients treated according to pre- prophylaxis (V1 -V20) and who visit the trial site less frequent 
than every 3 months. In addition all visits from V29 –VX will be scheduled every 24 weeks.
13It will be possible t o administer ED 11 -20 outside the trial site (except ED 15 and 20 since blood sampling is needed). This is only allowed if the trial site can ensure presence 
of a relevant health care professional qualified of handling anaphylactic reactions
14 IWRS to be used for screening, visit registration, trial drug dispensing, drug accountability and completion. Refer to Sectio n 10for more informat ion.
15 V0 and V1 can be combined to one visit, if the patient fulfils the in -and exclusions criteria
16Blood sampling for FIX .i nhibitor testing must be performed prior to administrating the first dose of N9- GP to the patient at v isit 1 . An inhibitor test must be performed before 
surgery  if the previous inhibitor test was performed more than 30 days prior to surgery.
17 V29 to VX will be performed every 24 weeks ± 4weeks until End of Trial VV-TMF-1261484|1.0|NN7999 -NN7999-3895
  Protocol  v 8|17 of 119
CONFIDENTIAL
Protocol UTN: U1111 -1135-9557 Date: 05 November 2019 Status: Final Novo Nordisk
Trial ID: NN7999 -3895 EudraCT No.: 2012 -004867 -38 Version: 8.0 Page: 18of 119
  18 At every dosing visit from V29 -VX, drug will be dispensed to cover up to 3 months of treatment
19When the patient has commenced prophylaxis, visits can for practical purposes be planned according to the predicted number of EDs based on th e patient’s prophylaxis 
regimen. A visit does not need to be re -scheduled even if the actual EDs between visits turn out higher due to treatment of bleeding episodes during the home treatme nt period
20 Allergic reaction testing can be taken at visit 0 or visit 1 pre -dose, taking the limitation of the allowed blood sam pling volume into account.
21Height will be collected at visit 0, visit 21, visit 23, visit 26, and at all visits from visit 28 toEOT visit. In case visit 1 is more than a month after visit 0, height needsto be 
redone at visit 1 .For patients who have already attended visit 23 and 28 height at these two visits ± 1 month will be collected retrospective if available in medical records
upon parent(s)/LAR(s) consent .
22Blood samples for PEG analysis should be taken at visit 0 taking the limitation of the allowed blood sampling volume into account. If not taken at visit 0, the blood sample 
should be taken at visit 1 pre-dose, if the blood volume allows.
23 Urine sample should be obtained if possible. It can be collected at home same day and brought to site if transported cold according to Section 8.4.2.8 . 
24The neurological examination can for all visits be made within ±1 month of the visits, except for the visit 1 and EOT visit where it can be made at visit date or up to 1 month 
ahead of the visit. 
25The neurocognitive assessments can for all visits be made within ±1 month of the visits, except for visit 1 and EOT vis it where it can be made at visit date or up to 1 month 
ahead of the visit. For details see Table 8-1and Table 8-2.VV-TMF-1261484|1.0|NN7999 -NN7999-3895
  Protocol  v 8|18 of 119
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 19of 119
3Back ground information and rationale for the trial
The tri al will be conducted in com pliance wi th this protocol , ICH GCP1and applicable regulatory 
requi rements, and in accordance with the Declaration of Helsinki.2
In thi s docum ent, the term  invest igator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
3.1 Background information
Haemophilia B is a recessive X -linked congenital bleeding disorder characterised by increased 
bleeding tendency due to either a partial or complete deficiency or dysfunction o f the essent ial 
blood coagulat ion factor IX (FIX ). It is caused by mutations in the F9gene, l ocated in the di stal part 
on the l ong arm  of the X -chromosome. The incidence o f haemophilia B is approximately 1 per 
25,000 m ale bi rths. Haem ophilia care i s based on prevent ion (prophylaxis) and/or “on -demand 
treatm ent” of bleeding episodes with a haemo staticagent.
With a deficiency or absence of FIX, activation o f coagul ation factor X (FX) becomes severely 
impaired, and consequent ly, the thrombin burst becomes delayed and insufficient for normal 
haemo stasis. The haemo static pl ug formed in these pa tients is therefore fragile and easily disso lved 
by norm al fibrino lytic activit y, leading to impaired haemostasis, prolonged bleeding and 
rebleeding3. Haem ophilia B is cl assified according to the plasma act ivity of FIX as severe (<1%), 
moderate (1 -5%) or mild (>5 -40%). 
The predominant treatm entfor pati ents wi th haemophilia B is factor replacement therapy  where 
concentrates of FIX are injected intravenously to replace the deficient and/or dysfunctional FIX. 
Haem ophilia care is based on treatment of a bleeding episode with a hae mostatic agent or -during 
recent decades -haemostatic agents are administered for longer periods to prevent bleeding 
(bleeding prophylaxis).
The m ost comm only used products for the treatment of haemophilia B are plasma derived FIX and 
recombinant FIX (rF IX). Both have half -lives of 18 -19 hours requiring 2-3 weekly injecti ons f or 
prophylaxis of bleeding episodes.4
The clinical manifestations o f haemophilia B are bleeding episodes due to impaired haemostasis. 
The bleeding episodes in pat ients with severe haemophilia B ty pically  occur spontaneous ly or after 
mild traum a in j oints, muscles and soft ti ssues. The bleeding episodes often occur in m uscles and 
weight bearing jo ints (elbows, knees and ankles) , causing acute haemarthrosis. In repeated cases 
this is fo llowed by  synovitis in the affected joi nt. Recurrent bleeding episodes in the same location, 
most comm only a weight -bearing jo int, may  lead to chroni c arthropathy , muscular atrophy  and
disabling deformities. Bleeding may  occur in all parts of the body  including rare, but life-
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 19 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 20of 119
threatening events such as: e.g. bleeding in the central nervous system (CNS), throat, neck or 
retroperitoneum.
3.2 Rationale for the trial
The rati onale for performing this trial is to invest igate safet y and efficacy of N9-GPin the treatment 
of previ ously untreated pati ents ( PUP) wi th haemo philia B, hereby  supporting ant icipated 
market ing authorisat ion of N9-GP and line extension in the PUP population. 
EMA requi res separate invest igation of PUPs as part of the development programme init iated 
before m arket authorisation (MA) gets obtained . A final gui deline on the clinical invest igation of 
recombinant and human plasma -derived factor IX products5from the Committee for Medical 
Product for Human Use (CHMP), describes the mandatory  com ponents for trials in PUP. In some 
countri es outsi de the EU, PUP Paediatric invest igation is necessary to achieve labelled indicat ion 
for all children.
3.3 N9-GP ( nonacog beta pegol)
Novo Nordisk A/S is developing a recombinant coagulat ion factor IX, N9 -GP (nonacog beta pegol), 
with a prol onged half -life for treatment of haemophilia B patients. The steady  state half -life based 
on PK from the phase 3 trial o f previously treated adults and ado lescents haemophilia B w as
determined to 111 hours . 
The l ong half -life is achieved by site -directed glycopegylat ion that m akes i t possible to attach a 40 
kilodalton polyethylene glyco l (PEG) m olecule to the FIX activat ion peptide.6Upon activat ion by 
FIX’s physio logical  activators, the activat ion peptide –with the attached PEG –is cleaved off, 
thereby leaving wild ty pe act ivated FIX (FIXa).
The product is intended for FIX replacement therapy  in adults and children with haemophilia B. 
N9-GP isunder devel opment f or both the control and prevention of bleeding episodes, including 
routi ne prophylaxis, and for treatment and prevention of bleeding during surgery .
For full informat ion on m edical aspects, non -clinic al data and qualit y of N9-GP,please refer to the 
current version of the Investigator’s Brochure (IB)7and any updates hereof.
For an overview of the trials in the clinical development programme of N9-GP, please refer to
Table 3-1
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 20 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 21of 119
Table 3-1 T he clinical development programme of N9-GP
Trial ID Trial description Status
NN7999 -3639
(paradigmTM1)A multi-centre, multi-national, open-label, dose escalation trial 
evaluating safety and pharmacokinetics of ascending intravenous 
doses of N9- GP in non-bleeding patients with h aemophilia BPhase 1 
(PK trial )Completed
NN7999 -3747
(paradigmTM2)A multi -centre, single -blind t rial evaluating safety  and efficacy, 
including pharmacokinetics, of N9-GP when used for treatment 
and prophylaxis of bleeding episodes in p atients with haemophilia 
BPhase 3a 
(safety and 
efficacy 
trial)Completed
NN7999 -3773
(paradigmTM3)An open -label, multi -centre, un -controlled trial to a ssess efficacy 
and s afety  of N9 -GP d uring surgical procedures in patients with 
haemophilia BPhase 3a 
(surgery  
trial)Completed
NN7999 -3775
(paradigmTM4)An open -label, multi -centre, multinational trial evaluating safety 
and efficacy of N9-GP in treatment of bleeding episodes and long-
term prophylaxis in haemophilia B patientsPhase 3b 
(extension 
trial)Completed
NN7999 -3774
(paradigmTM5)An open -label, sin gle-arm, multinational, non -controlled, 
confirmatory trial investigating safety, efficacy and 
pharmacokinetics of N9- GP in prophylaxis and treatment of 
bleeding episodes in children with haemophilia B with extension 
phasePhase 3 
(paediatric, 
safety and 
efficacy 
trial)On-going
(main 
phase 
completed)
NN7999 -3895
(paradigmTM6)An open -label ,single -arm,multicentre non -controlled trial 
investigating safety and efficacy of N9-GP in prophylaxis and 
treatment of bleed ing episode s in previously untreated patients 
with haemophilia BPhase 3 a
(safety 
trial)Current 
trial
3.4 Risk and benefits
Children are among those who might benefit significant ly from prophylaxis wit h N9 -GP. The m ost 
commo nly used products  for the treatment of haem ophilia B have short half -life o f 18-19 hours 
demanding frequent dosing for prophylaxis of bleeding episodes, with 2 -3 inject ions a week8. The 
prolonged half -life of N9 -GP offers an expected advantage of once weekly or potentially even less 
frequent inject ions, which reduces the burden of treatment while maintaining effect ive haemo stasis. 
Likewise i t may prom ote adherence to therapy  due to l ess frequent injections .6The pivo tal phase 3 
trial (NN7999 -3747) dem onstrated a prophylact ic protection of 40 IU/kg N9 -GP once weekly and 
showed that 99% of bleed ing episodes in the 40 IU/kg arm  were stopped wi th a single dose of N9 -
GP.
N9-GP is manufactured in a serum -free process. The r ecombinant FIX part of N9 -GP has an amino 
acid sequence i denti cal to human FIX and is produced from the Chinese hamster ovary (CHO) cell -
line, a m amma lian cell line shown to be free of known infectious agents. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 21 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 22of 119
The primary  concern in PUPs is the ri sk of de velopment of neutralising antibodies to FIX 
(inhibitors). Development of binding ant ibodies and inhibitors will be monitored closely throughout 
the trial.
Hypersensi tivity react ions may occur with the administrati on of  N9-GP, as with any  protein injected 
intravenously. Pati ents will  be closely m onitored for devel opment of  hypersensit ivity react ions, in 
relation to the first 20 exposures with N9 -GP. 
Correl ation between allergic react ions and the development of inhibitors have been observed with 
FIX treatm ent. If patients develop inhibitors, they  will be carefully  instructed how to react if an 
allergic reaction occurs fo llowing N9 -GP administrati on. 
Pegylat ion of proteins is a well- established technology  which is used in the treatment of a variet y of 
clinica l disorders .9In repeat dose toxicit y studi es in animals, PEG was shown to be bio -distributed 
to blood in connective ti ssue and cy toplasm of epithelial cells of the choroid plexus of the brain , for 
further informat ion refer to the current version of the Invest igator’s Brochure (IB)7. The potential 
clinical implications of these animal findings are unknown. No adverse neuro logicaleffects of PEG 
have been reported in infants, chil dren, and adol escents exposed to N9 -GP during clinical trials. 
The potential consequences o f long term  exposure have not been fully  evaluated. Due to this
theoreti cal safety  concern regarding PEG, potential clinical effects of longer- term exposure to N9 -
GPwith special emphasis on the choroid plexus and the two major excret ion organs (liver and 
kidney) will be investigated in more detail (neurological examinat ion, age -appropriate 
neurocognit ive assessments and laboratory  analyses of plasma PEG levels, liver and kidney  
param eters).
No safet y issues have been ident ified in the completed and ongoing clinical trials wit h N9 -GPand 
the risk/benefit ratio for N9 -GP is therefore expected to be favorable . For further inform ation refer 
to the current version of the IB7.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 22 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 23of 119
4Objective(s) and endpoint(s)
4.1 Objective(s)
Primary Objective
To evaluate immunogenicit y of N9-GP (nonacog beta pegol)
Secondary Objectives
To evaluate safety  of N9-GP (nonacog beta pegol)
To evaluate efficacy o f N9-GP (nonacog beta pegol)
oin long-term prophylaxis treatment 
oin the treatment of bleeding episodes 
othrough the surrogate marker: FIX activit y
othrough m onitoring of number of doses and consumpt ion of N9 -GP
4.2 Endpoint(s)
4.2.1 Primary Endpoint
Incidence of inhibitory  antibodie s against FIX
4.2.2 Secondary Endpoint
Number and f requency  of adverse events (AEs) ,serious AEs (SAEs) and Medical Ev ents of 
Speci al Interest (MESI) * 
Number of breakthrough bleeding episodes during prophyl axis (annualised bleeding rate) *
Haem ostati c effect by  4-point haem ostati c response scale (“excellent”, “good”, “moderate” and 
“poor”) *
Incremental  recovery  at 30 minutes (IR30min), FIX activit y at 30 minutes (C 30min) and trough 
level
Amount of drug administered and number of doses needed to treat a bleedi ng episode
*Key supportive secondary endpo int prospectively selected for posting on (e.g. clinicaltrials.gov 
and EudraCT).
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 23 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 24of 119
5Trial design
5.1 Type of trial
This is an open label, single -arm,multinational, non- controlled confirmatory  trial invest igating 
safet y and efficacy o f N9-GP in prophylaxis and treatment of breakthrough bleeding episodes in 
haemophilia B PUPs wi th FIX act ivity ≤ 2%.
The tri al has one treatm ent arm  in which at least 40 patients shoul d achieve 100 exposure days of 40 
IU/kg N9 -GP.
The tri al consist sof four parts: screening, main (i.e. core) phase, extensio n phase and a prophylaxis 
period until EOT , see Table 5-1.
EMA requires submissio n of safet y and efficacy data from a minimum o f 50 EDs in at least 20 
patients f or approval  of indicat ion in PUPs, with a post -approval extensio n phase according to 
guideline to follow in at least40 patients, for a minimum of 100 EDs. Sixty ( 60)patients are 
planned to enter screening.5When minimum 20 pati ents have reached a minimum o f50 EDs the 
analysis and evaluation for the main report will be performed. All pat ients will continue in the 
extensio n phase for the purpose of acquiring data for a minimum of 100 EDs in at least 40 patients. 
Results fro m all pat ients, in all parts of the trial, will be reported in a final report when the last 
patient has com pleted the tri al.
The tri al design is based on the guideline on clinical invest igation of recombinant and human 
plasma -derived factor IX p roducts developed by CHMP in EU.5
For Japan only: The NN7999 -3895 trial will be classified as a post -market ing clinical trial if 
obtaining market ing approval in Japan. The refore, the term  ‘chiken’, which is a term for a clinical 
trial conducted for getting market ing approval, is replaced in the protocol and other related 
materi als/docum ents wi th the term  ‘post -market ing clinical trial.’
5.2 Rationale for trial design
The tri al is design edto invest igate immunogenicity o f N9-GP in PUPs who are known to have the 
highest ri sk of inhibitor formation.10A minimum of 100 EDs will  provide the requi red exposure to 
N9-GP in order to invest igate the immunogenicit y,safet yother than immunogenicit yand efficacy  
of N9-GP.
A multinational design has been chosen to ensure a sufficient screening pool of pat ients with this 
rare disorder, to meet local regulatory  requi rements and to reflect the ant icipated pati ent popul ation. 
There will be no randomisat ion or stratificat ion.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 24 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 25of 119
5.3 Treatment of patients
The durati on of  a pati ent’s trea tment wi th N9-GP in the main phase of the trial is unt il Visit 23 ( 50 
EDs)hasbeen reached. 
The durati on of  N9-GP treatment in the extension phase is at least 50 EDs or until glo bal LPLV 
(30-Oct-2022). Thereafter treatment with N9 -GP will cont inue unt il LPLV. Trial overview will be 
as shown in Figure 5–1.
60 pati ents are pl anned to be screened and at least 40 patients are expected to complete the trial.
Figure 5–1 Patient flow chart 
The tri al is designed to reflect commo n practice in haemophilia treatment centres. Most children 
will init ially receive on -demand (episodi c) treatm ent for minor skin/ mucosa bleeding episodes, and 
after the first j oint and/or m uscle bleed, switch to prophylaxis in order to prevent bleeding episodes 
and musculo skeletal  damage. This i s usually done when the child is between 1 and 2 years of age. 
Prior to starting treatmen t at Visi t 1, the family  and investi gator will choose between prophylaxis 
and pre -prophylaxis treatment. One exposure day  is defined as each day  when a pati ent is 
administered N9- GP for any reason regardless of number of doses .
5.3.1 Previous exposure to FIX products
Due to the rarit y of the condi tion, recrui tment for clinical trials o f PUPs wi th severe or moderate 
Haem ophilia B is highly challenging. According to EMA guidelines only  PUPs are eligible for 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 25 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 26of 119
participat ion. However, patients that are ‘minimally expos ed’ (up to 3 EDs of commercial FIX) can 
enter this trial in agreement with PDCO at EMA. 
In addit ion to the above, maximum 5 previous blo od product (e.g. plasma, cry opreci pitate, 
erythrocyte concentrate or platelets) EDs are allowed. 
5.3.2 Pre-prophylaxis treat ment
If it is decided by  the invest igator and family not to init iate regul ar once weekly prophylaxis 
immediately  after Visi t 0, the pati ent can instead, unt il he is 24 months o f age or until 20 ED, be 
treated on -demand for bleeding episodes and/or have a s low start -up of prophylaxis (i.e. pre -
prophylaxis) with a dose of 40 IU/kg at intervals longer than a week. 
The decisio n regarding pre -prophylaxis treatment will be made at visit 0. Pre -prophylaxis treatment 
will be administered as a dose of 40 IU/kg N9 -GP (or 80 IU/kg for a severe bleed), see Section 
5.3.4 .
Pre-prophylaxis treated patients will have regular contact with trial site at least every 12 weeks, if 
dosing wit h N9 -GP is not pl anned and/or required, until init iation of prophylaxis.
5.3.3 Prophylaxis treatment
Regular prophylaxis must be init iated no later than 24 months of age or upon reaching 20 EDs 
whichever comes first, with a dose of 40 IU/kg N9 -GP administered every 7th day (± 1 day).  
If considered relevant, the invest igator is permitted to pr escribe administration o f extra N9 -GP 
bleeding preventive doses before demanding physical act ivities (e.g. sports). The next regular 
prophylaxis dose should not be postponed but be administered on the usual dosing day.
5.3.4 Treatment of bleeding episodes
The pa tient’s parent(s)/LAR(s) will be instructed by  the tri al site on how to treat a bleeding episode 
at hom e and record this in the eDiary , see Secti ons 8.1.12.1 , 8.6and 8.6.1 . 
In case of a treatm ent requi ring bleeding episode, immediate treatment with N9 -GP as intravenous 
inject ion of 40 IU/kg in case of mild or moderate bleeding or 80 IU/kg in case of a severe bleeding 
episode can be administered. The investigator must always be contacted in case of a severe bleeding 
episode. These doses can be repeated, but not exceeding 200 IU/kg per 24 hours Table 5-1.
An addit ional dose of 40 IU/kg for a mild/moderate bleeding episode is only allowed after 
consultation wit h the invest igator. If a mild/moderate bleeding episode has not improved within 24 
hours, the pati ent’s parent(s)/LAR(s) should contact the investigator. 
For treatm ent of bleeding episodes prior to reaching the first 20 EDs please refer to Section 5.3.5 .
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 26 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 27of 119
5.3.5 Requirements for the first 20 injections
The ri sk of anaphylaxis and allergic reactions is evaluated as being highest during the first 20 EDs.8, 
10Forthis reason i t is a requi rement in this protocol to administer the first 10 N9- GP injecti ons at 
the trial site and i t is recommended to administer at least the first 20 inject ions at the site. If the 
Invest igator in accordance wit h local pract ice or guide lines decides to allow treatment outside the 
trial site pri or to reaching 20 EDs this must be with a health care professional present that will be 
able to manage a nanaphylact ic react ion and could for example be at the emergency  room , local 
paedi atrician or at home, see Sect ion 8.1.3.1 .
5.3.6 Treatment of bleeding episodes in low titre inhibitor (<5 BU ) patients 
Low ti tre inhibitor pati ents who do not respond sufficient ly to N9 -GP treatment may be treated with 
bypassing agents according to local label for a period of up to 2 y ears. It is recommended to avoid 
FIX containing bypassing agents. Bypassing agents are not considered trial medicat ion. Pati ents
willstay in the tri al and continue the N9-GP tr eatment 40 IU/kg once weekly.
5.3.7 Treatment of suspected severe bleeding episodes
In case of an abdominal or head trauma where there is a risk of a severe traumat ic bleeding episode 
it is allowed to init iate treatmen t before clinical symptom s arise. This is defined as prevent ive 
treatm ent of suspected severe traumat ic bleeding episode. The recommended dose is 80 IU/kg. The 
site must be contacted and the event documented eit her in the eDiary or in the eCRF as treatment of 
bleeding episode.
5.3.8 Surgery
Minor surgery
Minor surgeries (procedures where only one dose of N9-GP is considered sufficient prior to the 
surgery ) can be perform edwhile participat ing in this trial by administering a dose of 40 IU/kg N9-
GP, see Table 5-1. 
Definition of minor surgery
Minor surgery  is defined as an invasive operative procedure where only  the skin, the m ucous 
membranes or superf icial connect ive tissue is manipulated. For this trial, examples of minor surgery  
include:
Implanting and removing ports in subcutaneous tissue (see * in Table 5-1)
Skin excisio ns 
Drainage of abscess
Simple dental procedures 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 27 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 28of 119
Circumcisio n 
Major surgery 
Major surgery  may be performed after 20 EDs in the current trial. 
In a separate completed N9 -GP surgery  trial (NN7999 -3773/ paradigm™3) 13 adults and ado lescent 
patients underwent major surgery  where the haemostatic effect in all study  parti cipants was reported 
as either good or excellent and the N9-GPappeared to have a safe and well tolerated profile.
Major surgery  in the current trial should be planned and conducted in accordance wit h the 
recommendat ions in the WFH Guidelines for the management of haemophilia .8Determinat ion of
dose and dose intervals to achieve adequate haemostasis should include close m onitoring of FIX 
activit y trough and peak l evels , taken into consi derati on the half -life of N9- GP a nd ongoing clinical 
evaluat ion of the haemostatic effect.
Major surgery  may be perform ed using general anaesthesia, spinal anaesthesia, epidural 
anaesthesia, conscious sedat ion, local anaesthesia or wi th a combinat ion of these modalit ies. The 
used sedat ive products should be listed in the concomitant medication. 
Further details and require ments when performing major surgery  are provi ded in Sect ion 8.7.
Definition of major surgery
Major surgery  is defined as any  invasive operative pro cedure that require several days o f FIX 
subst itution therapy  and/or where any one or m ore of the fo llowing occur: 
A body  cavit y is entered 
A mesenchymal barrier (eg pleura, peritoneum or dura mater) is crossed
A fascial plane is opened
An organ i s removed
When normal anatomy is operatively altered
Major elective orthopaedic surgery
Treatment with N9 -GP during surgery  will be included in the overall count of N 9-GP EDs. Upon 
completion of the surgical/invasive procedure the patient will continue prophylact ictreatm ent wi th 
N9-GP as before the surgery .
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 28 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 29of 119
Table 5-1 Intravenous N9 -GP treatment
Indication Dosage * Frequency
Pre-prophylaxis during main phase  
(prior to 20EDs)
(pt. less than 24 months of age)40 IU/kg On-demand or intervals longer than 
once weekly 
Prophy laxis during main phase 40 IU/kg Once weekly (±1 day)
Prophy laxis during 
extension phase 40 IU/kg Once weekly (±1 day)
Mild/moderate bleeding episode 40 IU/kg Single dose for bleeding episodes. 
Additional doses only after 
consultation with the investigator
Severe bleeding episode
(The investigator must be contacted)80 IU/kg, not exceeding 200 IU/kg 
per 24 hoursSingle dose for bleeding episodes. 
Severe bleeding episodes can be 
treate d with further dose if instructed 
by the investigator
Minor surgery 40 IU/kg 
(*Port implantation: 80 IU/kg)Single dose prior to surgery
Major surgery, only allowed after 20 
EDsIn accordance with the WFH 
Guidelines8and local standard of 
practise In accordance with the WFH 
Guidelines8and local standard of 
practise 
Low titre inhibitor 40 IU/kg Once weekly (±1 day)
*The dos e to administer will be calculated by IWRS and defined in whole mL fordoses above 3mL .
5.3.9 Vaccinations
Vaccinat ions are allowed before entering the trial but should preferably not take place unt il 3 
months after the first N9- GP exposure, as vaccinatio n activates the immune system, thereby
potenti allyincreasing the risk of inhibitor development.
5.4 Treatment after end of trial
After tri al end the invest igator will agree wit h the patient’s parent(s)/LAR(s) upon the best available 
treatm ent for the pati ent. Novo Nordisk will not provide any trial product to a patient after the end 
of the tri al unless requi red in accordance wit h local law or regul ation.
When discont inuing the trial product the patientshoul d be swi tched to a sui table m arketed product 
at the di screti on of  the invest igator.
It is expected that N9 -GP will be granted market ing authorisat ion and is co mmercially available 
when the patients complete this trial. However, this cannot be guaranteed .
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 29 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 30of 119
5.5 Rationale for treatment
Lack of co mpliance with a frequent inject ion schedule is one of the most commonly cited reasons 
for failure of prophylaxis with coagulat ion factor treatment6. The increased half -life of N9 -GP will  
allow for prophylaxis wit h fewer injections than currently available products and will mo st likely  
resul t in improving com pliance.
The dose levels for this trial are based on PK data from  the phase 1 PK trial (NN7999 -3639), PK 
data from 10 IU/kg and 40 IU/kg inthe pivotal  trial (NN7999 -3747) and PK data from  children 
participat ing in the paediatric trial (NN7999 -3774).
Please refer to the IB7and any updates hereof for further non
-clinical and clinical da ta.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 30 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 31of 119
6Trial population
6.1 Number of patients
Number of patients planned to be screened: 60
Number of patients planned to be started on trial product: 60
Number of patients e xpected to complete the trial: 40
6.2 Inclusion criteria
For an eligible subject, all inclusion criteria must be answered "yes".
1.Inform ed consent obtained before any trial-related activit ies. Tri al-related activit ies are any 
procedures that are carried out as part of the trial, including act ivities to determine suitabilit y 
for the tri al. (Note: By  consent ing to this trial, the parent(s)/LAR(s) accepts that genotype of
the pati ent’s haemophilia B mutation is analysed/recorded and used for trial purposes).
2.Male, < 6 y ears of age at the time of signing informed consent.
3.Patients wi th the di agnosis of haemophilia B (FIX activit y level  ≤ 2%) based on medical 
records or cent ral laboratory  resul ts.
4.Previously  untreated or exposed to FIX containing products less than or equal to 3 EDs (5 
previous exposure day s to bl ood com ponents are acceptable).
6.3 Exclusion criteria
For an eligible patient, all exclusio n criteria must be answered “no”.
1.Known or suspected hy persensi tivity to trial product or related products .
2.Previous participat ion in this trial. Participat ion is defined as first dose administered of trial 
product .
3.Receipt of any  investi gational medicinal product wit hin 30 days before screening .
4.Congenital or acquired coagulat ion disorder other than haemophilia B .
5.Any chronic disorder or severe disease which, in the opinion o f the invest igator, might 
jeopardi se pat ient’s safet y or com pliance wi th the protocol .
6.Patient’s pare nt(s)/LAR(s) m ental  incapacit y, unwillingness to cooperate, or a language barrier 
precl uding adequate understanding and cooperation .
7.Any history  of FIX inhibitors (defined by medical records)
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 31 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 32of 119
6.4 Withdrawal criteria
The patient maywithdraw at will at any  timeeither by  the pati ent or by  thepatient’s parent(s) or the 
patient’s LAR. The patient’s request to discont inue must always be respected.
The patient may  be wi thdrawn from  the tri al at the di screti on of  the invest igator due to a safet y 
concern or if judge d non -compliant with trial procedures.
The patient must be withdrawn if the following applies :
1.Dosed in the trial, but not fulfilling the inclusio n and/or exclusio n criteria
2.Development of FIX inhibitors ≥ 5 BU confirmed by two consecutive tests (central laboratory) 
and associated with N9 -GP binding antibodies (the patient must be withdrawn fro m N9-GP 
treatm ent upon confirmat ion of FIX inhibitor ≥ 5 BU and attend three inhibit or follow-up visit s) 
3.Anaphylactic reaction to the trial product, for definit ion see sect ion 11.1
4.Major surgery  prior to 20 EDs. see section 5.3.8
5.Significant thromboembo lic event , see Section 11.1
6.Incapacit y or unwillingness to fo llow trial procedures
7.Parti cipation in another clinical trial while part icipating in this trial
If a patient experiences treatment failure where haemostatic response is rated as poor according to 
Secti on 8.6, the invest igator should consider if it is in the patient’s best interest to continue in the 
trial.
All data collected prior to withdrawal will be used in the trial analyses.
Temporary  or p ermanent discont inuation of  treatment wi th trial product will  not lead to wi thdrawal
from the trial.
6.4.1 Only applicable for Spain: Temporary discontinuation of trial treatment
Temporary  treatm ent di scont inuat ion is allo wed at the discret ion of the invest igato r and the reason
for discont inuat ion must be recorded in the eCRF. Treatment with trial product may be resumed if 
the circumstances l ater all ow. Date and l ast tri al product dose shoul d be recorded i n the eCRF. 
Resupply status in the IWRS should be put on h oldwhen a patient is on treatment pause. The 
eDiary will not be used during temporary  discont inuation of trial product.
6.5 Patient replacement
Withdrawn patients may be replaced to ensure that at least 40 patients complete the trial wit h a 
minimum o f 100 ED.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 32 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 33of 119
6.6 Rationale for trial population
The select ion of the trial populat ion is based on the specific requirements found in the final 
guideline on the clinical invest igation o f recombinant and human plasma -derived factor IX 
products5from the CHMP and in the Paediatric Investigation Plan (PIP) in agreement with the 
Paedi atric Co mmit tee (PDCO).
Children are among those who might benefit significant ly from prophylaxis. Less frequent 
inject ions wit h N9 -GP as com pared to other treatm ent opti ons are likely  to im prove com pliance, 
avoid int errupti ons of daily  life and thereby  increase the qualit y of life of the patients.
6.6.1 Rationale for inclusion criteria
Criterion no. 1 is included in accordance with Internat ional Conference on 
Harm onisat ion/Good Clinical Pract ice (ICH -GCP).
Criterion no. 2 is included due to N ovo Nordisk A/S has decided to use an age cut -off 
of 6 years.
Criterion no. 3 is included to select the patient group based on the CHMP guideline5.
Criterion no. 4 is included to select the patient group based on the CHMP guideline 
and in accordance with recent PIP modificat ion allowing inclusio n of minimally 
treated pati ents.
6.6.2 Rationale for exclusion criteria
Criteria nos. 1 and 5 are included to prevent unnecessary  exposure of potentially 
fragile pat ientsto a new compound.
Criterion no. 2 is included to ensure that a patient only  counts once in the data 
analyses.
Criterion no. 3 is include d to minimise any effect of external compounds on the 
patient's coagul ation and immune system. 
Criterion no. 4 is chosen to exclude pat ients with endogenous abnorm alities of the 
coagul ation system, other than haemophilia B .
Criterion no. 6 is included to ensure enro lment of patients likely to be compliant with 
the protocol, and to preclude enro lment of particularly vulnerable pat ients.
Criterion no. 7 is included to exclude patients with FIX inhibitors since inhibitor 
development is the primary  safety endpo int of the tri al.
6.6.3 Rationale for withdrawal criteria
Criteria nos. 1 -7are included to protect the patient's safet y and reliabilit y of the data.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 33 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 34of 119
7Milestones
Planned durati on of  recrui tment peri od: First pati ent first visit (FPFV ) to l ast pati ent fi rst visit 
(LPFV): 75months 
First Patient First Visit:  02-Jul-2014
Planned L ast P atient First Visit: 30-Sep-2020
End of tri al is defined as L ast 
Patient Last Visit: 30-Oct-2022
The durati on of  N9-GP treatment in the trial is a minimum o f 100 EDs for at lea st 40 pati ents and 
will cont inue unt il Last Pati ent Last Vi sit for the trial, which will be 30 October 2022 . 
Planned co mpletion o f clinical trial report (CTR): Q 2 
2023
Recruitmen t
The screening rate will be fo llowed cl osely via the interact ive web response system (IWRS) in 
order to estimate when to stop screening. All investigators will be notified immediately when the 
recrui tment peri od ends, after which no further consent will be sought fro m additional families and 
the IWRS will be closed for further screening , unless addit ional screening is needed due to patient 
replacement.
All subjects included in the screening period and eligible for the trial will enter the trial. 
Trial regis tration
Inform ation of the trial will be disclo sed at clinicaltrials.gov ,novonordisk -trials.com and 
clinicaltrials.jp . According to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure, it 
will also be disclosed according to other requirements such as those of the International Co mmittee 
of Medical Journal Editors (ICMJE)11, the Food and Drug Administration Amendment Act 
(FDAAA)12, European Commissio n Requirements13and other relevant recommendat ions or 
regul ations. If a pat ient requests to be included in the trial via the Novo Nordisk e -mail contact at 
these web sites, Novo Nordisk may disclose the investigator’s contact details to the patient. As a 
resul t of increasing requi rements for transparency, some countries require public disclosure of 
investigator names and their affiliat ions.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 34 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 35of 119
8Methods and assessments
8.1 Visit procedures
Specific procedures, assessments and methods for the scheduled visit s are described in the sect ion 
below, and the list of assessments for each visit is presented in the flow chart, see Table 2–1and 
visit flow diagram Table 8-1.
Figure 8–1 Visit flow diagram 
Screening and enrolment log
The invest igator must keep a patient screening log, a patient ident ificat ioncode list and a patient 
enrolment log .The patient screening log and pat ient enrolment log may be combined in one list.
At screening, patients will be provided with a trial card stating that they  are participat ing ina trial 
and given contact address (es) and telephone number(s) of relevant trial site staff. Pati ent’s
parent(s)/LAR(s) shoul d be instructed to return the trial card to the investigator at the last trial visit 
or to destroy the trial card after the l ast vi sit.
It must be stated i n the medical records that the patient is participat ing in the trial , including the 
patientnumber .
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 35 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 36of 119
Informed consent procedure
The patient’s parent(s) / LAR(s) will be provided with full written and verbal informat ion about the 
trial prior to conduct of any trial -related procedures/act ivities, in accordance with GCP and local 
requi rements , see Section 17.1. 
A child assent form will be provided to patients above 3 y ears of age according to local 
requi rements. This can be performed on a separate day . As this is a l ong term  trial the invest igator
shoul d check the progressing maturation of the child and its abilit y to assent throughout the trial.
Inform ed consent including haemophilia B mutation genoty ping at screening must be obtained. 
Screening failures
Screening failures are defined as pat ients for whom  the parent(s)/LAR (s)have signed the Informed 
Consent Form but fail to comply with the inclusio n and /orexclusio n criteria or if the consent i s 
withdrawn pri or to dosing. 
For screening failures, the screening failure form in the electronic case report form (e CRF) must be 
completed with the reason for not continuing in the trial.
Serious and non -seriousadverse events (AE) from screening failures must be transcribed by the 
investigator i nto the case report form (eCRF) . Follow -up of SAEs must be carried out acco rding to 
Section11.3. A screening failure sessio nmust be made in the IWRS. The case book must be signed.
Re-screening is notallowed after the fi rst dose of tri al product –see excl. criteria no. 2 in Section 
6.3.
For withdrawn patients
Withdrawn patients are defined as patients who meet the withdrawal criteria after dosing, see 
Secti on 6.4
If a patient is wit hdrawn from the trial, the invest igator m ust aim  to perf orm the end of tr ial visit, as 
soon as possible except for patie nts with a high ti tre inhibitor.
The end o f trial form must be completed, and final drug accountabilit y must be performed even if 
the pati ent is not able to com e to the tri al site. A withdrawal  sessi on must be m ade in the IWRS and 
the case book must be signed. 
All data collected in the period the patient participated in the trial must be documented .
Although a patient or pati ent’s parent(s)/LAR(s) is not obliged to give his/her reason(s) for 
withdrawing from  a trial, the invest igator must make a reasonable effort to ascertain the reason(s), 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 36 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 37of 119
while fully respect ing the patient’s rights. Where the reasons are obtained, the primary  reason(s) for 
discontinuat ion must be specified on the end -of-trial form in the eCRF e.g.:
Adverse events (AEs)
Protocol  violation
Lack of efficacy
Lost to follow up
Withdrawal by pat ient or parent(s)/LAR(s) 
Technical problems
Other
End of trial 
The end o f trial (EOT) form shoul d be filled in at the End- of-Trial visi t or the l ast vi sit of the 
patient. If  a pati ent is withdrawn pri or to com pletion of the trial, all attempts must be made to 
sched ule the end of trial visit for the patient. 
For a pati ent wi th high titre inhibitor the EOT visit  shoul d be perform ed in connection wit h the thi rd 
follow-up visit . 
In general
Review of eDiary  reports, l aboratory  reports etc. must be documented either on the front page of the 
docum ents and/or in the patient’s medical record. 
In accordance with local law a caregiver may take over the responsibilit ies from the 
parent(s)/LAR(s) of handling and administrating the trial drug, filling in the eDiary and attendin g 
visits at si te. The caregiver m ust be trained to the sam e extent as the parent(s)/LAR(s) in the 
relevant responsibilit ies. 
Prior to a visi t the invest igator must request the patient’s parent(s)/LAR(s) to return any tri al 
medicat ion ,solvent or inject ion kits if this woul d expire during the fo llowing ho me treatment 
period. The pati ent’s parent(s)/LAR(s) must also be instructed in never using any expired trial 
materi als.
Any corrections made by the investigator to the eDiary  entries must be discussed with the patient’s 
parent(s)/LAR(s) and the concl usion docum ented in the medical record. Care mustbe taken not to 
bias the patient ’s parent(s)/LAR(s) .
8.1.1 Visit 0 –screening visit
The patient’s parent(s)/LAR(s) must give signed and dated info rmed consent pri or to any  trial 
related activit ies. Signing of the informed consent can take place before visit 0, if allowed by local 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 37 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 38of 119
law. All pat ients will be provided wit h a copy  on the pat ient informat ion and a copy  of the signed 
and dated Informed Con sent Form .
For all patients with a signed Informed Consent/Assent form, the patient will be assigned a unique 6 
digits pati ent number, which will fo llow the patient throughout the trial.
A screening period (interval between visit 0 (V0) and V1) is allowed unt il the first dose of N9- GP is 
requi red. 
The screening visit (V0) can be combined wit h the first treatment of N9 -GP (V1), hereby allowing 
patients to be enrolled in the trial and treated for their first bleeding episode immediately  after 
having confi rmed incl usion and exclusio n criteria.
All results necessary  for evaluat ing the inclusio n and exclusio n criteria mustbe available before 
determining whether or not the patient can continue in the trial and whether it will be possible to 
receive the first dose of N9- GPat the same day .
If the screening results do not become available during the screening visit, and if the next visit is not 
planned, the pati ent’sparent(s)/LAR(s) must be informed when eligibilit y has been evaluated by the 
investigator.
Asses sments for V0 are listed in Table 2–1.
Reminders:
Dispense tri al card, see Secti on 8.8.1
Screening call in the IWR S, see Secti on 10
Discuss treatm ent regimen: prophylaxis versus pre -prophylaxis
In case V1 is not planned or performed within 3 month fro m visit 0 the invest igator must 
contact the patient’s parent(s)/LAR(s) at least every  12 weeks ± 1 week , See Sections 8.8.4 and 
8.1.10 .
During the screening period the patient cannot be treated with commercially  available FIX 
product
8.1.1.1 Pre-prophylaxis treatment
Pre-prophylaxis is optional and is the period before start of regular prophylaxis. The pre -
prophylaxis period stops when the patient has reached 20 EDs or has turned 24 months of age, 
whatever co mes first.
During pre -prophylaxis the fo llowing dosing regimen sapplies: 
dosing wit h 40 IU/kg N9-GP
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 38 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 39of 119
individualised prophylaxis dosing intervals but less frequent than once weekly
on-demand treatm ent of  bleeding episodes
minor surgery
See further Section 5.3.2 and 5.3.8 .
Dosing visit s during the pre -prophylaxis period can be performed at any time unt il ED 20. Visits 
during the pre -prophylaxis period without dosing should be performed as unscheduled visits, see 
Secti on 8.1.10 . 
The site must make sure that the patient’s parent(s)/LAR(s) are contacted at least every 12 weeks ± 
1 week if no further visit is planned , Secti on 8.8.4. 
Visit 1-20 occurs when the patient needs treatment of a bleed and /or is planned individually  per 
patient at the invest igator and patient’s parent(s)/LAR(s) discret ion.
8.1.1.2 Prophylaxis treatment
Prophylaxis treatment can begin at visit 1 or at any time during the pre -prophylaxis period andmust 
be initiated latest when the patient has reached 20 EDs on pre -prophylaxis or has turned 24 months 
of age, whatever comes first.
The dosing frequency is once weekly ±1 day (preferable the same day  of the week).
For patients that enter the prophyl axis treatm ent after a peri od of  pre-prophylaxis the next visit in 
the sequence will be determined by the numbers of EDs. 
8.1.2 Visit 1 –first dosing with N9 -GP
Visit 1willtake pl ace af ter the screening visit (V0) whenever the first treatment of N9 -GP is 
administered, if not already  combined wi th V0.
Before administrating the first dose of N9 -GP the FIX inhibitor test for central laboratory must be 
taken and sent to c entral laboratory  for analysis. In case of s ubject ive signs of illness and/or fever 
within 48 hours pri or to the first inject ion of N9 -GPthe dose should be postponed, if possible.
The patient will cont inue treatment on either:
Pre-prophylaxis treatment . See Sections 5.3.2 and 8.1.1.1 .
Prophylaxis treatment .See Sections 5.3.3 and 8.1.1.2 .
Assessments for V1 are listed inTable 2–1. In case V0 and V1 have been combined into one visit, 
assessments should only be perform ed once , but recorded at both visits in the eCRF .
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 39 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 40of 119
Reminders
Next visit should be scheduled if applicabl e, see Secti ons 8.1.1.1 and 8.1.1.2
In case V2 is not planned or performed within 3 month sfrom visit 1 the Invest igator must 
contact the patien t’sparent(s)/LAR(s) at least every  12 weeks ± 1week. See Secti ons 8.8.4 and 
8.1.10 .
Drug accountabilit y of trial product at V1 m ust be recorded in the IWRS, see Sect ion 10
Recording of body  weight, see Secti on 8.3.1 , and dispensing of N9- GP for tri al site dosing via 
IWRS, see Section 10.
8.1.3 Visit 2 -20 – main phase
The 10 first N9 -GP exposure days (EDs) (V1-V10) must take place at the trial site. 
ED11-20 should preferable take place at trial site however administration can take pl ace outsi de the 
trial site, if
 a heal th care professio nal qualified of handling anaphylact ic react ions is present, see 
Secti on 5.3.5 . Visit 15 (ED 15 ± 1) and visit 20 (ED 20 ± 1) are m andatory  at si te due to bl ood 
sampling.
All doses shoul d be registered in the eCRF. In case the patient is treated outside the trial site the 
trial site shoul d be informed and the details her eof shoul d be entered in the eCRF.
Assessments for V 2-V20 are listed in Table 2–1.
Reminders
In case next visit is not planned or performed wit hin 3 month sfrom the previous visit the 
investi gator m ust contact the patient ’sparent(s)/LAR(s) at least every  12 weeks ± 1week. See 
Secti ons 8.8.4 and 8.1.10 .
Recording of body  weight, see Secti on 8.3.1 , and disp ensing of N9- GP for trial site dosing m ust 
be perform ed via IWRS, see Section 10
Drug accountabilit y of trial product m ust be recorded in the IWRS, see Section 10
eDiary dispensing , see Sect ion 8.8.3.1
eDiary training , see Secti on 8.8.3 and 12.3
8.1.3.1 Treatment outside trial site
It is the responsibilit y of the invest igator to ensur e the safet y of the p atient and adherence to the 
protocol , ICH, GCP and local regulations also when the pati ent is treated outside trial site.
Prior to all owing treatm ent outsi de tri al site at ED 11 to ED 14 and ED 16 to ED 19 theInvestigator 
must have a plan describing how this can be done in a safe and respo nsible manner. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 40 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 41of 119
The pl an shoul d be prepared for each individual patient and should describe the circumstances 
under which the treatm ent outsidetrial site is performed, e.g. how it can be ensured that a health 
care professio nal qualified to handle anaphylactic reactions can be present , how training is 
perform ed, and how appropriate documentation is obtained. The pl an must al so address that the 
patient may  need trial  drug at hom e/not at hom e. 
The pl an shoul d include an instruction for the patient’s parent(s)/LAR(s) with the di rections for use 
and describe the importance of having a healt h care professio nal present to handle anaphylact ic 
reacti ons during administrati onand how to act in case of emergency  bleeding episode s.
The process should be discussed with Novo Nordisk ,if applicable approved by IRB/IEC, and must 
always com ply wi th local regulati ons. 
8.1.4 Visit 21-22 – main phase
From  V21 all pat ients (including pat ients previously on pre -prophylaxis) will be on prophylaxis 
treatm ent wi th N9-GP. Between the visits the patient will receive N9-GP treatment at home if 
comfortable with ho me administrations or at the site, see Section 8.1.12
Visits at EDs: 30 ± 2 EDs, and 40 ± 2 EDs.
The visits shoul d be scheduled taking into account the patient’s regul ar dosing day in the week.
Assessments for V21 and V22 are listed in Table 2–1.
Reminders
An appo intment for the next visit should be made
Recording of body  weight, see Secti on 8.3.1 , and dispensing of N9- GP for si te dosing/home 
treatm ent m ust be perform ed via IWRS, see Section 10
Drug accountabilit y of trial product m ust be recorded in the IWRS, see Section 10
The Investigator must prior to the visit instruct the patient’s parent(s)/LAR(s) in returning any 
trial medicat ion, solvent or inject ion kits that would expi re during the following home treatment 
period
Hom e treatment training , if the trialsite suspects that the patient’s parent(s)/LAR(s) is not fully 
confident with administrati on and how to deal with safet y related si gns and symptom s, see 
Secti ons 8.5and Sections 8.6
eDiary training , see Secti on 8.8.3 and 12.3
eDiary com pliance review, see Sect ion 12.3.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 41 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 42of 119
8.1.5 Visit 23 –end of main phase
Visit 23 shoul d take pl ace at either ED 50, ED 51 or ED 52. 
Assessments for V23 are listed in Table 2–1.
Reminders
An appo intment for the next visit should be made
Recording of body  weight, see Secti on 8.3.1 , and dispensing of N9- GP for tri al site dosing/home 
treatm ent m ust be perform ed via IWRS, see Secti on 10
Drug accountabilit y of trial product m ust be recorded in the IWRS, see Section 10
The Investigator must prior to the visit instruct the patient’s parent(s)/LAR(s) in returning any 
trial medicat ion, solvent or inject ion kits that would expi re during the following home trea tment 
period
Hom e treatment training , if the tri al site suspects that the pati ent’s parent(s)/LAR(s) is not fully 
confident with administration and how to deal with safet y related s igns and symptoms, see 
Secti ons 8.5and 8.6
eDiary training, see Section 8.8.3 and 12.3
eDiary com pliance review, see Sect ion 12.3.
8.1.6 Visit 24 -27 – extension phase
The patient will cont inue prophylaxis throughout the extensio n phase, wi th 40 IU/kg N9 -GP once 
weekly. See Table 2–1.
Visits at EDs: 60 ± 2 EDs, 70 ± 2 EDs, 80 ± 2 EDs, and 90 ± 2 EDs.
The visit sshoul d be scheduled taking into account the patient’ s dosing day .
The durati on of  the extension phase is approximately 1 year for a pati ent to achi eve a total  of 100 
EDs.
Assessments for V24- V27 are listed in Table 2–1.
Reminders
An appo intment for the next visit should be made
Recording of body  weight, see Secti on 8.3.1 , and dispensing of N9- GP for tri alsite dosing/home 
treatm ent m ust be perform ed via IWRS, see Section 10
Drug accountabilit y of trial product m ust be recorded in the IWRS, see Section 10
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 42 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 43of 119
The Investigator must prior to the visit instruct the patient’s parent(s)/LAR(s) in returning any 
trial medicat ion, solvent or inject ion kits that would expi re during the following home trea tment 
period
Hom e treatment training ,see Secti on 8.1.12 and8.8.2.
eDiary training, see Section 8.8.3 and 12.3
eDiary compliance review, see Sect ion 12.3
8.1.7 Visit 28 -end of extension phase
V28 shoul d take pl ace at either ED 100, ED 101 or ED 102 .
Assessments for V28 are listed in Table 2–1.
Reminders
An appo intment for the next visit should be made
Recording of body  weight, see Secti on 8.3.1 , and dispensing of N9- GP for tri alsite dosing/home 
treatm ent m ust be perform ed via IWRS, see Section 10
Drug accountabilit y of trial product m ust be recorded in the IWRS, see Section 10
The Investigator must prior to the visit instruct the patient’s parent(s)/LAR(s) in returning any 
trial medicat ion, solvent or inject ion kits that would expi re during the following home trea tment 
period
eDiary compliance review, see Sect ion 12.3
8.1.8 Visit 29 -X until end of trial
After visit 29 visit s are scheduled 24 weeks ± 4 weeks apart. This schedule will last until End of 
Trial. 
At every  dosing visi t from V29-VX, drug will be dispensed to cover up to 3 months of treatment. If 
the visit is a N9- GP di spensing visit only , the pati ent is not required to attend the clinic only  for th is 
purpose. Assessments for V29
-X are listed in Table 2–1.
Reminders
An appo intment for the next visit should be made
Recording of body  weight, see Secti on 8.3.1 , and dispensing of N9- GP for tri alsite dosing/home 
treatm ent m ust be perform ed via IWRS, see Section 10
Drug accountabilit y of trial product m ust be recorded in the IWRS, see Section 10
The Investigator must prior to the visit instruct the patient’s parent(s)/LAR(s) in returning any 
trial medicat ion, solvent or inject ion kits that would expi re during the following home treatment 
period
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 43 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 44of 119
eDiary compliance review, see Sect ion 12.3
8.1.9 End-of-trial visit
The EOT vi sit is the last visit in the trial. 
The EOT will take pl ace after com pletion of at least 100EDs or if the pat ient is withdrawn fro m the 
trial.For a pati ent wi th high ti tre inhibitor the EOT visit should be performed in connect ion with the 
third inhibi tor follow -up visit, for scheduled visits other than inhibitor follow- up visit s, the EOT 
visit may  replace a scheduled visit if this scheduled visit is scheduled within two weeks of the 
planned EOT visit . 
Assessments for the EOT are listed in Table 2–1.
Reminders 
Drug accountabilit y of trial product m ust be recorded in the IWRS, see Section 10
eDiary com pliance review, see Sect ion 12.3
eDiary LogPad collect ion, see Section 8.8.3.1
Com plete EOT form
8.1.10 Unscheduled visit 
Unscheduled visits of trial related character can be performed at any  time during the trial and the 
purpose m ust be docum ented.
The fo llowing forms can be found in the unscheduled visit in the eCRF:
Central  lab
Dosing o f N9-GP
Surgery  (Record on ‘unscheduled visit ’ form in eCRF even if performed on a regular visit)
PK sessio n (Record on ‘unscheduled visit’ form in eCRF even if performed on a regular vis it)
8.1.11 Inhibitor Follow -Up visit 
The inhibitor follow-up visi t (IFU) shoul d be perform ed when a pati ent has a confirmed high titre 
inhibitor ( ≥5BU) accordi ng to secti on 8.4.2.2 . The patient must be withdrawn from N9 -GP 
treatm entupon confirmat ion of the second test of high titre inhibitor .Three inhibitor fo llow-up 
visitsmust be scheduled with 4 weeks ±7days inter val after confirmat ion of the inhibitor.
The end o f trial visitand EOT assessments should take place in connection wit h the third IFU visit.
The IWRS wit hdrawal sessio n should not be perform ed before EOT visit.
In case the patient has been treated with FIXcoagulat ion factors including plasma -derived act ivated 
prothrombin co mplex concentrates (pd-aPCC) within 4 days or FVIIa wi thin 1 day  prior to the fi rst 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 44 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 45of 119
inhibitor follow up visit, the visit must be postponed, please refer to Section 8.4.2.2 for further 
details.
In the rare case where a patient develops N9-GP binding antibodies and where it at the same time is 
evaluated by the Invest igator that the patient should not continue in the trial based on e.g. decreased 
drug efficacy, the patient should attend inhibitor follow up visits similar to those described for 
patients wi th inhibitors.
Assessments to be performed
Adverse Events
Concomitant medicat ion
Sampling for inhibitor test
Sampling for FIX activit y test
Sampling for N9 -GP binding antibodies
Sampling for Lupus anticoagulant
Reminder
Follow up on any  AEs according to Section 11.2
8.1.12 Home treatment
Hom e treatment wi th N9-GP can commence any  time after the first 20 EDs and the patient’s 
parent(s)/LAR(s) are comfortable with the reconst itution and administration process. See Section
5.3.5
8.1.12.1 Prophylactic home treatment
During m ain and extensio n phase, the dose for prophylaxis is 40 IU/kg once weekly  ±1 day , See 
Table 5-1and Section 8.5
Bleeding episodes must be treated as described in Section 8.6.
The fo llowing procedures must be performed during ho me treatment between visits:
N9-GP administrations once weekly ±1 day (preferable same week day)
Prior to each N9 -GP administration the patient’s parent(s)/LAR(s) must check that neither N9 -
GP, solvent nor inject ion kit have expi red
Contact to the invest igator/medically qualified person in case of severe bleeding episodes or if 
bleeding episodes has not responded sufficient ly to treatment within 24 hours
Com pletion of the patient eDiary , including details of all bleeding episodes and N9- GP 
administrations 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 45 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 46of 119
8.1.12.2 Home treatment of bleeding episo des
Bleeding episodes must be treated as soon as identified according to Table 5-1and Section 8.6. 
Patient’sparents(s)/ LAR(s) will be instructed by  the invest igato r on how to treat their child for a 
bleeding episode at home and how to record this in the eDiary.
The following procedures must be performed
N9-GPadministration for treatment of any bleeding episodes , see Secti on 8.6
Com pletion of the patient eDiary , including details of all bleeding episodes and N9-GP 
administrations.
8.2 Patient related information
8.2.1 Concomitant illness and medical history
Aconcomitant illness is any illness that is present at the start of the trial at the first visit,(V0) or 
found as a result of a screening procedure . All concomi tant illnesses shoul d be reported including
the disease under invest igation.
Medical history is a medical event that the patient has experienced in the past, which should be 
obtained during the screening procedure including haemophilia treatment history . In the event that a 
diagnosis is unknown, the descript ion of symptoms will be recorded. All significant symptom s 
and/or illnesses since births should be recorded.
The informat ion collected for concomitant illness and medical history should include diagnosis, 
date of onset anddate of reso lution or continuat ion, as applicable .
Any change to a conco mitant illness should be recorded during the trial. A clinically significant 
worsening of a conco mitant illness must be reported as an AE.
8.2.1.1 Details on haemophilia and haemophilia treatment history
All available information on haemophilia ,prior to screening shoul d be recorded including 
diagnosti c FIX activit y level , if known. If possible , informat ion about relat ives with haemophilia B 
and inhib itors shoul d be obtained.
Any previous exposures to FIX concentrates and/or blood product components prior to visit 0 must 
be recorded incl. t ype or brand, dose/kg body weight and date of administration
8.2.1.2 Allergies
Any allergies, including any drug sensit ivities should be recorded . 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 46 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 47of 119
8.2.2 Concomitant medication
A concomitant medication is any medicat ion including vaccinat ion, other than the investigational 
medicinal product ( N9-GP), which is taken during the trial until EOT.
Details o f any conco mitant medicat ion must be recorded at the first visit , (V0) . Changes in 
concomitant medicat ion must be recorded at each visit as they  occur.
The informat ion collected for each conco mitant medi cation includes (at a minimum) trade name or 
generic name, indicat ion, start date and stop date or continuat ion.
If a change in medicat ion is due to an AE, then this must be recorded and reported according to 
Section 11.2. If the change influences the patient’s eligibilit y to continue in the trial, the monitor 
must be informed.
8.2.3 Treatment of bleeding episodes in low titre inhibitor patients <5 BU
Bleeding episodes in low titre inhibitor patients that do not respond sufficient ly to N9 -GP treatment 
may in addit ion be treated with bypassing agents accordin g to l ocal label for a peri od of  up to 2 
years. It is recommended to avoid FIX containing bypassing agents. Patients will stay in the tri al 
and continue the 40 IU/kg N9-GP tr eatment. The time of administration of other haemostatic 
medicat ion (including bypassing agents) should be entered in the eCRF/eDiary. 
8.2.4 Prohibited medication
Treatments with other FIX concentrates are not allowed, during the course of the trial. 
If possible, use of Tranexamic acid shoul d be avoided.
Heparin sealing of central venous access ports and cannula is allowed .
8.2.5 Demograph y
Dem ographic data will be collected as allowed per local law:
Date of birth, year or age (year:m onths)
Ethnicit y 
Race
8.3 Clinical assessments 
Clinical assessments should preferably be performed prior to blood sampling and prior to 
administration of N9-GP unless it is stated otherwise. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 47 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 48of 119
8.3.1 Body measurements
Height will be collected at visit s according to Table 2–1. F or pati ents who have already attended 
visit 23 and/or visit 28 height at these visits ± 1 month will be collected retrospectively if 
available in medical records upon parent(s)/LAR(s) consent
Body  weight, wearing light clothing only
Body  weight shoul d be measured in connect ion with regularly visits where trial drug isdispensed. 
For practical purposes when dispensing trial drug the body  weight from an earlier m easurement (or 
visit) can be used if the measurement was performed within the previous 12 weeks (in children < 3 
years o f age, within 6 weeks). After visit 29, a body weight measured within the previous 12 weeks 
for all age groups c an be used. If new body  weight is not needed to be measured at a visit, the body  
weight from last wei ghing shoul d be used.
8.3.2 Physical examinations
The physical examinat ions will be performed according to local procedure and should include:
General appearance
Head, ears, ey es, nose, throat and neck
Lymph node palpat ion
Abdo men
Skin
Respiratory  system
Musculoskeletal system
Central  and peri pheral  nervous systems (general evaluat ion)
Elaborated neurologic alexamination, see Section 8.3.2.1
Cardi ovascular system
8.3.2.1 Neurological Examination 
Following aspect sof the neurological examinat ion will be assessed:
General appearance including language, social and developmental aspects, h andedness, head 
circumference, fontanelle assessment (<18 months), and level o f consciousness
Cranial nerves in relat ion to sight including react ion to light, visual fields and acuit y, and eye 
movements, facial sensat ion and m ovement, hearing, palate sound and tongue movement, and 
trapezi us muscle funct ion
Tone of truncal, upper and lower extremit y right and left, and general tone (<18 months)
Strength of upper and lower extremit y right and l eft
Reflexes of biceps, triceps, knee and ankle jerk, all right an d left, Babinski  as well as infant ile 
reflexes (<6 months)
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 48 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 49of 119
Sensory  aspect of col d, pin pri ck, light touch and proprioception (toe up/down)
Gait with regards to walking, running, on heels and toes, tandem (toe/heel walk), stand/hop on 
one l eg/foot ri ght and left, and Ro mberg sign
Coordinat ion and Fine Motor including finger -to-nose, rapid index finger tab and rapid finger 
movement right and left 
The timing of the n eurol ogical assessments shoul d be planned to allow as much flexibilit y for the 
patients as possible and can be made within ±1 month of the visit s, except for the visit 1 and EOT 
visit where the neuro logical assessments can be made at the visit date or up to 1 month ahead of the 
visit. In addit ion to thi s after trying to obtain the various assessments within acceptable limits 
without success the individual assessments ca n be omitted . Moreover, s ome aspects of the 
neuro logical examinati on may not be applicable for children in particular age groups as evaluated 
by the Invest igator .Each aspect of the neurological examinat ion will be categorised into normal, 
abnorm al (pre -exist ing or new) or not examined .
8.3.3 Neurocognitive assessments
Neurocognit ive assessments should be performed according to Table 2–1, Table 2–2, Table 8-1and 
Table 8-2
The fo llowing dom ains will  be assessed in all countri es:
Execut ive function 
Attention/processing speed /working memory  
Further, the fo llowing dom ains will be assessed in English speaking countries (e.g. Australia, 
Canada, United Kingdo m, and the United States ):
Neurodevelopment or cognitive function and intelligence 
Emotional behaviour 
Adapt ive behavi our
The timing of the neurocogni tive assessments should be planned to allow as much flexibilit y for the 
patients as possible and can be made within ±1 month of the assessment visits, except for the visit 1 
and EOT visit where the neurocognit ive assessments can be made at the visit date or up to 1 month 
ahead of the visit. The f irst assessment should be planned for the visit immediately  afterthepatient 
turns either1or 2yearsof age depending on country . Hereafter the visit schedule as found in Table 
8-1and Table 8-2shoul d be fo llowed except if the next planned assessment visit is wit hin three 
months of the init ial assessment. All assessments shoul d be perform ed using generally  accepted 
standardi sed test ing parameters to ensure opt imal condit ions for performance. A descript ion of
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 49 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 50of 119
neurocognit iveassessments, training, equipment and related procedures will be provided in the
Manual for neurocognit ive assessments.
An independent External Expert Review Panel will evaluate the results of the neurocognitive 
assessments in context of the Structured Developmental History  and Haemophilia History  for each 
patient. Informat ion regarding responsibilit ies, procedures , meeting frequency and workflow to be 
used by the External Expert Review Panel arespecified in the External Expert Review Panel 
charter.
A CRO will provide the results from the External Expert Review Panel to Invest igator as narrative 
reports including normalised domain scores and categorical assessment . It is the responsibilit y of 
the Invest igator to report any findings if considered qualifying for an AE. If any findings are present 
at V0 i t shoul d be recorded as medical history . 
The fo llowing Structured Developmental History and Haemophilia History  data will be collected in 
connection wit h the neurocognitive assessments:
Dem ographics
Parents/caregivers
Brothers/sisters/other children
Child´s residence
Pregnancy
Birth
Development
Medical history
Family  health
Educati onal history
Haem ophilia history
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 50 . -  | 1
 |
CONFIDENTIAL
Protocol UTN: U1111 -1135-9557 Date: 05 November 2019 Status: Final Novo Nordisk
Trial ID: NN7999 -3895 EudraCT No.: 2012 -004867 -38 Version: 8.0 Page: 51of 119
  Table 8-1 Neurocognitive assessments by age for all countries 
Dom ainStructured Developmental History 
and Haemophilia HistoryExecutive Function Attention / Processing Speed
Assessment visitsThe first assessment should be planned for the visit immediately after the patient turns 2 years of age. Hereafter the follow ing 
visit schedule should be followed except if the visit is within 3 months from the initial assessment: Visit 1, visit 20, visit 23, visit 
26, visit 28, visit 29, and all subsequent visits until and including EOTPatient age (year:months)
1:0 to 1:11
2:0 to 3:6 Structured Developmental History 
and Hae mophilia HistoryBRIEF -P (BRIEF -P 2:0 -5:11y Parent)
3:7 to 3:11Structured Developmental History 
and Hae mophilia History BRIEF -P (BRIEF -P 2:0 -5:11y Parent)
4:0 to 5:11 Structured Developmental History 
and Hae mophilia History BRIEF -P (BRIEF -P 2:0 -5:11y Parent)  (Custom Battery -Peds (4 -9)
6:0 to 6:11Structured Developmental History 
and Hae mophilia History BRIEF -2 (BRIEF2 5 -18y Parent)  (Custom Battery -Peds (4 -9)
7:0 to 7:11 Structured Developmental History 
and Hae mophilia History BRIEF -2 (BRIEF2 5 -18y Parent)  (Custom Battery -Peds (4 -9)
8:0 to 9:11Structured Developmental History 
and Hae mophilia HistoryBRIEF -2 (BRIEF2 5 -18y Parent)  (Custom Battery -Peds (4 -9)
10:0 to 10:11Structured Developmental History 
and Hae mophilia HistoryBRIEF -2 (BRIEF2 5 -18y Parent)  (Custom Battery -Adult (10 -21)VV-TMF-1261484|1.0|NN7999 -NN7999-3895
  Protocol  v 8|51 of 119
CONFIDENTIAL

Protocol UTN: U1111 -1135-9557 Date: 05 November 2019 Status: Final Novo Nordisk
Trial ID: NN7999 -3895 EudraCT No.: 2012 -004867 -38 Version: 8.0 Page: 52of 119
  Table 8-2 Additional neurocognitive assessments by age for English speaking countries (e.g. Australia, Canada, United Kingdom, 
and the United States)
Dom ainDevelopmental History and 
Haemophilia HistoryNeurodevelopment / General 
Intelligence Behavioural / Emotional Adaptive behaviour
Assessment visits The first assessment should be planned for the visit immediately after the patient turns 1 year of age. Hereafter the following visit 
schedule should be followed except if the visit is within 3 months from the initial assessment: Visit 1, visit 23, visit 28, visit 30, 
visit 32, visit 34, …, until and including EOTPatient age (year:months)
1:0 to 1:11Structured Developmental History 
and Hae mophilia HistoryBayley -IIIABAS- 3 (0-5y Parent)
2:0 to 3:6Structured Developmental History 
and Hae mophilia HistoryBayley -IIIBASC3 (PRS -P Parent 2 -5) ABAS- 3 ( 0-5y Parent)
3:7 to 3:11Structured Developmental History 
and Hae mophilia HistoryBASC3 (PRS -P Parent 2 -5) ABAS- 3 (0-5y Parent)
4:0 to 5:11Structured Developmental History 
and Hae mophilia HistoryWPPSI-IVBASC3 (PRS -P Parent 2 -5) ABAS- 3 (0-5y Parent)
6:0 to 6:11Structured Developmental History 
and Haem ophilia HistoryWPPSI-IVBASC3 (PRS -C Parent 6 -11) ABAS- 3 (5-21y Parent)
7:0 to 7:11Structured Developmental History 
and Hae mophilia HistoryWASI-II BASC3 (PRS -C Parent 6 -11 
form)ABAS- 3 (5-21y Parent form)
8:0 to 9:11Structured Developmental History 
and Hae mophilia HistoryWASI-IIBASC3 (PRS -C Parent 6 -
11form and SRP -C 8-11 patient 
form)ABAS- 3 (5-21y Parent form)VV-TMF-1261484|1.0|NN7999 -NN7999-3895
  Protocol  v 8|52 of 119
CONFIDENTIAL
Protocol UTN: U1111 -1135-9557 Date: 05 November 2019 Status: Final Novo Nordisk
Trial ID: NN7999 -3895 EudraCT No.: 2012 -004867 -38 Version: 8.0 Page: 53of 119
  10:0 to 10:11Structured Developmental History 
and Hae mophilia HistoryWASI-IIBASC3 (PRS -C Parent 6 -11 
form and SRP -C 8-11 patient 
form)ABAS- 3 (5-21y Parent form)VV-TMF-1261484|1.0|NN7999 -NN7999-3895
  Protocol  v 8|53 of 119
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 54of 119
  8.3.4 Vital signs
When dosing the first time (V1), vital signs should be recorded pre -dose and post -dosing of N9 -GP. 
Hereafter vital signs will only be measured pre- dose and according to Table 2–1.
Before measurement of vital signs the patient should preferably rest comfortably for at least 
threeminutes and all measurements should, if possible, be performed using the same method and 
position (e.g. si tting) throughout the trial for each individual patient. 
Vitals signs include assessment of:
Body  temperature (C/F)
Blood pressure (BP) (mm Hg)
Pulse (beats/min)
If not possible to perform so me or all o f the above measurements, it is allo wed to eval uate the child 
for normal  appearance checking for signs and symptoms of acute or chronic disease.
If a change in clinical assessments after V0 is due to an AE, then this must be recorded and reported 
according to Section 11.2.
8.4 Laboratory assessments
Blood samples for laboratory  analysis of safet y, and efficacy parameters will be drawn as outlined 
in Table 2–1. Approximate total vo lumes of blood to be taken fro m each pat ient see Section 8.4.3 .
The sample taken 30 minutes (±10 minutes) post- dose can be taken fro m the sam e vein as used for 
administration of N9 -GP if more than 30 minutes have passed after the inject ion. The same devic e 
used for trial drug inject ion cannot be used for blood draw post -dose.
Laboratory  resul ts being out of norm al range m ust be categori sed as “out of normal range, not 
clinically significant” or “out of normal range, clinically significant”. A laboratory  result evaluated 
as “out of normal range, clinically significant” must be recorded as an AE, or if present at V0 it 
shoul d be recorded as concomitant illness.
The central laboratories provide results to the trial site in the units preferred by the trial sit es while 
the resul ts that are transferred to the trial database will always be in SI units.
The l aboratory  equi pment m ay provide analyses not requested in the protocol but produced 
autom atically in connection wit h the requested analyses according to specif ications in the laboratory  
standard operating procedures. Such data will not be transferred to the eCRF or the trial database, 
but abnormal values must be reported to the investigator. 
The invest igator must review all laboratory results for concomitant il lnesses and AEs and report 
these according to this protocol.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 54 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 55of 119
  8.4.1 Local laboratory assessments 
The tri al site must be able to analyse for F IXactivity  and inhibitors locally if needed to decide on 
the appropriate medical care. Results of any a nalyses performed locally  will not be recorded in the 
eCRF except for results at Visit 0.
Local  laboratory  resul ts are consi dered as source data and must be signed, dated and categorised by  
the invest igator. 
Storage handling, and disposit ion of samples analysed at local l aboratori es will  be perform ed 
according to local laboratory  procedures.
8.4.1.1 FIX activity
FIX activit y (% or IU/m L)
If V0 and V1 are combined, as one combined screening visit, and if F IXactivity ≤ 2% has not been 
docum ented in the pati ent m edical  records, i t should be analysed locally and documented in the 
patient medical records.
FIX activit y can be m easured using a one -stage cl otting or a chrom ogenic assay . If an aPTT based 
one-stage clotting assay  is used i t shoul d be calibrated wi th a N9 -GP reference standard. 
The reference standard will be provided by  Novo Nordi sk together wi th a descri ption of how to 
handle, store and use. The site must ensure that the reference s tandard has not expired and order 
new when relevant.
Dependent on the ty pe of aPTT reagent used by  the l ocal laboratory  an exempt ion from this 
requi rement of using the N9- GP reference standard can be made, in such cases Novo Nordisk will 
need to approve th e suggested assay  set-up on an individual basis. For approval of aPTT reagents in 
the one -stage clotting assay the invest igator must contact Novo Nordisk.
FIX activit y may also be measured wit h a chro mogenic assay if available at the local laboratory . In 
such cases the N9 -GP reference standard is not needed.
8.4.2 Central laboratory assessments 
Central  laboratory  will throughout the protocol cover both the central laboratory  as well  as 
specialised laboratory  analysing samples for all sit es. The central laborator y will analyse and report 
all laboratory  data to Novo Nordisk A/S electronically  in a manner that anonymit y of pat ients will 
be maintained. The central laboratory  resul ts will be reported to the invest igator. 
The qualit y control of the central laboratory  test resul ts will  be perf ormed according to the 
regul ations and specificat ions set by the authorit ies at the l ocati on of  the central  laboratory  used for 
this trial.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 55 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 56of 119
  A detailed description o f procedures for sampling, handling, shipment of laboratory  samples and all 
materi als such as test tubes and labels will be provided in the laboratory  manual  by the central  
laboratory . The central  laboratory  manual and the central laboratory  resul ts will include the 
reference ranges.
8.4.2.1 FIX activity
The analysis of plasma FIX activit y will be performed at a laboratory  selected by  Novo Nordi sk 
A/S or at a Novo Nordisk laboratory . The procedures for analyses will fo llow the recommendat ions 
provi ded by Novo Nordisk A/S. A description o f the method will be included in the final report of 
this trial.
FIX activit y samples shoul d be taken according to Table 2–1.
FIX activit y will be measured by the use of the FIX one -stage clo tting assay.
Until the implementation of Amendment 6 to the protocol any surplus samples were analysed for 
FIX activit y using the chrom ogenic assay  if deemed rel evant.
One-stage clotting assay
The FIX one -stage clotting assay  is a m odified act ivated partial thromboplast in time (aPTT) assay.
The one -stage assay  measures the activit y of the compound in a specific process (clot format ion).
8.4.2.2 Antibody assessments
The analysis will be performed at a laboratory  selected by  Novo Nordi sk A/S or at a Novo Nordi sk 
laboratory . The procedures for analyses will fo llow the recommendat ions provi ded by Novo 
Nordi sk A/S. A descript ion of the method will be included in the final report of this trial.
Plasma sam ples will be collected for assessment of:
N9-GP binding antib odies 
FIX inhibitors
HCP ant ibodies
Antibody  samples shoul d be taken according to Table 2–1.
N9-GP binding antibodies 
Screening for antibodies is based on assays that are validated according to internat ional recognised 
guidelines.14-16Samples m easured above the assay  cut-point will be subject to a confirmat ion test. 
Samples posi tive in the confirmatory  test will be characterised for specificit y to N9 -GP, rFIX, and 
PEG. Isoty ping of the anti -drug ant ibodies will possibly also be performed. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 56 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 57of 119
  Samples will  be analysed regul arly for N9 -GP b inding antibodies and will be reported to the 
investi gators at the end of the trial , or when considered relevant . A posit ive binding ant ibody  
sample will not by  itself call  for any act ion, but will be part of the continuous evaluat ion by sponsor 
of patientsafet y and treatm ent efficacy. In case of clinical suspici on of  reduced treatm ent efficacy, 
an unscheduled visit must be scheduled by the investigator for measurement of FIX inhibitors, N9-
GP binding ant ibodies and peak/trough FIX activit yrespect ively .
FIX inhibitors 
A FIX inhibitor test is defined as posi tiveif the titre is ≥0.6 BU. 
A pat ient has inhibitory  antibodies (inhibitor) if tested posit ive for inhibitors ( ≥0.6 BU) at two 
consecut ive tests performed at the central laboratory and also tested posi tive for N9 -GP binding 
antibodies .
If the result of an inhibitor test is positive, a second confirmatory  inhibi tor test shoul d be perform ed 
by the central  laboratory  (except for the visit 1 sample that will not need to be confirmed). The 
confir matory  samples should be collected between 1 and 4 weeks after the first positive inhibitor 
test, but no sooner than 7 days after the last dose of N9 -GP. Sam pling for assessments of FIX 
activit y (trough and recovery ), N9-GP binding ant ibodies and lupus ant icoagul ant must also be 
perform ed at the same time. 
If the result from the lupus ant icoagulanttest i s posi tive and N9 -GP binding ant ibody test is 
negat ive the patient is considered inhibitor negat ive and can continue in the trial . Ifthe resul t from 
the lupus anticoagulant test is posit ive and N9 -GP binding ant ibody  test i s posi tive the patient is 
considered inhibitor posit ive.
The confirmatory  test will define the level of inhibitors. Inhibitors will be considered a s low ti tre 
between 0.6 BU and <5 BU a nd high titre ≥ 5 BU .
If a patient has a confirmed high titre inhibitor N9 -GP treatment must be stopped and inhibitor 
follow-up visits must be planned, see Sect ion 8.1.11.
If FIX inhibitor development is suspected during the course of the trial due to for instance increased 
number of bleeding episodes, bleeding episodes difficult to treat, recovery  and trough l evels below 
expected values or a positive local inhibitor test, the patient must attend an unscheduled visit as 
soon as possible and a plasma sample must be shipped to a central laboratory  for inhibi tor analysis.
If an invest igator decides to perform inhibitor testing locally, he/she must send a duplicate sample 
for inh ibitor testing at a central laboratory . The resul ts from the central  laboratory  will be used in 
the analysis o f trial data. A posi tive inhibitor test must always be reported as a MESI irrespect ive of 
the test being performed locally or at the central laboratory  (refer to Secti on 11.2, 11.1 ).
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 57 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 58of 119
  Assessment for FIX inhibitors will be carried out using a heat modified Nijmegen FIX Bethesda 
assay analysed at a central laboratory . The assay  is validated according to internat ional recognised 
guidelines .14, 17The assay is based on measurement of the abilit y of a plasma sample to inhibit FIX 
in norm al plasma.
PK session (conditional) 
In the event of a concern about reduced treatment efficacy  it is strongly reco mmended to perform an 
unschedule d visi t where pre-dose and 30 min post- dose FIX activit y (through and peak) and binding 
antibodies will be assessed. In case o f development of binding ant ibodies a PK sessio n is 
recommended to be performed with a dose of 40 IU/kg . The PK sessio n will help to address the 
impact on the efficacy  of the N9 -GP treatment. 
Novo Nordisk can decide based on bleedings, N9 -GP usage and the PK profile to call for a safet y 
committee meet ing regarding recommendat ion on the trial cont inuation o f the pati ent and how the 
patient shoul d be f ollowed if reco mmended to con tinue in the trial. The invest igator will be 
inform ed of the recommendation fro m the safet y committee.
The suggested time -points for bl oodsampling for aPK profile sessio n are: pre-dose (within 1 hour 
prior to dosing ), 30 min (± 10 min), 24 h (± 8 h), 48 h (± 8 h) . Opti onal time-points are 72 h (± 8 h) 
and 96 h (± 8 h).
HCP antibodies 
All patients will be assessed for the development of ant ibodies against Chinese hamster ovary host 
cell proteins (HCP). Screening for Chinese hamster ovary  HCP ant ibodies is based on assays that 
are validated according to internat ional recognised guidelines.14-16Samples measured above the 
assay cut -point will be subje ct to a confi rmation test, where the signal will be sought inhibited with 
excess HCP ant igen. The samples will be analysed at a laboratory selected by Novo Nordisk A/S or 
at a Novo Nordisk laboratory .
HCP ant ibodies will be taken according to Table 2–1. Samples will be analysed at the end of the 
trial, or when confirmed relevant by Novo Nordisk .
8.4.2.3 HIV testing and CD4+ lymphocyte count 
All patients will be assessed for HIV a t visit 0, if status is unknown, or if HIV negat ive results in 
medical record are older than 6 months. Sampling can be postponed to the earliest convenient visit 
to ensure that the allowed blood volume is not exceeded .
Tests for CD4+ l ymphocy te count and HIV viral load are only required for HIV posit ive pat ients. 
HIV posi tive pati ents shoul d have CD4+ lymphocy tes >200/µL and the HIV viral load <400,000 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 58 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 59of 119
  copies/mL. If the patient is not immunocompetent according to the above ment ioned cri teria 
relevant anti -HIV treatm ent shoul d be ini tiated.
Results can be transferred from the medical records if obtained wit hin the last 6 months. 
HIV antibodies (posi tive/negative)
CD4+ lymphocy te count 
HIV vi ral load
HIV and CD4+ samples shoul d be taken according to Table 2–1.
8.4.2.4 Haematology
Haem oglobin ( g/L)
Haematocrit (%)
Leucocy tes (x109/L)
Thrombocy tes (x109/L)
Haematology  samples shoul d be taken according to Table 2–1however
If test results for the above ment ioned haematology  parameters are available from within one 
monthprior to V0 they can be used for the V0 haematology  assessment
If test resul ts are  more than one month old at visit 0  a new sample must be drawn and shipped 
for analysis at the central laboratory
If V1 is more than a month afterV0a new h aematol ogy sample for central laboratory  must be 
drawn at visit 1 prior to administration the first dose of N9- GP. 
Results fro m haematol ogy samples taken with in±1 month of visits 23 and 28, or within 1 
month before EOT, can be used for the respective visit s if analysed at the central  laboratory .
8.4.2.5 Biochemistry
The fo llowing analyses will be performed by  the central  lab 
Creatinine 
Alanine aminotransferase (ALT) 
C-reactive protein (CRP) 
Urea / BUN 
Total  bilirubin 
And to the extent the blood volume co llected allows:
Sodium
Potassi um
Albumin 
Aspartate aminotransferase (AST) 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 59 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 60of 119
  Gamma glutamyl transferase (GGT)
Alkaline phosphatase
Biochemistry samples shoul d be taken according to Table 2–1; however
If test results for c reatinine , alanine aminotransferase , and C-reactive protein are available 
from within one month prior to V0 they can be used for the V0 biochemistry assessment
If V1 is m ore than a m onth after V0a new b iochemistry  sample for central laboratory must 
be drawn at visit 1 prior to administrating the first dose of N9- GP
If biochemistry  assessments at V0 were local assessment sa new b iochemistry  sample for 
central  laboratory  must be drawn at V1 prior to administrating the first dose of N9- GPif the 
blood volume allows
Results fro m biochemistry samples taken wi thin± 1 month of visits 23, visit 26, and at all 
visits from visit 28to EOT visi t can be used for the respective visits if analysed at the 
central  laboratory .
8.4.2.6 F9and HLA genotype testing
At Visit 0, all pat ient’s parent(s)/LAR(s) will be asked about documentation of previous F9 and 
Hum an Leucocy te Ant igen ( HLA ) genoty petests and results should be recorded in the eCRF, if 
available . If not available or if it needs to be re -tested, based on the invest igators discret ion, F9 and 
HLA genotype sample shoul dbe taken prior to administrating the first dose of N9 -GPor as soon as 
possible taking the limitat ion of the allowed blood sampling vo lume into account. The F9 and HLA
genoty peanalysis will be performed at a laboratory  selected by  Novo Nordi sk A/S . No analysis will 
be perform ed concerning other genes than F9 and HLA .Samples wil l be disposed appropriately 
after the test and all test results are kept confidential .
Only applicable for Israel: The parent(s)/LAR(s)/caregiver of w ithdrawn trial patients enrolled 
under protocol version 1, dated 4 November 2013, w ill be approached for c onsent to obtaining the 
F9 genotype, if already available. 
8.4.2.7 Investigation of allergic reactions
Allergic reaction testing will only  be perform ed in pati ents developing a severe allergic react ion 
which by  the invest igator is assessed to be related to the N9 -
GP treatment. The baseline sample 
taken at Visit 0 or Vi sit 1 pre -dose will only be analysed in this case and further blood sam ples 
shoul d be taken at an unscheduled visit as soon as convenient, but no later than 2 months after the 
event. The allergic react ion assessments will be performed at a laboratory  selected by  Novo Nordi sk 
A/S or at a Novo No rdisk laboratory . 
Tests to be performed: 
N9-GP IgE antibodies
FIX IgE antibodies
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 60 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 61of 119
  FIX inhibitors
Tryptase
N9-GP/rFIX binding antibodies
Other supportive allergic tests related to an allergic reaction may be performed by Novo Nordisk:
HCP IgE antibodies
HCP IgG antibodies
Histamine ( Only  relevant if sample is drawn within 15 min of the allergic reaction )
Com plement activat ion test (C3, C4) ( Only relevant if sample is drawn wit hin 15 min of the 
allergic reaction )
If relevant, baseline levels for optional testscan be set using samples fro m other pati ents enrolled in 
the trial.
Patientsdeveloping a severe allergic react ion should be carefully  invest igated and followed up for 
inhibitor development.
8.4.2.8 Urinalysis
Urine samples shoul d be taken according to Table 2–1. Urin e samples shoul d be obtained if 
possible , but to increase flexibilit y for pati ent, i t can be m ade at home same day  of visit and brought 
to site if transported in a cooling bag. The fo llowing parameters will be evaluated based on a urine 
sample:
Albumin/Creat inine ratio
Blood
Leucocy tes
Protein
Glucose
pH
Albumin/ Creatinine ratio will be measured at the central laboratory  the rest will be analysed wit h 
dip-stick at site.
8.4.2.9 Exploratory analysis of PEG in plasma
The plasma concentration of PEG will be analysed for exploratory  purposes according to Table 2–1. 
Blood sam ples f or PEG analysis should be taken at visit 0 taking the limitat ion of the allowed blood 
sampling vo lume into account. If not taken at visit 0 the blood sam pleshoul dbe taken at visit 1 pre -
dose, if the blood volume allows.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 61 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 62of 119
  8.4.3 Blood sampling in infants and children
The blood sampling vo lume for the pati ent m ust not exceed 1% of the total blood volume at one 
occasi on or 3% wi thin in 28 days. This is in accordance with European regulatory  guidelines 
(Directive 2001/20/EC).18
If all samples are taken t he total vo lume of blood to be collected for each patient per visit will not 
exceed 18 mL.
Detailed instructi ons will be provided to the trial sites regarding blood sampling vo lumes and 
priori tisation of samples. If trial sites as part of routine assessments perform addit ional blood draws, 
they must ensure that the blood sampling volume will not exceed the above requi rements.
It is recommended not to attempt venepuncture more than 3 times for the purpose of obtaining 
sufficient blood sampling. Documentation must be available in medical records .The vein used for 
trial drug inject ion cann otbe used for blood sampling unt il more than 30 minutes have passed after 
the inject ion. The same device use dfor trial drug inject ion cann otbe used for blood draw post -dose.
Port-a-caths and other central venous access devices should preferably not be use d for blood 
sampling due to a risk of dilut ion or con taminat ion with drug s (e.g. heparin). Should it be necessary  
to use such a device, it should preferably have been locked with saline prior to use. 
Only applicable for Portugal: For venous punctures, pai n control  measures are allowed according 
to local pract ice.
8.4.4 Storage of samples
Storage and disposit ion of samples analysed at local laboratories will be performed according to 
local laboratory  procedures. 
All remaining blood samples stored at the central laboratory  will be destroy ed after finalisat ion of 
the CTR , except for samples for antibody  assessment and other biospecimens (see Section 23.2).
Antibody  samples (samples for binding ant ibodies and inhibitors) will be stored until drug approval 
by Food and Drug Administration (FDA) and/or European Medicines Agency (EMA). The retaine d 
antibody  samples m ay be used for further characterisat ion for antibody  responses towards trial drug 
if required by healt h authorit ies or for safet y reasons, see Sect ion 23.2.
8.5 N9-GP administration
N9-GP will be administered while the patient is in a comfortable posit ion and according to Table 
5-1. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 62 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 63of 119
  The first 20 EDs with N9-GP shoul d be administered at the trial site. It is however possible to 
administer EDs 11 -20 outside trial site if this is according with local procedures and must b e under 
supervisio n of a healt h care professional qualified of handling anaphylact ic react ions. 
Precauti ons to take when inject ing the first dose of N9 -GP (V1 )
The patient has to be observed for 60 minutes in a hospital setting after N9-GP has been fully 
administered, with the line u sed left in place, if possible
The first 0.5 mL of N9-GPshoul d be administered slowly  (for the durati on of  1 minute), while 
the rem aining N9-GPvolume shoul d be administered over a period of at least 2 minutes. The 
patient is to be observed closely during this administration, and the inject ion shoul d be stopped 
immed iately if any  signs of  allergic or anaphylactic reactions appear
The date and the actual time of co mpletion o f the inject ion m ust be recorded in the eCRF
Precauti ons to take when inject ing the second dose of N9- GP (V2 )
The patient has to be observed for 60 minutes in a hospital setting after N9 -GP has been fully 
administered, with the line u sed left in place, if possible
The dose of N9- GP shoul d be administered as an i.v. bo lus inject ion(maximum  4 mL/min). The 
patient is to be observed closely during this administration, and the inject ion shoul d be stopped 
immediately  if any signs of  allergic o r anaphylactic reactions appear 
The date and the actual time of completion o f the inject ion m ust be recorded in the eCRF
Precauti ons to take when inject ing ED 3 -20of N9-GP (V3 -V20)at trial site
The inject ion shoul d be perform ed as an i .v. bolus inject ion (maximum  4 mL/min). 
The date and the actual time of co mpletion of  the inject ion m ust be recorded in the eCRF
Precauti ons to take when inject ing ED 11 -20of N9-GP ( V11-V20) outsi de the tri al site
Presence of a relevant healt h care professio nal qualified of handling anaphylact ic react ions
The inject ion shoul d be perf ormed as an i .v. bolus inject ion (maximum  4 mL/min). 
The date and the actual time of co mpletion o f the inject ion m ust be recorded in the eCRF
Trial inject ion kits(butterflies etc) will be provided by  Novo Nordisk. Choi ce of butterfly or 
cannula for N9-GP inject ions is at the discret ion of the investigator . 
The actual  time of co mpletion o f the inject ion will be recorded and corresponds to trial t ime 
point =0. 
Home treatment from ED 21 and until EOT
Hom e treatment wi th administrati on of  N9-GP can st art after 20 EDs if the pat ient or the patient’s 
parent(s)/ LAR(s) are comfortable with the reconst itution and administration process. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 63 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 64of 119
  Hom e treatment m ay be given by  the pat ient’sparent(s)/ LAR(s) or a home nurse, as applicable
The inject ion shoul d be perf ormed as an i .v. bolus inject ion (maximum  4 mL/min). The date and 
the actual  time of co mpletion of the inject ion must be re corded in the patient’s eDiary
All treatment requiring bleeding episodes should be treated and registered independent ly of the 
on-going prophylaxis treatment regime
If a bleeding episode occurs earlier at the same day as the planned prophylaxis, the dose should 
be registered for the bleeding episode and not as prophylaxis and the planned prophylaxis dose 
later sam e day  should be o mitted
When a prophy laxis dose has been taken and a bleeding episode occurs later the same day, the 
bleeding episode should be treated and registered independent of the prophylaxis dose .
8.6 Bleeding episodes
All bleeding episodes and treatm ents wi th N9-GP must be recorded in the eCRF by the invest igator
or in the eDiary by  the pat ient’s parent(s)/ LAR(s) . Bleeding episodes and other symptoms (eg 
synovit is, arthralgia, inject ion site haematoma) in connection wit h bleeding episodes should not be 
reported as AEs/SA Es unless the event is fatal, life -threatening or evaluat ed by  the invest igator as 
related to tri al product or tri al procedure. In ca se of life -threatening bleeding episode, it should 
always be reported as a SAE.  
8.6.1 Assessments of bleeding episodes and treatment response
The severity of bleeding episodes is defined as
Mild/moderate: Bleeding episodes that are uncomplicated jo int bleeding episodes , muscular 
bleeding episodes without com partm ent syndrom e, mucosal -or subcutaneous bleeding 
episode s. These b leeding episodes can be treated at home after visi t 20and details of the 
bleeding episodes shoul d be entered in the eDiary  by the pati ent’sparent(s)/LAR (s).
Severe: All intracranial, retroperitoneal, iliopsoas and neck bleeding episodes must be 
categori sed as severe. Muscle bleeding episodes wit h compartment syndrome and/or bleeding 
episodes associated with a significant decrease in the haemoglo bin level (>3g/dl) should also be 
reported as severe (it is the invest igators decisio n if haem oglobin measuremen ts shoul d be 
perform ed). The investigator must be contacted if a severe bleeding episode occurs .
In case of treatment requiring bleeding episode occurs outside the trial site’s opening hours and 
prior to hom e treatment or treatm ent outsi de tri al site (Sect ion 5.3.5 )has been initiated, the patient 
must be treated according to local procedure.
Bleeding Episode -information to be collected
Inform ation about bleeding episodes prior to the 20 ED (V20) shou ld always be recorded in eCRF. 
In case the patient is treated outside the trial site the trial site should be informed in case of a 
bleeding episode and the details hereo f. After 20 EDs bleeding episodes must be recorded either in 
the eDi ary (if treated at home) or in the eCRF (if treated at the trial site), see Secti on 12.3. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 64 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 65of 119
  Classificat ion and recording of severe bleeding episodes is the responsibili ty of the invest igator and 
shoul d always be registered in the eCRF.
Date and time the bleeding epi sode started
Date and time the bleeding episode stopped
Cause of the bleeding episode
i.e. spontaneous, traumatic or due to surgery
Anatomical locat ion of bleeding episodes
Treatment of bleeding episodes
amount, date and time of each dose of N9-GP
Severit y of treatm ent requi ring bleeding
mild/moderate, severe
Haem ostati c response assessed by  the 4-point scale defined in the below Table 8-3
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 65 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 66of 119
  Table 8-3 4- point scale
Classification N9-
GP dosing Description
Excellent One dose within 8 hours Abrupt pain relief and/or clear 
improvement in objective signs of 
bleeding 
Good One dose within 8 hours Noticeable pain relief and/or 
improvement in signs of bleeding 
Moderate More than one dose within 8 
hoursProbable or slig ht beneficial effect 
after the first injection
Poor More than one dose within 8 
hours No improvement or worsening of 
symptoms 
Re-bleed
Classificat ion of re -bleed will be performed at the time of the statist ical analysis, according to the 
following criteria: 
A re-bleed is defined as a new bleed ing episode within 72 hours after stopping of a previous 
bleed ing episode at the same or a subse t of the same anatomical lo cations
If a bleeding episode occurs in the same locat ion later than 72 hours after stopping the treatment it 
is considered as a new bleeding episode
8.7 Surgery
Before any  surgery  is performed blood samples for assessment of FIX inhibitors must be taken and 
sendto central  lab unless samples has already  been sentto central  lab wi thin the last 30 days. T he 
resul ts do not have to be available before the surgery .
Emergency  surgeri es are all owed in this tri al if adequate supply of N 9-GPis available at site to 
ensure haemo stasis and wound healing.
Patients undergoing surgery  will cont inue the regular visit schedule, but addit ional visits may  be 
perform ed in the peri -operative peri od as deci ded by  the investi gator. Surgery  will be docum ented 
as unscheduled visits. It is up to the invest igator to decide how long the post -surgery  period shoul d 
be and when the patient should resume regular prophylaxis or pre -prophylaxis treatment. All N 9-GP 
doses administered in relation to a surgery  must be registered on the surgery  form in the eCRF or 
eDiary.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 66 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 67of 119
  8.7.1 Minor surgery
Prevent ive N9 -GP treatment before minor surgery  including placement or removal of central 
venous access port can be performed within this trial at the invest igator’s discretion according t o 
local guidelines. A dose of 40 IU/kg N9 -GP prior to minor surgery is reco mmended to prevent 
perioperative bleeding episodes, see Table 5-1. Definit ion of minor surgery , see Secti on 5.3.8 . For 
minor surgery  the f ollowing should be recorded in the eCRF:
Date, time and vo lume of prevent ive dose before surgery
Typeof surgery
Indicat ion for surgery  
Locati on of  surgery  
Date of s urgery
Start and stop date and time of surgery
8.7.2 Major surgery
Major surgery  can be perform ed while part icipating in the present trial. For d efinit ion of major 
surgery , see Secti on 5.3.8 . Novo Nordisk must be contacted in due time prior to surgery, to ensure 
sufficient supply  of N9-GP.
N9-GP dosing prior to, during and after surgery  shoul d aim at FIX activit y levels as define d and 
recommended in the WFH Guidelines for the management of haemophilia .8The preoperative N9 -
GP dose should aim at FIX activit y level of approximately 100% which is expected to be achieved 
with dose of 40 or 80 IU/kg of N9 -GP. Trough and peak levels, and incremental recovery  of the 
particular pati ent m ust be taken into consideration by  the Invest igator when deciding the dose.
During the post -operati ve phase, clinical haemostatic response co mbined with cl ose FIX activi ty 
monitoring is recommended to determine appropriate intervals for postoperative dosing of 40 IU/kg 
N9-GP. The dose interval should be adjusted in order to reach postoperative FIX activit y levels as 
recommended by  the WFH Gui delines for the managem ent of  haemophilia .8
It is the responsibilit y of the Invest igator to determine when the patient must stop the weekly 
prophylaxis administrations of N9 -GP pri or to the surgery  and when these should be res umed after 
the surgery . If the pati ent has not resumed weekly prophylaxis within 6 days from the day  of 
surgery  the reason m ust be documented. The first weekly prophylaxis dose after surgery  shoul d be 
omitted if it falls on the same day  (± 1day ) as the las t postoperative dose. The fo llowing m ust be 
docum ented:
Date and time the patient stops the weekly prophylaxis wit h 40 IU/kg N9 -GP prior to the 
surgery
Date and time the patient resumes the weekly prophylaxis wit h 40 IU/kg N9 -GP after the post -
surgery  period
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 67 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 68of 119
  During this period, all bleeding episodes and any haemostatic treatment administered must be 
recorded in the eCRF when the pati ent is at the si te and in the eDiary  when the pati ent is at hom e, 
refer to Section 12.3.
Perioperative procedures, assessments and blood sampling will be performed at the Invest igators 
discreti on and documented in the patients’ medical records. 
Type of surgery  (e.g. arthroscopy ), indicat ion (e.g. prosthetic knee replacement) and location
Elect ive or emergency surgery
Durati on of  surgical  procedure: The date and time of first incisio n (knife -to-skin) and skin 
closure (last sti tch)
Concomitant medicat ion, including anaesthet ics and haemostatic medicat ion
Clinical narrative incl. descript ion of any  com plicati on, estimated blood loss, if any re -
operati onsetc.
Blood product transfusio ns, if any: Ty pe, vo lume (m Ls), Start date and time
Other i.v. infusio ns, if any: Ty pe (ex. saline, c rystalloids/co lloids), concentration and vo lume
(mLs), Start date and time
Haem oglobin measurements, if any  
Clinical evaluat ion of haemostatic response to be evaluated upon complet ion of the surgical 
procedure by the Surgeon, Anaesthesio logist and/or Inv estigator , based on experience as 
follows:
Excellent: Better than expected/predicted in this type of procedure
Good: As expected in this t ype of procedure
Moderate: Less than optimal for the ty pe of procedure but haemostatic response 
maintained  without c hange of treatment regimen
Poor: Bl eeding due to inadequate therapeutic response with adequate dosing, change of 
regimen required
8.8 Training and reminders
8.8.1 Trial card dispensing
At V0 the patient’s parent(s)/LAR(s) will receive a trial card stating that the patient is participat ing 
in a clinical trial. Telephone numbers and contact persons at the trial site will be listed.
8.8.2 Home treatment training
Hom e treatment training with administrati on of  N9-GP can start after a dministrations of the fi rst 3 
EDs at trial site unt il V20(see Sect ion 8.1.12 ),but may be postponed unt il the patient’s 
parent(s)/ LAR(s) are comfortable with the reconst itution and administration process .
A home treatment guide for the reconst itution will  be availabl e as handout sfor the patient’s 
parent(s)/LAR(s) .
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 68 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 69of 119
  Training in reconst itution and administration must be performed unt il parent(s)/LAR(s) feel 
comfortable in handling the treatment. The training must be documented in the medical records.
All patient ’s paren t(s)/LAR(s) must be carefully instructed in recognising and dealing with signs 
and symptoms of an anaphylact ic react ion. If the patient does not fo llow the pl anned dosing 
schedule, the invest igator must retrain the patient ’sparent(s)/ LAR(s) .
8.8.3 Electronic di ary (eDiary)
Pre-prophylaxis treatment, prophylaxis treatment and bleeding episodes shoul d be re corded in 
eCRF for the first 20 EDs. When the first 20 ED shave been administered, the data will be captured
either in eCRF and/or eDiary according to Section 12.3.
Parent(s)/LAR(s) should be trained in using the eDiary before or when they receive the eDiary. If 
needed the training must be repeated until t he parent(s)/LAR(s) use the eDiary  as intended.
It will be the responsibilit y of the invest igator to assess the eDiary data throughout the conduct of 
the trial and to ensure entry  com pliance.
During the ho me treatment period the patient’s parent(s)/LAR(s) shoul d ensure that all prophylactic 
home treatment, bleeding episodes, treatment of bleeding episodes as well as haemostatic 
evaluat ion of the treatment of bleeding episodes are captured in the eDiary .
8.8.3.1 eDiary dispensing and collection
The eDiary  will be dispensed to the patient ’sparent(s)/LAR(s) l atest at the visit when ho me 
treatm ent is started.
For details regarding patient’s diary , please refer to Secti on12.3.
For pati ents com pleting the trial or in case o f withdrawal , the eDi ary will be collected at the EOT 
visit.
8.8.4 Contact between the investigator/medically qualified person and the patient
The i nvest igator and/or medically qualified person must establish contact with the patient’s 
parent(s)/LAR(s) at least every  12 weeks ± 1 week, if site visit s are more than 3 months apart, either 
by visits at the tri al site or other contact e.g. tel ephone calls . All trial related contactsmust be 
captured i n eCRF.
The patient and patient’s parent(s)/LAR(s) should be notified that they  will be contacted according 
to the protocol. 
The communicat ion will focus on the well -being of the pat ient, including enquiry ofall AEs, and 
any medical treatment (including treatment of bleeding episodes) since the last con tact. The 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 69 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 70of 119
  investigator/medically qualified person should not suggest specific AEs to patient’s 
parent(s)/ LAR(s) , but shoul d inquire e.g. “how is your child doi ng?”, “has y our child had any  
probl ems since the last contact?” and “have y ou remembered to enter all treatments in the eDiary?”
The expir ationdate of the drug and solvent that the pati ent has received should be checked by the 
site staff before the patient’s next visit to determine if an extra visit is relevant and to inform the 
patient of  which unused vials to return to the site. Expiry of inject ion kits shoul d be discussed.
All attem pts to contact the patient’s parent(s)/LAR(s) must be documented in a source docum ent. If 
a successful contact cannot be made after 3 documented attempts no further attempts are required. If 
the pati ent’s parent(s)/LAR(s) have wit hdrawn consent, this must be documented.
At each contact the investigator will at a minimum capt ure/evaluate
Assessment of bleeding episodes
Adverse events 
Concomitant Medication 
eDiary com pliance
N9-GP administration co mpliance
8.8.5 Interactive web response system
Please refer to Section 10regarding the IWRS. 
For details on how to use the IWRS, please refer to the trial specific IWRS user documents 
provi ded to the tri al site. 
8.9 Patient compliance
Throughout the trial the invest igator will remind the patient’s parent(s)/LAR(s) to fo llow the tri al 
procedures and requirements to ensure patient compliance. If a patient is found to be non -compliant, 
the invest igator will remind the patient’s parent(s)/L AR(s) of the importance of fo llowing the 
instructi ons given including taking the trial product as described. 
Assessment of patient compliance with protocol procedures for determinat ion of continuat ion of the 
trial will be done bythe invest igator. 
Failur e to com ply wit h scheduled visits and N9- GP administration may  resul t in withdrawal in 
accordance with the protocol withdrawal criteria, see Section 6.4.
Treatment with FIX concentrate, other than N9 -GP, during the trial is not allowed and vio lation of 
this may  lead to withdrawal due to non -compliance (pl ease refer to Secti on 8.2.4 ). Regarding by -
passing agent, see Section 8.2.3 .
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 70 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 71of 119
  Com pliance wi th N9-GP treatment mu st be addressed at each visit. Compliance check includes a 
cross check between number of inject ions recorded in eDiary, expected number of injections and 
the used/returned vials.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 71 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 72of 119
  9Trial supplies
Trial supplies com prise tri al product and auxiliary  supplies. Addit ional details regarding trial 
supplies can be found in the Trial Material Manual (TMM) and Handling instruction.
Trial product m ust not be di spensed to any  person not included in the trial (excluding patient’s 
parent(s)/LAR(s)).
Auxiliary  supplies com prise supplies other than trial product s, e.g. needles and syringes.
9.1 Trial product
The fo llowing tri al product will be provi ded by Novo Nordisk A/S, Denmark .
Table 9-1 Trial Product
Trial Product Strength Dosage form Route of 
administration
N9-GP (nonacog 
beta pegol )500 IU/vial
2000 IU/vialFreeze -dried Powder 
for solution for 
inject ioni.v. injection
N9-GP is supplied as a sterile freeze -dried powder for solut ion for inject ion in single use vials wit h 
a nominal content of 2000 IU/vial or 500 IU/vial to be reconstituted with 4.2 m LHisti dine so lvent. 
After reconstitution each vial contains 500 IU/mL or 125 IU/mL N9 -GP, respectively. The 
reconstituted solut ion is a clear and colourless so lutionfreefrom clearly visible particles . The 
reconstituted solut ion must not be diluted further. The trial product must not be used if it does not 
appear cl ear and co lourless free from clearly visible particles .
After reconstitution the appropriate volume of the vials will be drawn into a syringe. Maximum 4 
mL shoul d be withdrawn fro m each vial o f reconstituted N 9-GP. The content of several vialsmay 
be co mbined in one syringe. N9-GP may not be added to or mixed wit h any other material than 
Histidine.
Administrati on of  the appropri ate vol ume of N9-GP w ill be given as i.v. bo lus inject ion. Maximum 
inject ion rate i s 4 m L/min (pl ease refer to Secti on8.5)
.
The invest igator must explain to the patient ’s parent(s) /LAR(s) how much this corresponds to in 
terms of inject ion time when administering N9-GP at home . 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 72 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 73of 119
  The m aximum  dose to be administered to a patient within 24 hours i s 200 IU/kg, wi th a maximum  
individual dose of 80 IU/kg to be administered no more than every hour. These doses are only 
relevant in case of trauma, severe bleedings or surger y.
Histidinefor reconsti tution of  the N 9-GP trial product will be supplied by Novo Nordisk. Novo 
Nordi sk wi ll not supply  anyfurther N
on Invest igatio nal Medical Product s(NIMPs) .
9.2 Packing, l abelling and dispensing
Labelling of the trial product will be in accordance with Annex 1319, local regulati onsand trial 
requi rements. Novo Nordisk A/S will label and pack the trial product.
N9-GPand Hist idine will be provided in boxes. The boxes will be provided wit h labels containing 
the following informat ion: product name, expiry date andstorage condit ions. Each tri al product box
will have a unique Dispensing Unit Number (DUN) for identification and traceabilit y. 
The details o f the packaging and labelling o f the trial product will  be provi ded in the TMM supplied 
by Clinical Supplies Coordinat ion, Novo Nordisk A/S.
The IWRS will allocate the trial product in uniquely numbered DUs to the pati ent at each 
dispensing visit. The DUs will be dispensed in accordance with the patient’s body  weight. Tri al 
product will be dispensed at dispensing or assessments visit s, as appropriate .
The invest igator must document that direction for use is given to the patient’s parent(s)/LAR(s) 
orally  and/or in wri ting at each dispensing visit according to the Handling instr uction.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 73 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 74of 119
  9.3 Storage
Storage must be done according to the table below .
Table 9-2 Storage
Products Storage conditions
(not-in-use)In-use conditions
N9-GP (nonacog beta pegol) 2-8°C 
Protect from light4 hours below 30°C 
Do not freeze
Avoid direct sunlight
Histidine 2-25°C
Protect from light N/A
The tri al product N9 -GP powder and Hist idine so lvent must be stored in a secure place at trial site. 
For N9-GP under refrigeration at 2 -8°C, and for Hist idine so lvent at 2 -25°C, both protected from
light and are hereby stable unt il the expiry date given. It is recommended to use the reconstituted 
N9-GP immediately fo llowing reconst itution. If not used immediately, the reconstituted product can 
be stored in the vial for up to 4 hours below 30°C. Exposure to direct sunlight as well as freezing 
must be avoided after reconstitution. As for other parenteral preparations, the product should be 
inspected visually  for parti culate m atter and discolorati on pri or to administration and discarded if 
either is present. ‘In use time ’starts fro m completion of the reconstitution ,see the Handling 
instructi on for further details. The tri alsite must carefully instruct the patient s’parent(s)/ LAR(s) in 
how to store the trial product. No temperature monitoring is required after the trial product istaken 
home by the pat ient.
The invest igator must ensure the availabilit y of proper storage condit ions, record and evaluate the 
temperature. The invest igator must inform Novo Nordisk immediately if any trial product has been 
stored outside specified condi tions (e.g. outsi de temperatu re range).
Unused tri al product m ust be stored separately from used trial product .
Trial product that has been stored improperly must not be dispensed to any  patient before i t has 
been re -evaluated and approved for further use by  Novo Nordisk. The invest igator m ust take 
appropriate action to ensure correct storage.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 74 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 75of 119
  9.4 Drug a ccountability and destruction
Drug accountabilit y is the responsibilit y of the investi gator. The invest igator or delegated person, 
e.g., a trial nurse will perform drug accountabilit y in the IWRS Drug Accountabilit y Modul e. 
Once a pat ient is dosed, all trial drug product vials (dispensed, used, partly used or unused, returned 
and lost/damaged) must be recorded in the IWRS Drug Accountabilit y Modul e. 
Drug accountabilit y is not required for Histidine solvent used for reconst itutions, b ut it is the 
responsibilit y of the invest igator or delegate to fo llow Histidineexpiry and prevent pati ent use after 
expiry .
Returned trial product (used/partly  used or unused including empt y packaging material) can be 
stored at room temperature and must be stored separately fro m non
-allocated tri al product.
All tri al drug products m ust be retained for drug accountabilit y checked bythemonitor. The 
monitor will , upon com pletion of drug accountabilit y, arrange fo r the destruction of used, expired ,
unused and broken vials o f the supplied trial drug products.
Destruction will be done according to local procedures after accountabilit y is finalised and verified 
by the m onitor. Destructi on of  products m ust be docum ented.
For Japan only: Responsibilit y for storage and drug accountabilit y of the trial  drug products at the 
trial site rests wi th the head of the trial site. The head of the trial site could assign so me or all o fthe 
responsibilit ies for accoun tabilit y of the trial drug products at the trial sites to a tri al product storage 
manager (a pharmacist in principle). The trial product storage manager should control and take 
accountabilit y of the trial drug products in ac cordance wit h procedures specified by Novo Nordisk 
A/S. The head o f the trial site or the tri al product storage m anager m ust ensure the availabilit y of 
proper storage condit ions, and record and evaluate the temperature.
9.5 Auxiliary supply
Auxiliary  supplies are equi pment such as needles, sy ringes, butterflies, sterile swabs, vial adaptor 
etc.These will be provi ded by Novo Nordisk A/S , if applicable.
9.6 Shipment of trial product to patient’s home 
For selected coun tries and if permitted by  local regul ations, the invest igator may o ffer to send trial 
product and auxiliaries fro m the trial site or pharmacy  to the pati ent’s ho me by courier service.
The process for sending trial product from the trial site or pharmacy to a patient’s ho me is described 
in the “Trial sit e/pharmacy instruction for shipment of trial product to patients’ homes” 
docum ent.  This docum ent contains detailed instructions for preparing packaging and setting up the 
pick-up of  trial product, handover of trial product from the trial site or pharmacy  staff to the courier, 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 75 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 76of 119
  requi red tem perature m onitoring of  trial product, delivery  to and recei pt of tri al product by  the
patient. The process for returning trial product to the trial site or pharmacy  by couri er is also 
described in this document.
Invest igators, tri al site/pharm acy staff and pati ents who will be invo lved in shipment of trial product 
to the patient’s home will be adequately  trained in thi s process.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 76 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 77of 119
  10Interactive /web response system (IWRS)
A trial specific IWRS will be set -up, which can be acce ssed at any  time via internet or via 
telephone. Access to the IWRS must be restricted to and controlled by authorised persons.
IWRS isused for:
Screening
Screening failure
Medicat ion arrival
Dispensing
Withdrawal *
Com pletion
Drug accountabilit y
Data change
* For inhibitor patients attending inhibitor fo llow-up the IWRS withdrawal sessio n shoul d not be 
perform ed pri or to EOT on the third inhibitor follo w-up visit.
IWRS call can be done the day  before the actual  visit.
IWRS user manuals will be provi ded to each tri al site.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 77 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 78of 119
  11Adverse events and technical complaints 
11.1 Definitions
Adverse event:
An adverse event (AE) i s any  untoward m edical occurrence in a pat ient administered a product, 
and which does not necessarily have a causal relat ionship wit h this treatm ent.
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory  
findi ng), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
A clinically  significant worsening of a concomitant illness.
A clinical laboratory  adverse event (CLAE): A clinical laboratory  abnorm ality which is 
clinically significant, i .e.an abnormalit y that suggests a disease and/or organ toxicit y and is of a 
severit y that requi res act ive management. Active management includes active treatment or 
further invest igations, for examp le change o f medicine dose or more frequent fo llow-up due to 
the abnormalit y.
The following should not be reported as AEs:
Bleeding episodes and other symptoms (eg synovit is, arthralgia, inject ion site haematoma) in 
connection wit h bleeding episodes should not be reported as AEs/SAEs unless the event is fatal, 
life-threatening or eval uated by  the invest igator as related to trial product or trial procedure. In 
case of life -threatening bleeding episode, it should always be reported as a SAE. All bleeding 
episodes and other findings related to underlying disease will be captured in Sect ion 8. 
Pre-exist ing condit ions, including those found as a result of screening procedures (pre -existing 
condi tions shoul d be reported as medical history  or concomitant illness).
Pre-planned proced ures unless the condit ion for which the procedure was planned has worsened 
from the first tri al related activi ty after the subject has si gned the inform ed consent .
The following three definitions are used when assessing an AE:
Severity assessment
Mild -no or transient symptoms, no interference with the patient's daily  activi ties.
Moderate -marked symptoms, moderate interference wit h the patient's daily  activi ties.
Severe -considerable interference with the patient 's daily act ivities; unacceptable.
Causality assessment
The fo llowing term s are used when assessing the relat ionship between an AE and the relevant 
trial product:
Probable -Good reason and sufficient documentatio n to assume a causal relat ionship.
Possible -A causal relat ionship is conceivable and cannot be dismissed.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 78 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 79of 119
  Unlikely -The event is most likely related to aetiology other than the trial product.
Final outcome of an AE
Recovered/resolved -The patient has fully recovered, or by  medical or surgical treatm ent 
the condi tion has returned to the level observed at the first trial -related activit y after the 
patient’sparents/LAR(s) signed the informed consent.
Recovering/resolving -The condit ion is improving and the patient is expected to recover 
from theevent. Thi s term  is only  applicable if the patient has co mpleted the trial or has 
died from another AE.
Recovered/resolved with sequelae –Thepatienthas recovered fro m the condi tion, but 
with lasting effect due to a disease, injury , treatm ent or procedu re. If a sequela meets an 
SAE cri terion, the AE m ust be reported as an SAE.
Not recovered/not resolved -The condition o f the patienthas not improved and the 
symptoms are unchanged, or the outcome is not known.
Fatal -This term is only applicable if the patientdied from a condi tion rel ated to the 
reported AE. Outcomes o f other reported AEs in a patientbefore he/she died should be 
assessed as "recovered/reso lved", "recovering/resolving", "recovered/reso lved with 
sequelae" or "not recovered /not resol ved". An AE wi th fatal outcom e must be reported as 
an SAE.
Unknown -This term is only applicable if the patient is lost to follow -up.
Serious adverse event:
A serious adverse event (SAE) is an experience that at any  dose resul ts in any  of the fo llowing:
Death.
A life-threateningaexperience.
In-patient hospi talisati onbor prol ongat ion of exist ing hospitalisat ion.
A persistent or significant disabilit y or incapaci tyc.
A congenital anomaly or birth defect.
Important m edical events that may not result in death, be life threateningaor requi re 
hospi talisat ionbmay be considered an SAE when -based on appropriate medical 
judgement -they may jeopardi se the patientand may  requi re medical  or surgi cal 
intervent ion to prevent one of the outcomes listed in the definit ionof SAEd. 
Suspi cion of transmissi on of infect ious agents via the trial product and format ion of 
inhibitor antibodies must always be considered an SAE.
FIX inhibitory  antibodies (confirmed by two consecutive tests, see Section 8.4.2.2 must 
always be considered a SAE
a. The term "life threatening" in the definit ion of SAE refers to an event in which the patientwas at 
risk of death at the time o f the event. It does not refer to an event which hypothetically might have 
caused death if it was more severe.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 79 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 80of 119
  b. The term  "hospi talisati on" is used when a patient: 
Is admitted to a hospital or in- patient, irrespect ive o f the duration of physical stay , or 
Stays at the hospital for treatment or observat ion for more than 24 hours
Medical judgement must always be exercised, and when in doubt, the hospital contact should be 
regarded as a hospitalisat ion. Hospitalisations fo r administrative, trial related and social purposes do 
not consti tute AEs and should therefore not be reported as AEs or SAEs. Hospital admissio ns for 
surgi cal procedures, planned before trial inclusio n, are not considered AEs or SAEs.
c. A substant ial disrupti on of  a patient's abilit y to conduct normal life functions (eg fo llowing the 
event or clinical invest igation the patienthas significant, persistent or permanent change, 
impairment, damage or disruption in his/her body  function or structure, physical activity and/or 
qualit y of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasiasis or convulsio ns that do not result in hospitalisation or development of drug 
dependency  or drug abuse.
Non-serious adverse event
A non-serious AE is any  AE which does not fulfil the definit ion of an SAE.
Medical event of special interest
A medical event of special interest (MESI) is an event which, in the evaluat ion of safet y, has a 
special focus. A MESI is an AE ( SAE or n on-serious AE) which fulfils one or more of the below 
defined MESI criteria.
1.Medicat ion errors concerning trial product:
Administrati on of  wrong drug 
Wrong route of administration
Accidental  administrati on of  a lower or hi gher dose than intended. The administered dose 
must deviate fro m the intended dose to an exten twhere clinical consequences for the trial 
patientwere likely to happen as judged by the investigator, although not necessarily did 
happen.
2.Inhibitor format ion against FIX. Blood sample s for measurement of FIX inhibitors will be 
analysed at a central laboratory  selected by  Novo Nordi sk A/S. If an invest igator obtains 
inform ation of a posi tive central  laboratory  resul t or any  indicat ion of inhibitor format ion by 
clinical signs or local la boratory  resul ts, thi s should be reported as a MESI prior to confirmat ion 
by two central laboratory  resul ts.
3.Thromboembo lic events (clini cal signs or laboratory  indicat ions of arteri al and venous 
thrombosis including my ocardial  infarct ion, pulmonary embo lism, cerebral  
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 80 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 81of 119
  infarction/thro mbosis, deep vein thrombosis, other clinically significant thormboembo lic events 
and peripheral artery  occl usion, see definit ions below).
4.Anaphylactic reaction as defined by Sampson et al 200620(see below).
5.Allergic reactio n including, but not limited to, any  acute immunogl obulin E (IgE) m ediated 
reacti on of  delayed ty pe hypersensi tivity (clinical  signs may  include vari ous ty pes of skin 
rashes) that does not meet the definit ion of anaphylaxis as described by Sampson en al20.
6.CNS -related adverse events, including but not limited to any  learning and behavioural deficits . 
Examples include but are not limited to:
Headache
Seizures
Vision problems
Acute chang es in mental  status
Developmental, cognit ive or behavioural issues
7.Renal adverse events including new onset of renal disorder or renal impairment or acute and 
chronic renal failure
Definition of an acute, evolving, or recent myocardial infarction :
Either one of the fo llowing two criteria sat isfies the di agnosis for an acute, evolving or recent 
myocardial  infarct ion:
1.Typical  rise and gradual  fall in troponin T or m ore rapi d rise and fall in creat ine kinase, muscle 
and brain or biochemical markers of myo cardial necrosis with at least one of the fo llowing:
Ischaemic symptoms
Subsequent development of pathologic Q waves on the ECG
ECG changes indicative of ischaemia (ST segment elevat ion or depression)
Coronary  artery  intervent ion (e.g.angioplast y)
2.Pathol ogic findings of an acute myo cardi al infarct ion (i.e., pathologic findings of an acute 
myocardial  infarct ion will be defined when criteria a and b below are fulfilled):
a)Increase in troponin T above the "diagnostic" limit : i.e. > 0.03 µg/L
b)Patients wi th:
ST-segm ent el evati on: New ST -segm ent el evation at the J point in two or more 
conti guous l eads wi th the cut -off points >= 0.2mV in leads V1, V2 or V3 and 0,1 
mV in other leads (contiguit y in the frontal plane is defined by the lead sequence 
aVL, I inverted aVR, II, aVF, III)
No ST -segment elevat ion: ST -segm ent depressi on and or T -wave inversio n in two or 
more conti guous l eads >= 0.1 m V
Definition of pulmonary embolism:
Obstruction of a pulmo nary artery  or one of i ts branches, m ost frequent ly by detached frag ments of 
thrombus fro m a leg or pelvic vein, diagnosed by at least one of the following:
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 81 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 82of 119
  Positive findings in ventilat ion/perfusio n scan
Positive findings in a spiral(helical) computed tomography  or angi ography
Positive findings in a magnet ic resonance ima ging
Positive findings in a pulmo nary angi ography
Definition of cerebral thrombosis/infarction:
Acute neuro logical injury that persists for at least 24 hours and occurs as a result of either a 
thrombosis or embo lic process, diagnosed by at least one of the following:
Com puteri sed tom ography
Magnet ic resonance scan
Magnet ic resonance angiogram
Cerebral angiography
Deep vein thrombosis: 
Venous thrombosis demo nstrated by  com pressi on ultrasound, dupl ex ul trasound, or col our Doppl er 
imaging.
Definition of other clinically significant thromboembolic events:
Sign or suspi cion of clinically  significant thromboembolic event, e .g.:
visceral arterial embo lus/thro mbus, 
extremit y arteri al embo lus/thrombus or 
portal  venous thrombosis.
Superficial thrombophlebit isis not considered a clinically significant thromboembo lic event unless 
evaluated so by  the investi gator.
Peripheral artery occlusion: 
Clinical signs of acute arterial occlusio n verified by either ankle -brachial index test, Doppler or 
ultrasound (Dupl ex)imaging, computed tomographic angiography, magnetic resonance 
angiography , or convent ional angiography .
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 82 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 83of 119
  Clinical criteria for diagnosing anaphylaxis (infants and children only) (Sampson et al. 
200620): 
Anaphylaxis is highly  likely when any  one of the following 3 criteria are fulfilled:
1. Acute onset of an illness (minutes to several hours) with invo lvement of the skin, mucosal t issue, 
or both (e.g., generalized hives, pruritus or flushing, swollen lips -tongue-uvula) AND AT LEAST 
ONE OF THE FOLLOWING
a)Respiratory  com promise (e.g., dyspnea, wheeze- bronchospasm, stridor, reduced PEF, 
hypoxemia)
b)Reduced BP or associated symptoms of en d-organ dy sfunct ion (e.g., hy potoni a [collapse], 
syncope, incont inence)
2. Two or more of the fo llowing that occur rapidly  after exposure to a likely  allergen for that patient 
(minutes to several hours):
a)Involvement of the skin -mucosal t issue (e.g., genera lized hives, itch -flush, swollen lips -
tongue -uvula)
b)Respiratory  com promise (e.g., dyspnea, wheeze
-bronchospasm, stridor, reduced PEF, 
hypoxemia)
c)Reduced BP or associated symptoms (e.g., hy potonia [collapse], syncope, incontinence)
d)Persi stent gastrointestin al symptom s (e.g., cram py abdominal pain, vomit ing)
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours):
a)Infants and children: low systolic BP (age specific) or greater than 30% decrease in systolic 
BPfrom that perso n’s baseline*
*Low sy stolic blood pressure for children is defined as less than 70 mm Hg from 1 month to 1 year, 
less than (70 mm Hg + [2x age]) from 1 to 10 y ears.
Technical complaint
A technical complaint is any written, el ectroni c, or oral  communication that alleges product 
(medicine or devi ce) defects. The technical co mplaint may be associated with an AE, but does not 
concern the AE itself.
Examples of technical co mplaints:
The physical or chemi cal appearance of tri al product (e.g.disco loration, parti cles or 
contaminat ion)
The packaging material (e .g. leakage, cracks, rubber membrane issues or errors in labelling text)
11.2 Reporting of adverse events
All events meet ing the definit ion of an AE must be collected and reported. This includes event s 
from the first tri al-related activit y after the pati ent’sparent(s)/LAR(s) has signed the informed 
consent until the end of the trial. The events m ust be recorded in the applicable CRF forms in a 
timely  manner. See timelines below.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 83 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 84of 119
  AEs experienced after signing of informed consent and before first dosing should only be reported 
if associated with trial related activit ies.
During each contact with the trial site staff ( trial site visits and telephone contacts) the pati ent 
and/or patient’s parent(s)/LAR (s) must be asked about AEs and technical co mplaints, e.g. “Have 
your child experience any problems since the last contact?”
All AEs, ei ther observed by  the invest igator or reported by the patient, must be reported by the 
investigator and evaluated. Novo Nordi sk assessment of expectedness is performed according to the 
following reference documents: Investigator’s Brochure7, N9-GP, current versio n and any updates 
thereto.
For Japan only: If obtaining market ing approval in Japan, sponsor’s assessme nt of expectedness is 
done according to the package insert of the commercial products in Japan. 
All AEs must be recorded by  the invest igator on an AE form. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the inves tigator shoul d record each si gn and 
symptom  as an individual AE using separate AE forms.
For each SAE and MESI an electronic Safet y Informat ion Form  (eSIF) shoul d be co mpleted in
addition to the AE form  in the eCRF. If several symptoms or diagnoses occur a s part of the same 
clinical picture, one SIF may be used to describe all the SAEs. All concerned AE numbers must be 
included in the AE number field on the SIF.
MESIs, regardless of seriousness, must be reported using both the AE form and the safet y 
inform ation form. For MESIs of allergic aet iology, the hypersensit ivity questi onnai re must be 
completed.
The AE form  for a non -serious AE should be signed when the event is reso lved or at the end of the 
trial.
Timelines for initial reporting of AEs:
The invest igator must complete the fo llowing forms in the eCRF/CRF within the specified 
timelines:
SAEs and MESIs : The AE form within 24 hours and the safety information form within 5 calendar days 
of the investigator's first knowledge of the event .
Both form smust be signed within 7 calendar day s from the date the informat ion was entered in the 
eCRF. 
MESIs of allergic aetiology: The hypersensitivity questionnaire must be completed within 14 days
If the eCRF is unavailable, the concerned AE and SIF (if applicable) informat ion must be reported 
on paper forms and sent to Novo Nordisk by fax, e- mail or courier within the same timelines as 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 84 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 85of 119
  stated above. When the eCRF beco mes available again, the invest igator must re -enter the 
inform ation on the appropriate forms in the eCRF. 
Contact details (fax, telephone, e- mail and address) are provided in the invest igators trial file.
Reporting of trial product -related SUSARs by the sponsor:
Novo Nordisk will notify the invest igator of trial product- related suspected unexpected serious 
adverse reactions (SUSARs) in accordance with local requirements and GCP1. In addi tion, the 
investigator will be informed of any  trial-related SAEs that may warrant a change to any  trial 
procedure.
In accordance with regulatory  requi rements, Novo Nordi sk will inform the re gulatory  authori ties, 
including EMA, of trial product -related SUSARs. In addit ion, Novo Nordisk will inform the 
IRBs/IECs of trial product -related SUSARs in accordance with local requirement and GCP1, unless 
locally this is an obligat ion of the invest igator.
11.3 Follow -up of adverse events
The invest igato r must record follow -up informati on by updat ing the forms in the eCRF.
Follow up inform ation must be reported to Novo Nordisk according to the fo llowing:
SAEs : All SAEs must be foll owed unt il the outcome of the event is "recovered/resolved", 
"recovered/res olved with sequelae" or "fatal", and unt il all queries have been resolved. Cases of 
chronic condit ions, cancer or AEs ongoing at time of death (where death is due to another AE) 
may be closed with the outcome "recovering/reso lving" or "not recovered/not re solved". Cases 
can be closed wit h the outcome of "recovering/resolving" when the patient has co mpleted the 
follow-up period and is expected by  the invest igator to recover.
The SAE fo llow-up inform ation shoul d only include new (e .g.corrections or additiona l) 
inform ation and m ust be reported within 24 hours of the invest igator's first knowledge of the 
inform ation. This is also the case for previously non -serious AEs which subsequent ly beco me 
SAEs. 
Non-serious AEs: Non-serious AEs m ust be f ollowed unt il the outcom e of the event i s 
"recovering/reso lving", "recovered/reso lved" or "recovered/resolved with sequelae" or until the 
end of the fo llow
-up peri od stated in the protocol, whichever comes first, and unt il all queries 
related to these AEs have been resolved . Cases o f chronic condit ions, cancer or AEs ongoing at 
time of death (where death is due to another AE) may be closed with the outcome 
"recovering/reso lving" or "not recovered/not resolved". Cases can be closed with the outcome of 
"recovering/reso lving" w hen the patient has completed the fo llow-up peri od and i s expected by  
the invest igator to recover.
Non-serious AE fulfilling the MESI criteria: Follow -up inform ation on MESIs should only 
include new (e .g.corrections or additional) information and must be reported within 14 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 85 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 86of 119
  calendar days of the investi gator's fi rst knowl edge of  the information. This is also the case for 
previously reported non -serious AEs which subsequent ly fulfil the MESI criteria. 
The invest igator must ensure that the worst case severit yand seri ousness of an event is kept 
throughout the trial. A worsening of an unreso lved AE m ust be reported as fo llow up wi th re-
assessment of severit y and/or seri ousness o f the event.
Queri es or foll ow-up requests from Novo Nordisk must be responded to within 14 calendar days
from the date of receipt of the request, unless otherwise specified in the follow -up request.
11.4 Technical complaints and technical complaint samples
11.4.1 Reporting of technical complaints 
All technical co mplaints on any  of the f ollowing products:
N9-GP 500 IU/vial
N9-GP 2000 IU/vial
Histidine vial
Novo Nordisk trial inject ion kit 
which occur from the time of first usage of product until the time of the l ast usage of the product,
must be collected and reported to Customer Co mplaint Cente r, Novo Nordisk.
Contact details (fax, e -mail and address) are provided in Attachm ent I to the protocol.
The invest igator must assess whether the technical complaint is related to any AE(s), SAE(s) and/or 
MESI(s). 
Technical co mplaints must be reported on a separate technical co mplaint form for each product 
listed. If the technical co mplaint invo lves more than one batch, lot number or more than one DU
N, 
a technical co mplaint form for each batch, lot number or for eac h DU Nmust be co mpleted.
The invest igator must complete the technical co mplaint form  in the eCRF within the fo llowing 
timelines of the trial site obtaining knowledge of the technical co mplaint:
Technical co mplaint assessed as related to an SAE within 24 ho urs
All other technical co mplaints within 5 calendar days
If the eCRF is unavailable or when reporting a technical co mplaint that is not patient related, the 
inform ation must be provided on a paper form by fax, e -mail or courier to Customer Complaint 
Cent er, Novo Nordisk, within the same t imelines as stated above.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 86 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 87of 119
  11.4.2 Collection, storage and shipment of technical complaint samples
The invest igator must collect the technical co mplaint sam ple and notify  the m onitor within 5 
calendar days of obtaining the sample at trial site. The m onitor m ust coordinate the shipment to 
Customer Com plaint Center, Novo Nordisk (the address is provided in Attachm ent I) and ensure 
that the sample is sent as soon as possible. A print or copy  of the technical com plaint form  must be 
sent with the sample.
The invest igator must ensure that the technical complaint sample contains the batch, lot number 
and, if available, the dispensing unit number (DUN).
If the technical co mplaint sample is unobtainable, the invest igator must specify on the technical 
complaint form  why i t is unobtainable.
Storage of the technical co mplaint sample must be done in accordance with the condit ions 
prescribed for the product. The shipment of the technical co mplaint sample should be done in 
accordance with the same condi tions as for storage, see Section 9.
11.5 Precautions and/or overdose
As wi th any protein injected i .v. hypersensit ivity reacti ons m ay occur. The possible events include 
rash, pruritus, fever, nausea, headache, vo miting and changes in blood pressure. If any of these 
events are suspected, further N9- GP administration should be stopped and the patient should receive 
treatm ent as appropri ate according to the hospital practice and guidelines prior to further treatment 
with N9-GP. 
If an overdose is suspected further N9 -GP administration should be stopped and the patient should 
receive treatment as appropriate according to hospital practice and guidelines prior to f urther 
treatm ent wi th N9-GP.
11.6 Committees related to safety
11.6.1 Novo Nordisk safe ty committee
Novo Nordisk will const itute an internal N9- GP safet y committee to perform ongoing safet y 
surveillance.
The safet y committee works according to a written guideline and will meet regularly to discuss and 
evaluate the overall safet y of N9-GP forthis trial and all other N9 -GP trials. 
Any event occurring after administration of N9 -GP fulfilling the SAE/MESI criteria must be 
reported to Novo Nordisk. If one of the below mentioned criteria is fulfilled, all invest igators will 
be informed in writ ing, and an extraordinary  safety commi ttee m eeting will be called for to decide 
whether or not the trial can continue with or without modificat ions. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 87 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 88of 119
  Anaphylaxis in two patients after trial product administration
Occurrence of two significant thromboembo lic events in two different patients (e.g. my ocardial  
infarction, pulmo nary embolism, cerebral  thrombosis/infarct ion or other significant 
thromboembo lic events)
Death rel ated to tri al product assessed by  Novo Nordi sk or by  the Invest igator
Dosing o f patients on treatm ent m ay continue while further evaluation of the SAE/MESI is made, 
but recruit ment of addit ional pat ients will be put on ho ld unless otherwise decided by the safet y 
committee. The evaluation o f fulfilment of the above criteria b y the safet y commit tee will  take into 
consideration whether or not the patient was dosed according to protocol.
Furtherm ore, the safet y committee will meet fo llowing every  inhibi tor (neutralising antibody , 
Bethesda unit of ≥ 0.6) confirmed by  two consecutive tests at the central laboratory . Recrui tment of  
new pat ients may continue during safet y committee assessment of inhibitor formation.
Finally , the safet y committee might meet in case of development of binding ant ibodies and 
suspicio n of decrease d drug efficacy.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 88 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 89of 119
  12Case report forms 
Novo Nordisk will provide a system for the electronic case report forms (eCRF). This system and 
support services to the system will be supplied by a vendor. The activit ies of this vendor will be 
under the direct ion and s upervisi on of Novo Nordisk.
The invest igator or delegated person should ensure that all relevant questions are answered, and that 
no em pty data field exists.
If a test or an assessment has not been done and will not be available, or if the quest ion is irrelevant 
(e.g.is not applicable), indicate this according to the data entry instructions.
The fo llowing will be provi ded as paper CRF:
1.Hypersensi tivity questi onnai re 
In addit ion paper AE forms, safet y informat ion formsand Technical Co mplaint form s will  be 
provi ded. These must be used when access to the eCRF is revoked or the eCRF is unavailable .
On the paper CRF form p rint legibly, using a ballpoint pen. Ensure that all quest ions are answered, 
and that no empt y data bl ocks exist. Ensure that no informat ion is recorded outside the data blocks.
If a test or an assessment has not been done and will not be available, indicate this by writ ing “ND” 
(not done) in the appropriate answer field in the CRF. If the quest ion is irrelevant (e .
g.is not 
applicable) indi cate this by wri ting “NA” (not applicable) in the appropriate answer field. Further 
guidance can be obtained from the instructions in the CRF.
The invest igator must ensure that all information derived fro m source documentation is consistent 
with the source informat ion. By  electroni cally  signing the case book in the eCRF, the investigator 
confirms that the informat ion in the eCRF including related forms is reviewed, complete and 
correct.
12.1 Corrections to case report forms
Correcti ons to the eCRF data m ay be made by  the investi gator or the invest igator's authorised staff. 
An audit trail will be maintained in the eCRF applicati on containing as a minimum: the old and the 
new data, ident ificat ion of the person entering the data, date and time of the entry and reas on for the 
correcti on.
If correcti ons are m ade by  the invest igator's authorised staff after the date the invest igator has 
signed the case book, the case book must be signed and dated again by  the invest igator.
Correcti ons to the data in paper CRFs may  only be made by drawing a straight line through the 
incorrect data and then writing the correct entry next to the data that were crossed out. Each 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 89 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 90of 119
  correcti on m ust be init ialled, dated and explained (if necessary) by the invest igator or the 
investigator’s autho rised staff. 
Correcti ons necessary after the paper CRFs have been remo ved from the invest igator’s trial site 
must be documented on a D ata Clarificat ion Form (DCF) or a Monitor-Initiated Discrepancy Form 
(MIDF).
12.2 Case report form flow 
The invest igator must ensure that data is recorded in the eCRF as soon as possible, preferably 
within 3 days after the visit. Once data have been entered, it will be available to Novo Nordisk for 
data verificat ion and validat ion purposes. 
Site specific eC RF data (in an electronic readable form at) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
When the final Clinical Tr ial Report (CTR) is available, the data will be archived by Novo Nor disk.
12.3 Electronic diary
Novo Nordisk will provide the patient’s parent(s)/LAR(s) with an eDiary for electronic recording of 
details o f their child’s prophylaxis administration, bleeding episodes and treatm ent hereof, see 
Sections 8.1.1 and 8.6. The eDiary and related support services will be supplied by a vendor 
working under the direct ion and supervisio n of Novo Nordisk. 
When init iating ho me treatment, t he patient’s parent(s)/LAR(s) will receive the eDiary and they will 
be trained in the use thereof by t he investigator or delegated person. D ata will be entered by the 
patient’s parent(s)/LAR(s) in the eDiary  device during hom e treatm ent. 
During tri al site visi ts, data will be recorded in the eCRF by the tri al staff and shoul d not be entered 
by the patient ’s parent(s)/LAR(s) in the eDiary . The eDi ary will be returned by  the pati ent’s 
parent(s)/LAR(s) at the EOT visit. 
All data entered will be transferred fro m the device to an electronic database, where it is kept as a 
certified copy  of the source data. Dat a entered in the device will upon confirmat ion of a successful 
back-up be del eted f rom the device.
The eDiary  will have buil t in edit checks and reminders, to ensure that all relevant questions are 
answered. 
eDiary data transferred to the electronic datab ase will be viewable to relevant trial site staff and 
Novo Nordisk personnel on a secure, password protected web portal.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 90 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 91of 119
  It is the responsibilit y of the invest igator or del egated staff to revi ew and thereby ensure the eDiary  
data quali ty. Following must be checked as minimum : that t he eDiary data is complete, consistent 
and according to the requirements defined in th is protocol . Upon revi ew the invest igator or 
delegated staff must docum ent that the review has taken place and any act ions requi red e.g. 
retrai ning of pat ients.
It must be confirmed by the patient’s parent(s)/LAR(s) if missing eDiary data need to be entered 
and/or if the transferred eDiary data needs to be corrected. This is done by  filling in and forwarding 
a Data Clarificat ion Form (DCF) to the eDiary vendor. An audit trail will be maintained.
12.4 Tablets for neurocognitive assessments
The CRO will provide the sites wit h tablets for neurocognitive assessments including Structured 
Developmental History  and Haem ophilia History . In some occurrences the collect ion of these 
assessments will be done on paper forms. 
Data will be entered on the tablet at si te by  the pat ient, patient’s parent(s)/LAR(s) and in so me cases 
by trained staff. All data entered will be transferred fro m the tabl et to a database. 
The results of the assessments will be viewable on a web based portal when transmitted from the 
tablet. The web based portal is password protected.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 91 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 92of 119
  13Monitoring procedures 
During the course of the trial, the monitor will visit the trial site to ensure that the protocol is 
adhered to, that all issues have been recorded, to perform source data ve rification and to monitor 
drug accountabilit y. 
After site i nitiation visit , siteshoul d be contacted every  quarter , and visited at least every  6 months . 
The contacts (calls or visits) can be part of a monitoring visit in another trial . Thesecontact sshou ld 
be docum ented. 
A monitoring visit must be performed as soon as possible after FPFV and no longer than 4 weeks 
after. The m onitoring intervals will depend on the outcome of the remote monitoring of the eCRFs, 
the trial site's recrui tment rate and the co mpliance of the trial site to the protocol and GCP. The 
intervals between mo nitoring visits must not exceed 12 weeks whilst patients are in the trial
between visit 0 and visit 28. I n the period after visit 28 , intervals between monitoring visits must 
not e xceed 2 4 weeks ± 4 weeks (whilst pati ents are on the trial) , provi ded si te contact at l east every  
12 weeks. The m onitor m ust be given di rect access to source documents (original documents, data 
and records). Direct access includes permissio n to examine, an alyse, verify  and reproduce any  
record(s) and report(s) that are important to the evaluat ion of the trial .If the el ectroni c medical  
record does not have a visible audit trail, the investigator must provide the monitor with signed and 
dated printouts. In a ddition,the relevant tri al site staff shoul d be available for discussio ns at 
monitoring visits and between monitoring visit s (e.g.by telephone).
For all data recorded the source document must be defined in a source document agreement at each 
trial site. 
There m ust only be one source defined at any  time for any  data el ement.
All data must be verifiable in source d ocum entati on other than the eCRF, except for the fo llowing 
data that may be recorded direct ly in the eCRF and will then be considered source data :
Ethnicit y
Race
The patient will only be ident ified by pat ient number and the monitor will verify and ensure that the 
eCRFs and eDiary  are com pleted. Also i t must be checked that the eDiary  data revi ew has been 
docum ented by  invest igator and that the nee ded acti on has been taken, if any .
Moni tors m ust revi ew the pati ent’s m edical  records and other source data (e .g. the diaries ) to ensure 
consistency and/or ident ify omissio ns co mpared to the CRF. If discrepancies are found, the 
investigator must be questioned about these.
A follow-up letter (paper or el ectroni c) will  be sent to the invest igator following each mo nitoring 
visit addressing any act ion to be taken.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 92 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 93of 119
  For screening failures: Data for the screen ing visit must be entered in the eCRF within pre ferably 
5 day safter data are available and the Screening Failure Form must be completed. Source data 
verification is not re quired except for informed consent, reason for screening failure and for data 
relating to any AEs if applicable. All data entered in the eCRF will be transferred into the trial 
database.
For withdrawn patients: All data collected in the period the patient participated in the t rial will be 
entered into eCRF.
All information captured during visit sto the tri al site will be co llected either in the eCRF , via tablet
or on paper questionnaires . When hom e treatm ent is ini tiated all bleeding episodes and inject ions 
with N9-GP occurring outside the trial site should be entered in the eDiary  by the pat ient’s 
parents/LAR ( seeSection8.8.3 ). The completed eDiary is considered source data. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 93 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 94of 119
  14Data management
Data m anagement i s always the responsibilit y of Novo Nordisk. 
Data m anagement m ay be delegated under an agreement of transfer of responsibilit ies to another 
data m anagement unit within Novo Nordisk or an external Clinical Research Organisat ion (CRO).
Appropriate measures, including encry ption of data files containing person identifiable da ta, will  be 
used to ensure confident iality of patientdata, when they are transmitted over open networks. 
Laboratory  data from  central  laboratori es will  be transferred electronically fro m the laboratory  
performing the analyses. In cases where laboratory d ata are transferred via non -secure el ectroni c 
networks, data will be encrypted during transfer.
The central and local laboratories will provide laboratory  reports to the investigator for storage at 
the trial site. The l aboratory  report m ust be signed and d ated by  the invest igator or delegated person 
and stored at the trial site as source data.
The patientand any  biological materi al obtained from  the patientwill be identified by patient 
number and trial ident ification number. Appropriate measures such as e ncryption or l eaving out 
certain identifiers will be enforced to protect the ident ity of patients in all presentations and 
publicat ions as required by local, regional and nat ional requirements.
The system and paper based quest ionnaires for neurocogni tive a ssessments and support services for 
the system swill be supplied by a CRO. The CRO will co llect, query ,and process data from 
Structured Developmental and Haemophilia History, as well as N eurocogni tiveassessments .The 
CRO will transfer assessment resul ts and outcomes from the External Expert Review Panel to Novo 
Nordisk. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 94 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 95of 119
  15Computerised systems
Novo Nordisk will capture and process clinical data using co mputerised systems that are described 
in Novo Nordisk Standard Operating Procedures (SOPs) and IT archit ecture documentation. The 
use and control of these systems are documented.
Invest igators working on the trial may use their own electronic systems to capture source data. 
Novo Nordisk will co llect informat ion on the practical use of these systems wit hin th e conduct of 
this clinical tri al. 
Novo Nordisk will use CONNECT as i nvest igator portal  to distribute and share trial -related 
docum ents and informat ion with the parti cipat ing sites.
The eDiary  and tablets for neurocognit ive assessments software and hardware implementation are 
compliant wi th the requi rements of FDA 21 CFR Part 11 and ICH E6 (EU directive for personal 
data protecti on)
.1, 21After tri al com pletion, each trial site will be supplied with lo ng-life CDs. These 
CDs will contain site -specific patient records including the patient’s eDiaries and audit trail 
including any  data addi tions and corrections made on each form. The e Diary vendor will  
furtherm ore retain and securely  store copi es of  all archived docum ents and data for 15 years or as 
requi red by l ocal data retenti on laws f or tri al data. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 95 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 96of 119
  16Statistical considerations
Novo Nordisk A/S will be responsible for the statistical analysis.
The m ain stati stical reporting of the tri al will be perform ed when at least 20 patients have 
completed m ain phase (minimum 50 weeks) wit h at least 50 EDs and completed visit 23. Data fro m 
patients not yet having completed main phase and data fro m patients that have entered extensio n 
phase at this po int will be included up to latest visit prior to this cut -off date. The data will be 
presented for the main phase and extension phase separately as well as co mbined. Except for the 
confidence interval for inhibitor rate and for annualised bleeding rate, the evaluat ion of data will be 
based on descript ive statist ics, i.e. summary  tables, list ings and figures. 
An updated statist ical reporting of the trial wit h supporti ve data will be performed when at le ast 40 
patients have had at least 100 EDs. Data from all patients will be included up to latest visit prior this 
cut-off date. The data will be presented for the main + extensio n phase and the extended 
prophylaxis period (bey ond 100 EDs) separately as well as co mbined. 
All data will be reported separately  in a final  report when the tri al is com pleted.
Figure 16–1 Individual patient flow and time period for main trial report
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 96 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 97of 119
  Multiple bleeding l ocati ons occurring fro m the same event (e.g. due to a fall) or at the same time 
point will be counted as one bleeding episode.
All bleeding endpo ints will be evaluated based on bleeding episodes treated with N9-GPunless the 
bleeding was considered clinically insig nificant (non -treatment requiring bleeding episode) and the 
associ ated treatm ent given was part of prophylaxis.
Neurocognit ive assessments will be evaluated primarily based upon reference ranges gained fro m 
children and young adults of a parallel observat ional haemophilia norm ative study  (HAEM -4436, 
eTHINK) and secondarily upon normative reference ranges fro m the general popul ationto the 
extent possible . Individual  case review by  an External Expert Review Panel, considering also 
analysis of factors influen cing outcome in haemophilia and reported in the structured developmental 
history , will  be reflected in narrative and categorical assessments (see Secti on8.3.3 ).
If necessary, a statistical analysis plan (SAP) may be written in addit ion to the protocol, including a 
more technical and detailed elaboration of the statistical analyses. If created, the SAP will be 
finalised before the first database lock . 
16.1 Sample size calculation
No formal sample size calculat ions have been performed. The sample size of 40 com pleters is based 
on EMA guideline5.
16.2 Definition of analysi s sets
Descript ions and analysis o f efficacy  will be based on the Full Analysis Set (FAS), as defined in 
ICH E9 gui delines .22The FAS includes all patients expos edto N9-GP. The safety  analysis and 
descript ions will be based on the Safet y Analysis Set (SAS). The SAS will consist of all pat ients 
exposed to N9-GP.
The patients or observat ionsto be excluded, and the reasons for their exclusio n must be documented 
and signed by  those responsible before database lock. The patients and observations excluded from 
analysis sets, and the reason for this, will be described in the clinical trial report .
16.3 Primary endpoint
The primary  endpoint is a safet y endpo int defined as incidence of inhibitory  antibodies against FIX.
The rate of inhibitory  antibodi es will be reported and a 1 -sided 97.5% upper confidence limit will 
be provided based on an exact calculat ion for a binomial distribut ion. For the calculat ion of the rate 
the numerator will include the patients with inhibit ors, while the deno minator will include all 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 97 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 98of 119
  patients wi th a minimum  of 10 exposure day s plus any pat ient with less than 10 exposure days but 
with inhibitors. 
16.4 Secondary endpoints
16.4.1 Confirmatory secondary endpoints
There are no confirmatory  secondary  endpoints.
16.4.2 Supportive secondary endpoints
16.4.2.1 Number of bleeding episodes during prophylaxis
Annualised bleeding rate will be summarised and a 95% two sided confidence interval will be 
provi ded based on a negat ive binomial regressio nmodel with number of bleeding episod es 
requi ring treatm ent wi th N9-GP (also referred to as breakthrough bleeding episodes ) as the outcome 
variable, and adjust ing for exposure time. For comparison wit h previous trials, a sensit ivity analysis 
based on a Poisson regressio n model allowing f or ov er-dispersio n will also be performed.
Since it m ust be expected t hat some pat ients will wit hdraw , it becom es essential  to account for how 
such wi thdrawals may affect the analyses of the prophylaxis effect. The analyses above already  
account for possible di fferent treatment durations by  using treatm ent durati on as an offset. Thi s is a 
proper adjust ment if withdrawal  is not rel ated to the observed bleeding frequency. However, since it 
is possible that patients will wit hdraw exact ly because of the observed ble eding rate i t is important 
to perform sensit ivity analyses that m ay account for withdrawn patients possibly being qualitat ively 
different fro m completing pat ients.
Specifically , this will be done by performing sensit ivity analyses for all prophylaxis analy ses using 
a last observat ion carri ed forward (LOCF) approach for all pat ients with at least 1 m onth 
prophylaxis treatment duration by calculat ing the yearly bleeding episode rate for withdrawn 
patients and use that as an endpo int. As an example ;a pati ent with 6 bleeding episodes in 4 months 
will have an endpo int value of 18 corresponding to a maintained bleeding rate of 18 bleeding 
episodes per y ear. For pati ents wi thdrawing wi thin 1 m onth thi s method is considered to give too 
uncertain LOCF values, hence imputation will not be attempted for such patients.
Annualised bleeding rate will also be summarised by  type of  bleeding episode.
16.4.2.2 Haemostatic effect
Descript ion of the haemostatic effect of N9-GP when used for treatment of bleeding episodes will 
be summarised and listed according to the four point scale for haemostatic response ( poor, 
moderate, good and excellent). 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 98 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 99of 119
  A success rate will be calculated based on counting good or excellent as successes and poor and 
moderate as failures and based only  on reported outcom es.
For the calculat ion of the success rate the numerator will include all treated bleeding episodes with 
a reported haemostatic response of good or excellent, while the deno minator will i nclude all treated 
bleeding episodes with a reported haemostatic response. A sensit ivity analysis will  also be 
conducted where the deno minator also includes treated bleeding episo des wi th missing response 
(i.e.missing response is counted as a failure).
Haemostati c effect will be determined based on haemostatic response for bleeding episodes 
occurring both during pre -prophylaxis and prophylaxis period.
Haem ostati c response will also be summarised by  type of bleeding.
16.4.2.3 FIX activity
Incremental  recovery 30 minutes post dosing (IR 30min), FIX activit y30 minutes post dosing (C30min),
and trough FIX activit ylevel will be assessed at visits according to Table 2–1.
FIX trough level is defined as the activit y recorded immediately before N9 -GP inject ion is given 
and reported as IU/mL. IR 30min is defined as the rise in FIX activit y per IU/kg administered and is
recorded 30 minutes after the end of N9 -GP inject ion, and reported as [ IU/mL] /[IU/kg]. It is 
calculated as the pre-dose subtracted FIX activit y recorded 30 minutes after ended N9- GP inject ion 
and dividing the administered dose (IU/kg body  weight (bw )).
16.4.2.4 FIX consumption 
Amount of N9-GPused for prophylaxis (IU/Kg/month /year)and amount consumed per bleeding 
episode ( number of doses and IU/ kg bw/bleeding episode) will be summarised and listed.
16.4.2.5 Safety endpoints
Adverse events including SAEs, MESI and development of HCP antibodies
Treatment emergent AEs (TEAEs, defined as AEs occurring after dosing wit h trial product) and 
treatm ent emergent SAEs (TESAEs) will be summarised by  frequency of events and frequency  of 
patients wi th any event. Similar summarie s cross -classified by severit y and by causal relat ion to 
trial produc twill also be m ade.
MESIs will be summarised similarly to AEs.
Furtherm ore, list ings will be provided displaying all TEAEs and TESAEs including pertinent 
clinical informat ion.
HCP ant ibodies will  be listed.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 99 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 100of 119
  All additional safet y parameters such as laboratory parameters , including calculation o f estimated 
glomerular filtrat ion rate (eGFR), and physical examinat ions, including neurological assessments,
will be summarised and listed.
16.5 Neuroco gnitive assessments
Age-adjusted d omain and com posite scores for each neurocognit ive instrum ent will be calculated 
using available methods.
The individual patient overall/do main/sub -scores for each neurocognit ive assessment instrument 
will be expressed as an individual’s Z- score (i .e. an indication o f how m any standard deviat ions a 
domain score is from the mean) and co mpared to reference ranges fromnorm ative data for children 
and y oung adul ts with haemophilia (adjusted for appropriate ident ified covariates) ( HAEM -4436, 
eTHINK study ). All the scores will be provided by a CRO. The individual score versus time o f 
exposure (y ears) will be presented graphically perpatient.
In addition, all  data and scores will be summarised and listed.
16.6 Interim reporting
All data from main phase of the trial will be analysed and reported when minimum 20 pat ients have 
completed m ain phase with at least 50 EDs and completed visit 23. This report will cover all 
endpo ints and will formthe basis for the paediatric indication . Data from  patients that have entered 
extensio n phase at this po int will be included up to latest visit prior this cut -off date. The data will 
be presented separately for the main phase and extensio n as well as co mbined. The main conclusio n 
from the trial will be drawn based on the main phase data.
Furtherm ore,interim analyses may be performed in associat ion with marketing authorisat ion 
applicat ionsor in connect ion with Heal th Authori ties e.g.FDA, EMA and PMDA req uirement 
for/during the regulatory  review or to obtain safet y data.
An updated report with supportive data will be made when minimum 40 pat ients have had at least 
100 EDs. A final report with supportive data will be made when all pat ients have co mpleted both 
parts of the trial.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 100 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 101of 119
  16.7 Sequential safety analysis and safety monitoring
Novo Nordisk A/S will const itute an internal safety  commi ttee to perform  on-going safet y 
surveillan ce. The tri al will  be subject to thresho lds evaluated by the safety  commi ttee (see Section 
11.6.1 ).
16.8 Reporting of F9and HLA genotype
Inform ation about underlying gene defects of F9 and HLA will be listed in the clinical trial report. 
No stati stical analysis will be performed. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 101 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 102of 119
  17Ethics
Parti cipation in this trial  coul d be a possible benefit for the patient in terms of closer monitoring of 
the pati ent by  the investi gator, com pared to standard care and possible avoidance of bleeding 
episodes. As with all investigational drugs, there is an anticipated ri sk of potential side effect (ref. 
IB).7
The tri al will be conducted in com pliance wi th ICH GCP1and applicable regulatory requirements, 
and in accordance with the Declaration o f Helsinki2. 
17.1 Informed consent 
In seeking and document ing informed consent, the inves tigator m ust com ply with applicable 
regul atory  requi rement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki2.
Before any  trial-related activit y, the invest igator must give the patient and/or the patient’s 
parent(s)/LAR(s)) verbal and written informat ion about the trial and the procedures invo lved in a 
form that the pati ent or the pati ent’s parent(s)/ LAR (s)can read and understand. This includes the 
use of an impartial wit ness where required. In this trial the notion of LAR is the legal 
representatives, as defined in Member States’ nat ional laws, who consent on behalf o f the child.
The patient or the pati ent’s parent(s)/LAR(s) must be fully informed of their rights and 
responsibilit ies while participating in the trial as well as possible disadvantages of being treated 
with the trial  product .
The invest igator must ensure the patient and /or patient’s parent(s)/LAR(s) ample time to come to a 
decisio n whether or not to participate in the trial.
The requi rement for obtaining informed consent from a patient’s parent(s)/LAR (s)is that the patient 
is unable to provi de inform ed consent, and the process has been approved by the relevant IRB/IEC.
A voluntary , signed and personally dated informed consent form mustbe obtained fro m the 
patient’sparent(s)/LAR(s) before any  trial-related activit y. In thi s trial where informed consent and 
exposure to the N9-GPmay occur on the same day, informed consent form must inclu de a time 
field next to the date field.
Consent : As a child is unable to provi de legally  binding consent, informed consent must be sought 
from the patient’s parent(s)/LAR on the child’s behalf. The specific and written informed consent of 
the parent(s)/LAR must be sought prior to enrolling a child in the trial. Informat ion about the trial 
shoul d be given by an experienced invest igator. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 102 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 103of 119
  For c hildren ,from birth to the age of 3 years o ld, it is not possible to obtain assent and 
understanding of research is not expected .18
Patients above the age of 3 y ears ol d shoul d sign a child assent form, if capable, and if required by  
local requi rements. Thi s can be perform ed on a separate day; especially for long -term trials here the 
investigator should check the progressing maturation of the child and its abilit y for assent.
The responsibilit y for seeking informed consent must remain with the investigator, but the task may 
be delegated by  the invest igator to a medically qualified person, in accordance wit h local
requi rements. The wri tten informed consent including time must be signed and personally dated by  
the person who seeks the informed consent before trial -related activit y.
The informe d consent form  contains a sect ion explaining that Novo Nordisk is asking permissio n to 
store l eft over bl ood f rom blood sam ples and use it  to analyse for further analyses characterising 
biomarkers within the trial. The accept is vo luntary and independent o n participat ion in the trial. If 
inform ation beco mes available that may be relevant to the patient’s willingness to continue 
participat ing in the trial, the investigator must info rm the pati ent and/or the patient’s parent(s)/LAR 
in a timely  manner, and a r evised written informed consent must be provi ded and a new informed 
consent must be obtained.
F9and HLA genotype testing/collection of previous genotype documentation :
If docum entati on of  the pati ents’ genoty pe al ready  exists, the data can be used for trial purpose. 
Only the F9and HLA genoty pe will be analysed by  the central  laboratory  selected by  Novo Nordi sk 
A/S and no other geno mic analyses will be carried out. Samples will be appropriately disposed of, 
after the test. All test results are kept strictl y confident ial in sufficient considerat ion of individual 
inform ation.
17.2 Data handling
If the patient is wit hdrawn from the trial or lost to follow up, then the patient ’s data will be handled 
as fo llows:
Data al ready  collected and data collected at the end -of-trial visit will be retained by  Novo 
Nordi sk, entered into the database and used for the trial report
Safety events will be reported to the Novo Nordisk and regulatory  authori ties according to 
local/nat ional requirements
If data are used, i t will  always be in accordance with local law and IRBs/IECs.
17.3 Information to patient, parent(s)/LAR(s) during the trial
The trial site will  be offered a communicat ion package to the patient and/or the patient’s 
parent(s)/LAR(s) during the conduct of the trial. The package content is issued by  Novo Nordi sk. 
The communicat ion package will contain the letters/booklets intended for distribut ion to the 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 103 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 104of 119
  patients. The l etters/bookl ets will be translated and adjusted to local requirements and distr ibuted to 
the pati entand/or the patient’s parent(s)/LAR(s) by discret ion of the invest igator. The patient and/or 
the pati ent’s parent(s)/LAR(s) may receive a "welcome to the trial letter" and a "thank for y our 
participat ion letter" at the end of the trial . Further the pat ient and/or the patient’s parent(s)/LAR(s) 
may receive trial letters and/or small toy during the trial period. 
All information inclusive material and toy s tothe patientswill be submitted to the healt h authorit ies 
and IECs/IRBs for appro val according to local regulat ions.
17.4 Premature termination of the trial and/or trial site
Novo Nordisk, the invest igator, the IRBs/IECs or a regulatory authorit y may decide to stop the trial, 
part of the trial or a trial site at any  time, but subject to the following procedure .
If a tri al is suspended or prem aturely  terminated, the invest igator must inform the patients prom ptly 
and ensure appropriate therapy  and fo llow-up. The invest igator and/or Novo Nordisk should also 
prom ptly inform the IRBs/IECs and pr ovide a detailed wri tten explanat ion. The relevant regulatory  
authori ties mustbe informed.
If, after the termination o f the trial, the risk/benefit  analysis changes, the new evaluat ion should be 
provi ded to the IRBs/IECs in case it has an impact on the pl anned fo llow-up of  patientswho have 
participated in the trial. If it hasan impact, the actions needed to inform and protect the patients
shoul d be described.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 104 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 105of 119
  18Protocol compliance
Deviat ions from  the protocol  shoul d be avo ided.
If deviat ions do occur, the invest igator must inform the mo nitor and the implicat ions of the 
deviat ion must be reviewed and discussed.
Deviat ions m ust be docum ented and explained in a protocol deviat ion by stating the reason, date, 
and the action(s) taken. Some deviat ions, for which correcti ons are not possible, can be
acknowledged and confirmed via edit checks in the eCRF or via list ings fro m the clinical database. 
Docum entati on on all protocol deviat ions must be kept in the invest igator’s trial file and Novo 
Nordi sk tri al master file.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 105 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 106of 119
  19Audits and inspections
Any aspect of the clinical trial may be subject to audits conducted by  Novo Nordisk or inspect ions 
from domestic or foreign regulatory authorit ies or fro m IRBs/IECs. Audit s and inspections may 
take pl ace during and after the tria l. The invest igator and the trial site staff as well  as Novo Nordi sk 
staff have an obligat ion to cooperate and assist in such audits and inspect ions. This includes giving 
auditors and inspectors direct access to all source documents and other documents at the trial site 
relevant to the clinical trial. This includes permission to examine, analyse, verify and reproduce any  
record(s) and report(s) that are relevant to the evaluation of the trial.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 106 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 107of 119
  20Critical documents
An Invest igator Portal (CONNECT) will be used as primary media for exchange and handling of 
investigator trial file documents between Novo Nordisk and the trial site.
Before a trial site is allowed to start screening patients, the fo llowing docum ents m ust be available 
to Novo Nordisk:
Regulatory  approval  and/or acknowl edgement of notification as required 
Approval/favourable opinio n from IRBs/IECs clearly ident ifying the documents reviewed as 
follows: protocol , any protocol  amendments, patient information/informed consent form, any 
other written information to be provided to the patient and patientrecruit ment materials
List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
Curri cula vitae o f investigator and sub -invest igator(s) (current, dated and signed -must include 
docum ented GCP training or a certificate)
Signed recei pt of  Invest igator's Brochure 
Signed and dated agreement on the final protocol
Signed and dated agreement on protocol amendment, if applicable
Financial agreement(s)
Source do cument agreement
Central  laboratory  certificat ion and norm al ranges
Insurance statement, if applicable
Signed and dated Invest igator Agreement
Financial disclosure form fro m investigator and sub -invest igator(s)
Only applicable for US trial sites: 
For US trial sites: verificat ion under di sclosures per Code of Federal Regulat ions (CFR) of 
Financial Conflict of Interest
For US tri al sites: FDA form  1572 m ust be com pleted and si gned by each invest igator
FDA form 1572:
For US si tes:
Intended for US trial sites
Conducted under the IND
All US inve stigators, as described above, will sign FDA Form 1572
For si tes outsi de the US:
Intended for participat ing trial siteoutsi de of  the US
Not conducted under the IND
All invest igators outside of the US will not sign FDA form1572
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 107 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 108of 119
  Novo Nordisk will analyse and report data from all trial sites together.
For l ocal lab param eters the fo llowing will be collected:
Laboratory  norm alranges
Laboratory  certificat ion/QA scheme/other documentation
Laboratory  methods (only non-standard assays) and/or analyt ic methods
By signing the protocol , each invest igator agrees to comply fully wit h ICH GCP1, applicable 
regul atory  requi rements and the Decl aration of Helsinki2. 
By signing the p rotocol , each invest igator also agrees to allow Novo Nordisk making invest igator's 
name and information about trial site name and address publically available if this is required by 
national or international regulat ions.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 108 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 109of 119
  21Responsibilities
All staff (Novo No rdisk, trial site, laboratory , CRO etc) will conduct the tri al in co mpliance wit h 
ICH GCP1, applicable regulatory  requi rements and the Declaration of Helsinki.2
The invest igator is accountable for the conduct of the trial at his/her trial site. If  any tasks are 
delegated, the investigator must maintain a list of appropriately qualified persons to whom he/she 
has delegated specified significant trial -related duties. The invest igator must ensure that there is 
adequate training for all staff participating in the conduct of the trial. It is the invest igator’s 
responsibilit y to superv ise the conduct of the trial and to protect the rights, safet y, and well -being of 
the pati ents. At least invest igator must be trained in the protocol at a Novo Nordisk meet ing or by 
web training in the protocol. It is recommended that all site staff takes the web p rotocol  training. A 
qualified physician, who is an invest igator or a sub- invest igator for the trial, must be responsible for 
all tri al-related m edical decisio ns.The investigator must ensure adequate supervisio n of the conduct 
of the tri al at the trial site. 
The invest igator will fo llow instructi ons fro m Novo Nordisk when processing data.
The invest igator is responsible for filing essential documents (i .e.those documents which 
individually  and collect ively permit evaluat ion of the conduct of a tr ial and the qualit y of the data 
produced) in the investigator’s trial file. The documents should be kept in a secure locked facilit y, 
so no unauthori sed persons can get access to the data. The patient ident ification code list should be 
kept securely and se parate from  the personal  data.
The invest igator will take all necessary technical and organisat ional safet y measures to prevent 
accidental  or wrongful destruction, loss or deterioration of data. The investigator will prevent any  
unauthori sed access to data or any  other processing of data against applicable law. The invest igator 
must be able to provide the necessary  information or otherwise demo nstrate to Novo Nordisk that 
such technical and organisat ional safet y measures have been taken.
During any period o f unavailabilit y, the i nvest igator should delegate responsibilit y for medical care 
of patients to a specific qualified physician who will be readily  available to patients during that 
time.
If the invest igator is no longer able to fulfil the role of invest igator (e .g.if he/she moves or retires), 
a new invest igator will be appo inted in consultation with Novo Nordisk. 
The invest igator and other site personnel must have sufficient English skills according to their 
assigned task(s).
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 109 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 110of 119
  22Reports and publications
The informat ion obtained during the conduct of this trial is considered confident ial, and m ay be 
used by Novo Nordisk for regulatory purposes and for the general development of the trial product. 
All information supplied by  Novo Nordi sk in connection wit h this trial shall remain the sole 
property  of Novo Nordisk and is to be considered confident ial information. No confident ial 
inform ation shall be disclosed to others without prior written consent fro m Novo Nordisk. Such 
inform ation shall not be used except in the performance o f this trial. The informat ion obtained 
during thi s trial may  be m ade available to other physicians who are conducting other clinical trials 
with the trial  product, if deemed necessary  by Novo Nordisk. Provi ded that certain condit ions ar e 
fulfilled, Novo Nordisk may grant access to informat ion obtained during this trial to researchers 
who require access for research projects studying the same disease and/or trial product studies in 
this trial.
Novo Nordisk may publish on its clinical tria ls website a redacted clinical trial report.
A principal invest igator will be designated as the signatory  investigator with the responsibilit y to 
review and sign the main report based on data from when at least 20 PUP have reached at least 50 
EDs.
22.1 Communic ation of results
Novo Nordisk commits to communicat ing, and otherwise making available for public disclosure, 
resul ts of trials regardl ess of outcom e. Public disclosure includes publicat ion of a paper in a 
scientific journal, abstract submissio n with a pos ter or oral presentation at a scient ific meeting, or 
disclosure by other m eans.
The results of this tri al will be subject to public disclosure on external web sites according to 
internat ional and nat ional regulat ions, as reflected in the Novo Nordisk Code of Conduct for 
Clinical Trial Disclosure23.
Novo Nordisk reserves the right to defer the release of data un til specified milestones are reached, 
for example when the clinical trial report is available. This includes the right not to release the 
resul ts of interim analyses, because the release o f such informat ion may influence the resul ts of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/o r 
communicat ion for up to 60 day s to protect intellectual property .
In all cases the trial result s will be reported in an object ive, accurate, balanced and co mplete 
manner, with a discussio n of the strengths and limitations. All authors will be given the r elevant 
statist ical tables, figures, and reports needed to evaluate the planned publicat ion. In the event of any  
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 110 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 111of 119
  disagreement on the content of any publication, both the invest igators’ and Novo Nordisk opinio ns 
will be fairly and sufficient ly represented i n the publicat ion.
Where required by  the j ournal , the principal  investigator from  each tri al site will  be named in an 
acknowledgement or in the supplementary  material, as specified by  the j ournal . 
Novo Nordisk maintains the right to be informed of plans b y any  invest igator to publish and to 
review any  scientific paper, presentation, communication or other informat ion concerning the 
investigat ion described in this protocol. Any  such communicat ion must be submitted in writ ing to 
the Novo Nordisk trial manage r before submissi on for comments. Comments will be given within 
four weeks from receipt of the planned co mmunication.
22.1.1 Authorship
Authorship of publicat ions should be determined in accordance wit h the Uniform Requirements of 
the International Co mmit tee of  Medical Journal Editors (sometimes referred to as the Vancouver 
Criteria24).
Authorship credit should be based on :
Substant ial contribut ions to conception and design, acquisit ion of data, or analysis and 
interpretati on of  data; 
Drafting the arti cle or revi sing i t critically for imp ortant intellectual content; and 
Final approval of the versio n to be published.
22.1.2 Trial s ite-specific publication(s) by investigator(s)
For a m ulti-centre clinical trial, analyses based on single -site data usually have significant statist ical 
limitations a nd frequently do not provide meaningful information for healt hcare professio nals or 
patients, and therefore may not be supported by  Novo Nordisk. It i s a Novo Nordisk policy that 
such individual reports do not precede the primary  manuscri pt and shoul d always reference the 
primary  manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publicat ions. Further to allow for the 
primary  manuscript to be published as the first, Novo Nordisk asks for deferment of publicat ion of 
individual trial site resul ts unt il the primary manuscript is accepted for publicat ion. As Novo 
Nordi sk wants to live up to the industry  publicati on policy, submission for publicat ion of such 
primary  policy  will take pl ace no l ater than 18 m onths after trial co mpletion.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 111 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 112of 119
  22.2 Investigator access to data and review of results
As owner of the trial database, Novo Nordisk has the discret ion to determine who will have access 
to the database. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 112 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 113of 119
  23Retention of clinical trial documentation and human biospecimens
23.1 Retention of clinical trial documentation
Patient’s medical records m ust be kept for the maximum period permitted by  the hospi tal, 
institution or private practice.
The invest igator must agree to archive the documentation (this includes both electronic and paper -
based records) p ertaining to the trial in an archive after complet ion or di scont inuat ion of the trial if 
not otherwise notified. The invest igator should not destroy  any docum ents wi thout pri or permissio n 
from Novo Nordi sk. If  the invest igator cannot archive the documents at the tri al site, Novo Nordi sk 
can refer the invest igator to an independent archive provider that has a system in place to allow only 
the invest igator to access the files.
The invest igator must be able to access his/her trial documents without invo lving N ovo Nordisk in 
any way. Trial site-specific CRFs and other patient data (in an electronic readable format or as 
paper copi es or pri nts) will be provided to the investigator before access is revoked to the sy stem s 
and/or electronic devices supplied by Novo Nordisk. These data m ust be retained by  the trial site. If  
the Novo Nordisk provided data (e .g.the CD -ROM) is not readable during the ent ire storage peri od, 
the invest igator can request a new copy, as a copy of all data will be stored by Novo Nordisk.
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for as long as the 
product is on the market plus 20 y ears. 
The files fro m the investigator trial site/insti tution must be retained for 15 y ears after the 
completion of the trial, or longer if required by natio nal regulat ions. The delet ion process must 
ensure confident iality of data and must be done in accordance with local regulatory  requi rements .
23.2 Retention of human biospecimens
Storage and disposit ion of samples analysed at local laboratories will be performed according to 
local labora tory procedures. 
Blood sam ples apart from  antibody  and bi ospecimen samples will be destroyed after the finalisat ion 
of the CTR. Ant ibody  samples (samples for binding antibodies and inhibitors) will be stored un til 
drug approval by  Food and Drug Administration (FDA) and/or European Medicines Agency  (EMA) 
or until the project terminates, but no longer than 15 years fro mend of trial. Biospecimens will be 
destroy ed at the l atest 15 years from  end of trial. As new bio markers related to the disease and/or 
safet y, efficacy, or mechanism of act ion of N9 -GP may evo lveduring the conduct of the trial, the 
analyses o f the stored biospecimens may also include bio markers that are unknown at present or 
have not been included in the scient ific hypotheses at init iation of the trial. The samples will be 
stored at Novo Nordisk A/S or a Novo Nordisk designated referral bio -reposi tory with access to the 
samples. Samples might be transferred to other countries, if not prohibited by local regulations. The 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 113 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 114of 119
  patient’s identi ty will remain confident ial and sampl es will  only be m arked and i dentified by  a 
unique sample ID (patient number and visit number). No direct ident ificat ion of the patient will be 
stored together with the samples. The analyses will not have any medical consequences for the 
patients or thei r relatives. Only Novo Nordisk staff and bio -reposi tory personnel (if applicable) will 
have access to the stored bio specimens. 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 114 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 115of 119
  24Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval  or favourabl e opini on must be obtained from  IRB/IEC pri or to commencement of 
the trial.
During the trial, the invest igator or sponsor, as applicable, must promptly report the fo llowing to the 
IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs where a causal 
relationship cannot be ruled out, protocol amendments ac cording to l ocal requi rements, deviat ions 
to the protocol implemented to eliminate immediate hazards to the patients , new informat ion that 
may affect adversely the safet y of the patients or the conduct of the trial (including new risk/benefit 
analysis in c ase it will  have an impact on the planned fo llow-up of  the patients ), annually written 
summaries of the trial status, and other documents as required by the local IRB/IEC.
The invest igator must ensure submission o f the clinical trial report synopsis to the IRB/IEC (not 
applicable for Japan).
Protocol  amendments m ust not be implemented before approval or favourable opinio naccording to 
local regulati ons, unless necessary  to eliminate immediate hazards to the patients .
The invest igator must maintain an accurate and complete record of all submissio ns m ade to the 
IRB/IEC. The records should be filed in the investigator’s trial file and copies must be sent to Novo 
Nordi sk.
Regulatory Authorities :
Regulatory  authori ties will  receive the clinical tri al applic ation (CTA), protocol amendments, 
reports on SAEs, and the CTR according to national requirements.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 115 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 116of 119
  25Indemnity statement
Novo Nordisk carries product liabilit y for its products, and liabilit y asassumed under the special 
laws, acts and/or guidelines f or conducting clinical trials in any  country , unless others have shown 
negligence.
Novo Nordisk assumes no liabilit y in the event of negligence, or any  other liabilit y of the si tes or 
investigators conducting the trial, or by  persons for whom the said siteor invest igator are 
responsible.
Novo Nordisk accepts liabilit y in accordance with:
Only applicable for Argentina: Novo Nordisk Pharma Argent ina S.A. has contracted insurance 
(policy  reference number 87828 and its respect ive updates) with the company  
. Domiciled in . Telephone 
number: .
Only applicable for Australia: Medicines Australia Guidelines for Compensation for Injury 
Result ing From Participation in a Co mpany -sponsored Clinical Trial. Versio n 160104B dated 16 
January  2004.
Only applicable for Austria: Arzneimittelgesetz (BGBI. Nr. 185/1983) last amended with BGBl. I 
Nr. 48/2013.
Only applicable for France: The French Public Health Code article L 1121- 10 (law n° 2004 -806 
of 9 August 2004 art. 88 I, IX Journal Officiel of 11 August 2004. "The sponsor is responsible for 
ident ificat ion of the harmful consequences of the bio medical research for the person lending 
himself thereto and for indemnificat ion of h is beneficiaries, except in case of proof, incumbent on 
it, that the prej udice is not attributable to his fault of or the fault of any intervening part y, without 
the sponsor's being ent itled to call on acts by a third party or the voluntary withdrawal o f the person 
who had init ially consented to cooperating in the research".
Only applicable for Netherlands: Wetgeving betreffende geneesmiddelen; geneesmiddelenwet 1 
juli 2007 (Medicines Law, 1 July  2007). De Wet Medisch -wetenschappelijk Onderzoek met mensen 
(WMO), 1 maart 2006 (Medical Research Involving Human Subjects Act, 1 March 2006). Besluit 
verplichte verzekering bij medisch -wetenschappelijk onderzoek met mensen 2015, 24 november 
2014 (Decree compulsory  insurance in medical research invo lving human subje cts 2015, 24 
November 2014). 
Only applicable for Poland: Novo Nordisk carries liabilit y for the Study  exclusively in the scope 
defined by the applicable laws and in particular by  the Civil Code and the Pharmaceut ical Law 
dated 6 September 2001 (uniform ve rsion Journal of Laws of 2008 No. 45 item 271 with 
amendments). In order to support potential claims for liabilit y attributable to the Study , Novo 
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 116 . -  | 1
 |
CONFIDENTIAL

Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 117of 119
  Nordi sk and Investigator are covered by  the Insurance Policy  issued according to applicable Polish 
law’.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 117 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 118of 119
  26References
1. International Conference of Harmo nisat ion. ICH Harm onised Tri partite Gui deline E6(R1): 
Guideline for Good Clinical Practice. 10 Jun 1996.
2. World Medical Associ ation. WMA Declarat ion of Helsinki -Ethical Principles for Medi cal 
Research Invo lving Human Subjects. Last amended by the 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.
3. Vander AJ, Sherman JH, Luciano DS. Hemostasis:The Prevent ion of Blood Loss. In: 
Vander AJ, Sherman JH, Luciano DS, editors. Human Physi ology. 6th ed: McGraw -Hill, 
Inc.; 1994. p. 741 -50.
4. BeneFIX -Summary of Product 
Characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Benefix/emea -
combined -h139en.pdf  . 2009.
5. EMA. Committee for medicinal products for human use (CHMP), Guideline on the Clinical 
Invest igation of Reco mbinant and Human Plasma -derived Factor IX Products, 
EMEA/CHMP/BPWP/144552/2009. 7/21/2011 2011.
6. Negri er C, Knobe K, Ti ede A, Gi angrande P, Moss J. Enhanced pharmacokinet ic properties 
of a glycoPEGylated re combinant factor IX: a first human dose trial in pat ients with 
hemophilia B. Blood. 2011;118(10):2695- 701.
7. Novo Nordisk A/S. Invest igator's Brochure, Nonacog beta pegol -Treatment and 
Prophylaxis o f bleeding in adults and children with Haemophilia B,8th Edition. 13 -Oct-
2017.
8. Srivastava A, Brewer AK, Mauser -Bunschoten EP, Key  NS, Ki tchen S, Llinas A, et al. 
Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1 -47.
9. Ivens IA, Baumann A, McDonald TA, Humphries TJ, Michaels LA, Mathe w P. PEGylated 
therapeuti c proteins for haemophilia treatment: a review for haemophilia caregivers. 
Haem ophilia. 2013;19(1):11 -20.
10. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of 
the ISTH -SSC international FIX inhibitor registry (1997 -2006). Haemophilia. 
2009;15(5):1027 -31.
11. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey  J, Horton R, et al. Clinical trial 
registrati on: a statem ent from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250 -1.
12. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Am endments Act of 2007. 27 September 2007.
13. The European Parliament and the Council o f the European Council. Direct ive 2001/20/EC 
of the European Parliament and of the Council o f 4 April 2001 on the approximat ion of the 
laws, regulations and administrativ e provi sions of  the Member States relat ing to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communit ies. 01 May  
2001.
14. Guidance for indust ry. Assay  devel opment f or immunogenicit y testing therapeuti c proteins. 
Food and Drug Administration. 2009 2009.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 118 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 05 November 2019 Novo Nordisk
Trial ID: NN7999 -3895 Version: 8.0
UTN: U1111 -1135-9557 Status: Final
EudraCT No.: 2012 -004867 -38 Page: 119of 119
  15. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. 
Reco mmendat ions for the design and optimization of immunoassays use d in the detection of 
host antibodies against biotechno logy products. Journal o f Immuno logical Methods. 
2004;289(1 -2):1-16.
16. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco -Kent D, et al. 
Reco mmendat ions for the validat ion of immunoassays used for detection of host antibodies 
against biotechno logy products. Journal  of Pharm aceuti cal and Bi omedical Analysis. 
2008;48(5):1267 -81.
17. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire -Sluis AR, et al . 
Reco mmendat ions for the des ign, optimizat ion, and qualificat ion of cell -based assays used 
for the detecti on of  neutralizing antibody  responses elicited to biological therapeut ics. 
Journal  of Immunol ogical Methods. 2007;321(1- 2):1-18.
18. European Medicines Agency. Ethical considerat ions for clinical tri als on m edicinal products 
with the paedi atric populati on. Recommendat ions of the Ad hoc group for the development 
of implement ing guidelines for Direct ive 2001/20/EC relat ing to good clinical pract ice in the 
conduct of clinical trials on medicinal  products for human use. 2008.
19. European Commissio n. The Rules Governing Medicinal Products in the European Unio n, 
Volume 4, Annex 13, Investigational Medicinal Products (ENTR/F/2/AM/an D[2010] 
3374). 03 Feb 2010.
20. Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et 
al. Second symposium on the definit ion and m anagement of  anaphylaxis: summary report --
Second National Inst itute of Allergy  and Infect ious Di sease/Food Allergy  and Anaphylaxis 
Network symposium. J A llergy  Clin Immunol . 2006;117(2):391-7.
21. U.S. Food and Drug Administration. Code of Federal Regulat ions, 21 CFR Part 11, 
Electronic Records, Electronic Signatures. 2009 2009.
22. ICH Harmonised Tripartite Guideline. Statist ical principles for clinical t rials. International 
Conference on Harmonisat ion E9 Expert Working Group. Stat Med. 1999;18(15):1905-42.
23. Novo Nordisk A/S. http://www.novonordisk -trials.com /websi te/content/how -we-disclose -
trial-inform ation.aspx.
24. International Co mmittee of Medical Journal Edi tors. Recommendat ions for the Conduct, 
Reporting, Edit ing and Publicat ion of Scho larly Work in Medical Journals; current versio n 
available at www.icmje.org.
  Protocol  v 8NN7999-3895 NN7999 0  | VV-TMF-1261484
119  of 119 . -  | 1
 |
CONFIDENTIAL
 
 16.1. 01 Protocol  Attachment  
 
Protocol Attachment I is located in the Trial Master File . 
If applicable , Protocol A ttachment II is also located in the Trial Master File . 
Content: Global key staff and Country key staff.  CONFIDENTIALDate: Novo Nordisk
Version:
Status:nonacog beta pegol
Trial ID: NN7999-3895 Final
Clinical Trial Report
Appendix 16.1.124 February 2023
1.0
Final
CONFIDENTIAL